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GENERAL ABSTRACT 
 The mechanisms behind the development and progression of Parkinson’s disease (PD) are 
still not fully understood. Several pathophysiological mechanisms have been implicated in the 
progression of the disease including oxidative stress, mitochondrial dysfunction, excitotoxicity, 
protein aggregation, and neuroinflammation. Since current therapeutic options for PD treat only 
the symptoms without influencing disease progression, recent translational studies have focused 
on identifying factors that protect against putative pathophysiological mechanisms of PD. We 
show herein, that the chemokine-like signaling protein, Prokineticin-2 (PK2), is expressed and 
secreted at higher levels in dopaminergic neurons during the acute phase of inflammatory or 
neurotoxic stress. Furthermore, we are the first to demonstrate that this protein can protect 
dopaminergic neurons from MPP+-induced cell death through the activation of the MAPK and Akt 
pathways. PK2 treatment also protected dopaminergic neurons from mitochondrial fragmentation, 
while increasing the mitochondrial biogenesis mediators Pgc1α and TFAM. Importantly, 
overexpression of PK2 by injecting PK2 AAV 2/5 into the mouse striatum significantly protected 
against MPTP-induced behavioral deficits and dopaminergic neuronal loss, whereas blocking PK2 
signaling with the receptor antagonist PKRA7 exacerbates both of these MPTP effects. 
 Activation of microglia and astrocytes are both hallmarks of PD in the brain, and blocking 
microglia-produced inflammation has been found to protect dopaminergic neurons in animal 
models of PD. However, the mechanisms behind the activation of these cells are not fully 
understood, especially in astrocytes. Both microglia and astrocytes constantly survey their 
environment and respond to specific stimuli. Microglia can shift their phenotype by expressing  
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either protective signaling molecules or inflammation-related factors, depending on the type of 
stimuli. Recent studies indicate that astrocytes undergo similar phenotypic changes that were 
previously known only for microglia.  
During our investigations of PK2, we made novel discoveries about this secreted 
chemokine-like protein’s role in microglial and astrocytic activation, and its contribution to 
neuroinflammation. PK2 treatment in microglia lead to a shift in the microglial activation state 
towards a more anti-inflammatory phenotype by reducing basal levels of damaging reactive 
oxygen species (ROS) and inflammatory cytokines and increasing protective factors such as 
Arginase1 and Nucelear factor E2-related factor 2 (Nrf2).  Similarly, recombinant PK2 (rPK2) 
attenuated the LPS-induced production of ROS, nitric oxide, pro-inflammatory cytokines and 
mitochondrial bioenergetic dysfunction. Overexpression of PK2 in vivo by injecting PK2 AAV 
into the striatum led to morphological changes in microglia, such as increased number and length 
of branch processes. Interestingly, PK2 AAV 2/5 protected microglia from MPTP-induced 
morphological changes, whereas the PK2 receptor antagonist PKRA7 exacerbated these effects. 
Our studies in astrocytes produced similar results, wherein PK2 treatment could induce the 
expression of protective factors such as Arginase1 and Nrf2 while decreasing inflammatory factors 
such as ROS and reactive nitrogen species (RNS). PK2 treatment in both mouse and human 
astrocytes increased the production and secretion of the neuroprotective glial cell-line derived 
neurotrophic factor (GDNF). Importantly, the GDNF produced and secreted by PK2 
overexpression significantly protected a human dopaminergic neuronal culture from MPP+-
induced cell death. Overall, we found that PK2 signaling has a direct neuroprotective effect, and 
that it can promote microglia and astrocytes to protect neurons through the reduction of 
inflammation and the production of neuroprotective factors.
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CHAPTER I 
GENERAL INTRODUCTION 
Thesis Layout & Organization 
The alternative format was chosen for this thesis and consists of manuscripts that have been 
published, or are being prepared for submission. The dissertation contains a general introduction, 
three research papers and a conclusions/future directions section that briefly discusses the overall 
findings from all chapters, and charts out where the research story will be taken next. The 
references for each manuscript chapter are listed at the end of that specific section. References 
pertaining to the background and literature review as well as those used in general conclusion 
section are listed at the end of the dissertation. The introduction section under Chapter 1 provides 
a background and overview of Parkinson’s disease (PD). The Background and Literature Review-
I section covers current evidence implicating the roles of activated microglia and activated 
astrocytes mediating progressive dopaminergic neuron loss in Parkinson’s disease. It also 
introduces the neurotrophic factor GDNF and studies that have examined the role of this protective 
factor, therefore an overview of the research objectives pertaining to Chapter V.  The Background 
and Literature Review-II provides an introduction to prokineticin signaling, Prokineticin-2 (PK2) 
in particular, and the role it plays in the CNS and throughout the body. The manuscript from 
Chapter 2 was recently accepted for publication in the Nature Communications. It explores the 
induction of PK2 and the role of this signaling protein in mediating dopaminergic neuroprotection 
in in-vitro and in-vivo models of PD.  Chapter 3 analyzes how the Prokineticin-2 protein, that is a 
secreted signaling peptide, can induce alternative activation of microglia through the Jmjd3-Irf4 
pathway. Chapter 4 examines how Prokinetcin-2 can promote astrocyte activation towards a 
neuroprotective phenotype, through the upregulation of anti-oxidant factors and the glutamate 
2 
 
transporter GLAST. Chapter 5 explores the induction of the neurotrophic factor GDNF by 
prokineticin signaling in astrocytes. Chapters 3, 4, and 5 are in the process of being submitted for 
publication. 
All of the research described by the author in this thesis was performed during the course 
of his doctoral studies at Iowa State University under the guidance of his major professors and 
principal investigators – Dr. Anumantha G. Kanthasamy and Dr. Arthi Kanthasamy. 
 
Introduction 
 
PD overview 
 
 Parkinson’s disease (PD) was originally described by James Parkinson in 1817 as the 
shaking palsy, and is currently the second most common neurodegenerative disease affecting over 
4 million people worldwide (de Lau and Breteler 2006, von Bohlen Und Halbach et al. 2004). The 
median age of onset for idiopathic PD is around 60 years and its risk increases with age. The 
disease is a chronic, progressive neurodegenerative disorder that is characterized by motor deficits 
that include akinesia (absence of movement), bradykinesia (slowness of movement), rigidity and 
postural instability. These symptoms are thought to arise from the pathological hallmark of PD, 
which is significant loss of the melanized dopaminergic neurons in the substantia nigra pars 
compacta (SNpc) and subsequent reduction of dopamine in the caudate putamen. By the time the 
motor symptoms are serious enough to be diagnosed, up to 70% of the dopaminergic neuronal cell 
bodies are lost in the substantia nigra along with 60-80% depletion of dopamine levels in the 
striatum (Cheng et al. 2010, Dauer and Przedborski 2003). Interestingly, the death of neurons in 
other regions, such as the ventral tegmental area (VTA), and locus coeruleus has also been 
documented (Alberico, Cassell and Narayanan 2015, Gesi et al. 2000). Non-motor symptoms also 
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develop in some but not all PD patients, such as sleep disorders, constipation, olfactory deficits 
and cardiovascular dysfunction. In most cases, these non-motor symptoms can precede the onset 
of motor symptoms by many years. PD affects 1% of the population over the age of 60, however 
that percentage jumps to 5% of the population over the age of 85 (de Lau et al. 2006, Wood-
Kaczmar, Gandhi and Wood 2006). Dopaminergic neuronal loss is also seen in normal aging, with 
an estimated loss of 4.7 – 9.8% of neurons per decade of life (Rudow et al. 2008, Fearnley and 
Lees 1991). However, natural aging does not lead to a PD-like pattern of dopaminergic neuronal 
loss in the ventral midbrain region, indicating that there are other factors involved in the 
development of PD (Reeve, Simcox and Turnbull 2014). Although aging appears to be the greatest 
risk factor for developing PD, the mechanistic basis for the selective vulnerability and progressive 
loss of nigral dopaminergic neurons has not been uncovered. The emerging hypothesis suggests 
that PD is a complex heterogeneous disease with multiple genetic mutations and environmental 
causative factors. Clinical and epidemiological studies have found several potential environmental 
risk factors for PD. These include heavy metal exposure, pesticide exposure, excess body weight, 
repeated head trauma and rural living ( Dick et al 2007, Priyadarshi et al 2001). 
 Most of the cases of PD are sporadic and are not directly linked to a genetic mutation, 
however, approximately 5-10% of all PD cases show an autosomal dominant or recessive mode of 
inheritance (Hardy 2010). There are currently 18 chromosomal regions, named PAKK genes, that 
are directly associated with PD. Recently, six of these PARK genes have been implicated in early-
onset of PD, such as α-synuclein (PARK1/PARK4), parkin (PARK2), PINK1 (PARK6), DJ-1 
(PARK7), ATP13A2 (PARK9) and SLC30A10. Similarly, the genes LRRK2 (PARK8) and VPS35 
(PARK17) have been linked to late-onset PD (Pankratz and Foroud 2007). The α-synuclein and 
LRRK2 gene regions are responsible for autosomal dominant PD (AD-PD), whereas the parkin, 
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PINK1, DJ-1 and ATP13A2 are linked to autosomal recessive PD (AR-PD) (Klein and 
Westenberger 2012). A mutation in one of these genes is sufficient to cause PD. Several of the 
genes associated with PD have multifactorial roles that may contribute to PD pathology, including 
neuroinflammation-related functions. For instance, LRRK2, PINK1, and DJ-1 are all implicated 
in normal autophagy in the cell, and have all been found to promote microglial pro-inflammatory 
responses (Moehle et al. 2012, Kim et al. 2013). Using accumulated genome-wide association 
studies (GWAS) over large population cohorts, several loci have been identified as PD risk loci 
that could contribute to the development of PD (Lill et al. 2012). However, approximately 40% or 
more of the population-attributable risk remains unexplained by the currently identified PD loci 
(Nalls et al. 2015).  
  The sporadic form of PD accounts for more than 90% of PD occurrences where onsets 
were likely caused by a complex interplay of genetic and environmental factors. Figure 1 details 
the known factors that either increase or decrease overall risk (OR) of developing PD. The major 
hallmark of sporadic PD is the cytoplasmic inclusion of aggregated proteins that contain the 
Kalia and Lang, Lancet 2015 
Figure 1. Genetic and environmental risk factors that either increase or decrease the overall risk 
(OR) of PD 
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protein α-synuclein, these inclusions are known as Lewy bodies and Lewy neurites. However, the 
presence of Lewy bodies and Lewy neurites is not sufficient in explaining the disease. Other factors 
such as mitochondrial dysfunction, oxidative stress, dysfunction in the ubiquitin proteasomal 
system (UPS), and excitotoxicity have been implicated in the development and progression of PD 
(Savitt, Dawson and Dawson 2006, Gandhi and Wood 2005, McNaught et al. 2003). Another 
major contributor to PD pathogenesis is the increased presence of activated microglia and pro-
inflammatory factors in the substantia nigra, which has been found in clinical subjects and all 
animal models of the disease (Mosley et al. 2006). It was previously thought that the increase 
number of activated microglial was just an indication of neuronal injury, however, mounting 
evidence indicates that reactive microglia and the subsequent inflammatory response plays an 
active role in the pathogenesis and progression of PD. One hypothesis has been proposed in which 
different causative factors and multiple neurotoxic insults accumulate throughout the years or 
possibly converge on the nigrostriatal system, thereby resulting in an obvious idiopathic onset of 
PD. This is known as the ‘multiple-hit’ hypothesis (Carvey, Punati and Newman 2006). Currently, 
most drugs and therapies prescribed for PD patients, such as L-DOPA and deep brain stimulation 
(DBS), only alleviate PD symptoms and do not slow the progression of the disease. Therefore, 
new therapeutic options are needed that can either protect dopaminergic neurons from cell death 
or regenerate already lost dopaminergic neurons. Understanding the mechanisms behind 
dopaminergic neuronal cell death, and the communication signals between neurons and glial cells, 
such as microglia and astrocytes, would be helpful in finding novel signaling pathways for 
reducing neuroinflammation and increasing neuroprotection.  
  
6 
 
 
Background and Literature review I 
 
 
 
Neuroinflammation in PD 
 
Inflammation is a necessary response that must protect the body against pathogens by 
performing critical functions such as clearing away dead or dying cell debris, which could 
otherwise lead to deleterious effects such as infection. However, inflammation also produces 
factors that can be toxic to cells, potentially leading to significant pathology if the inflammation is 
not tightly regulated (Glass et al. 2010). Several neurodegenerative diseases, such as Alzheimer’s 
disease (AD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) and Parkinson’s 
disease (PD) have been associated with an exaggerated neuroinflammatory component (Block, 
Zecca and Hong 2007, Minghetti 2005). The main source of this neuroinflammation is the 
microglia and astrocytes at the site of neurodegeneration. These two distinct cell populations 
undergo persistent hyperactivation and exacerbate the disease progression. It was previously 
thought that reactive gliosis would protect the neurons from cell death by maintaining 
environmental homeostasis and by increasing phagocytic clearance of dead and dying neurons in 
the CNS. Both microglia and astrocytes have important roles within the developing brain, and in 
keeping the brain in a healthy state. Microglia play a crucial role in establishing synapses while 
the brain is developing, and maintain neuronal health by producing multiple trophic factors 
(Aarum et al. 2003, Walton et al. 2006). Most neuroinflammatory responses are only transient 
actions that subside after clearance of the activating stimulus, however the neuroinflammation seen 
in neurodegenerative diseases such as Parkinson’s disease (PD) is chronic and progressive. This 
progressive inflammatory response has been demonstrated in human PD patients and in most 
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animal models of PD, such as MPTP, 6-OHDA, and LPS models (Imamura et al. 2003, Panicker 
et al. 2015). Higher amounts of inflammatory cytokines, including TNFα, IL-1β, IL-6, IL-2 and 
IL4, were found in the SN of PD patients compared to age-matched controls (Mogi et al. 1994, 
Mogi et al. 1996). Several animal studies have demonstrated that inhibiting pro-inflammatory 
cytokine signaling can reduce dopaminergic neuronal degeneration in mice. Nigral administration 
of anti-IL-1β neutralizing antibody (Arai et al. 2004, Arai et al. 2006), and the recombinant 
dominant negative TNF inhibitor XENP345 (McCoy et al. 2006) were both able to significantly 
protect against dopaminergic neurodegeneration. Neuroinflammation is a key mechanism in the 
progression of Parkinson’s disease and could be a target for therapeutic intervention to prevent 
dopaminergic neurodegeneration.  
 
 
Microglial role in PD 
 
Microglia are considered the resident macrophagic cells of the CNS since they were 
originally found to perform phagocytic functions similar to macrophages, microglia express high 
levels of MHC class II molecules, making them antigen-presenting cells (Hickey and Kimura 
1988). Interestingly, microglia arise from primitive myeloid progenitors that develop from the yolk 
sac (Ginhoux et al. 2013), which demonstrates that microglia do not arise from the bone-marrow 
hematopoietic stem cells as originally thought.  While microglia comprise 10-15% of the total cells 
in the brain, their density varies in different areas of the brain, with the highest concentrations 
found in the hippocampus and ventral midbrain. Microglia in the adult brain typically exist in a 
‘resting’ state, identified by a ramified morphology and small cell soma, in which they can perform 
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surveillance of the environment. Under normal circumstances, microglia produce and secrete anti-
inflammatory and neurotrophic factors that help to promote neuronal health and plasticity (Carson 
2002).   
Microglia have been found to be highly dynamic and mobile, with the ability to react to 
any signs neuronal injury. Studies have determined that microglial activation is the first response 
in the CNS to both acute and chronic neuronal injury (Nimmerjahn, Kirchhoff and Helmchen 
2005). Introduction of any potential pathogen or neuroinflammatory agent causes these cells to 
undergo a rapid transformation into an ‘activated’ state, which is characterized by an amoeboid 
morphology with de-ramified microglial 
branches (Figure 2). This ‘activated’ state is 
also identified by a rapid transcriptional 
activation of response genes and various cell 
surface proteins, such as cytokines and 
chemokine receptors.  The secreted or cell 
surface proteins produced by activated 
microglia can alter the site of neuronal injury or cell death. For instance, activation of microglia 
under normal conditions is a transient and highly regulated process, that promotes neuron survival 
and CNS homeostasis (Glezer, Simard and Rivest 2007, Napoli and Neumann 2010, Simard and 
Rivest 2007). Microglia have demonstrated the ability to protect neurons through the production 
of several factors, including BDNF, GDNF, IL-10 and TGFβ1(Patel et al. 2013). Similarly, the 
increase in the glutamate transporter GLT-1 in microglia protected neurons from excitotoxicity 
when astrocytic glutamate uptake was impaired (Persson et al. 2005, Shaked et al. 2005). Synapse 
removal and clearance of dead cells by phagocytosis are two other ways that microglia promote a 
VEHICLE MPTP 
Figure 2. DAB immunostaining images of Iba1-
positive cells in the mouse striatum of vehicle 
or MPTP treated mice 
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healthy environment. Microglia activation and trophic factor secretion around the site of injury 
promotes a return to homeostasis after infection (Kreutzberg 1996). 
 Neurodegenerative diseases result in a sustained microglial activation, which is then 
considered to evolve into hyperactivation at the site of neuronal loss. This sustained 
hyperactivation of microglia differs from the healthy, transient activation both by the secreted 
factors produced and by cell morphology (Lull and Block 2010). Along with becoming amoeboid, 
the activated microglia release reactive oxygen species (ROS), nitrite and pro-inflammatory 
cytokines that are toxic to neurons. Sustained neuroinflammation has been found to negatively 
affect neuron health in multiple cell culture models, animal models and post-mortem analyses of 
human brains (Aschner et al. 1999, Glass et al. 2010). Animal models of Parkinson’s disease 
display this activated microglial response along with an increase in the inflammatory factors that 
are mainly produced by microglia. MPTP is a selective dopaminergic neuronal toxicant and its 
acute injection paradigm (4 injections of 18mg/kg every 2 hours) is well characterized to induce 
de-ramification of microglia and pro-inflammatory factors (Hirsch and Hunot 2009, Sriram et al. 
2006, Wu et al. 2002, Wu et al. 2003). Inhibition of the microglial NOS2 gene and the NF-κB 
pathway can prevent this hyperactivation, thereby attenuating of MPTP-induced 
neurodegeneration (Du et al. 2001, Ghosh et al. 2007). Similar activation of microglia occurs in 
an MPTP non-human primate model and in the 6-OHDA mouse model (Stott and Barker 2014, 
Virgone-Carlotta et al. 2013, Vazquez-Claverie et al. 2009). Evidence is also pointing to an 
increase in neuroinflammation and activated microglia after genetic overexpression of α-synuclein 
and in a relatively new animal model of PD with selective knockout of the transcription factor 
TFAM specifically in dopaminergic neurons (Chung et al. 2009, Theodore et al. 2008)(Langley et 
al., unpublished). The strongest evidence comes from animals treated with Lipopolysaccharide 
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(LPS), which is the most widely used model for testing the role of neuroinflammation in PD. LPS 
is a component of the gram-negative bacterial cell wall and is a powerful inflammogen that evokes 
an innate inflammatory response from immune cells by acting as a pathogen associated molecular 
pattern (PAMP). LPS treatment selectively activates microglia, and the subsequent inflammatory 
response leads to dopaminergic neuronal death. This effect from LPS treatment has been 
demonstrated both by direct intranigral injection and by systemic, intraperitoneal administration 
(Castano et al. 1998, Herrera et al. 2000, Hsieh et al. 2002, Qin et al. 2007). Interestingly, 
administering LPS together with other neurotoxicants such as pesticides and metals has 
demonstrated that increased neuroinflammation can amplify the effects of PD-associated 
environmental insults, thereby resulting in even greater neuron loss (Liu, Gao and Hong 2003, 
Zhang et al. 2010). Similarly, combining LPS-induced microglial priming and the overall 
progressive inflammatory status of the aging brain can also increase the chances of developing a 
neurodegenerative disease (Perry and Holmes 2014). 
 Along with the studies that found microglial activation to be important in animal models 
of PD, numerous other studies have examined microglial activation and inflammation in human 
patients. For instance, post-mortem PD brains contain amoeboid microglia around the regions of 
dopaminergic neuron loss (Langston et al. 1999, Whitton 2007, McGeer et al. 1988). These 
reactive microglia displayed characteristics of phagocytic cells that are typically seen with aging 
(Jyothi et al. 2015). Besides activated microglia, PD patients have an increased level of pro-
inflammatory cytokines, such as TNFα, IL-1β, and IFNγ, in the cerebrospinal fluid and in the brain 
itself (Hirsch, Hunot and Hartmann 2005, McGeer et al. 1988, Hunot et al. 1997, Mogi et al. 2000). 
There is also an inverse correlation of CD68 immunoreactivity with PD progression, therefore 
finding elevated phagocytosis associated with ongoing tissue degeneration and decreasing in the 
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final stages (Croisier et al. 2005). Several single nucleotide polymorphisms (SNPs) that have been 
linked to PD development were identified by genetic linkage studies in PD patient and age-
matched control groups. Some of the SNPs are found within the promoter regions of pro-
inflammatory genes (Hakansson et al. 2005, Hamza et al. 2010, Nishimura et al. 2000, Nishimura 
et al. 2001). Microglial activation has been confirmed in living PD patients using postitron 
emission tomography (PET) imaging. Radioligands are used that bind to translocator proteins 
(TPSO) which is greatly enhanced in the presence of neuroinflammation, and therefore can give 
an indication of activated microglia (Banati et al. 2014, Papadopoulos and Lecanu 2009). This 
technique has allowed the visualization of increased inflammation seen in the pons, basal ganglia 
and frontal and temporal cortices of PD patients compared to control patients (Gerhard 2016). 
Importantly, it has recently been found and corroborated that regular use of NSAIDs, especially 
Ibuprofen, reduce the risk for developing PD (Gagne and Power 2010, Gao et al. 2011). Taken 
together, these results indicate that neuroinflammation plays an important role in PD, and that 
understanding that role could help to discover therapies to prevent the neuronal loss seen in PD. 
 
Microglial activation phenotypes 
 The above section on microglial activation describes what is known as ‘classical’ activation 
of microglia, recognized by its de-ramified, amoeboid morphology along with the increased 
production of inflammatory factors. However, recent studies are indicating that microglia exist in 
the brain as a heterogeneous population of activation phenotypes. These different phenotypes 
perform certain functions depending on the nature, intensity and duration of stimuli presented to 
the cell (Tansey and Goldberg 2010, Olah et al. 2011). Therefore, microglia seem to respond 
similar to other tissue macrophages. Their production of different cytokines, inflammatory 
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mediators, growth factors and cell surface molecules have all been used to classify microglia as 
either pro-inflammatory or anti-inflammatory. However, as previously stated, microglia exist in a 
heterogeneous population and activation of these cells cannot be simply classified as pro-
inflammatory or anti-inflammatory. Microglia activation was originally perceived to resemble that 
of T-cell polarization towards pro-inflammatory Th1, or anti-inflammatory Th2, and therefore 
were given the nomenclature of M1, for pro-inflammatory, or M2, for anti-inflammatory. 
However, unlike T-cells, microglia do not polarize to a particular set of functions, but can change 
their activation state depending on environmental situations and subsequent downstream signaling 
(Martinez and Gordon 2014). Therefore, microglial activation is currently designated as an “M1 
phenotype” that is considered cytotoxic and increases inflammatory factors, whereas an “M2 
phenotype” promotes tissue repair and the reduction of inflammation (Mills et al. 2000, Mackaness 
1962). Many studies have examined the signaling mechanisms driving microglial activation and 
the different states that microglia exist in under various neurodegenerative diseases, such as PD 
(Joers et al. 2016). 
 The M1 microglial phenotype, or ‘classical’ activation, is known to occur with introduction 
of the stimuli LPS or IFNγ. IFNγ is the main cytokine associated with this classical activation, and 
activates the downstream signaling pathways JAK2, STAT1 and IRF1 (Waddell et al. 2010). The 
classically activated cells produce high levels of inflammatory cytokines, such as TNFα, IL-1β, 
IL-6, and IL-12, along with cell surface markers such as major histocompatibility complex-II 
(MHC-II) and CD86, and the toxic nitric oxide molecule (Martinez et al. 2006, Nau and Bruck 
2002). These inflammatory factors produced by microglia are toxic to both astrocytes and neurons, 
and therefore lead to increased neuronal death (Boche, Perry and Nicoll 2013, Fan et al. 2016). A 
common signaling pathway for any of the M1 stimuli is the activation of the NFκB pathway. The 
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classical activation of microglia is a necessary function for the protection against any infections of 
the CNS from various pathogens, including viruses, bacteria, fungi, parasites, and prions (Rock et 
al. 2004).  
On the other hand, the M2 phenotype, or ‘alternative’ activation, is associated with wound 
healing and repair.  The alternative activation phenotype has been subdivided into M2a, M2b, and 
M2c to differentiate between the stimulus that induced the activation and the resulting gene 
expression changes. The M2a phenotype is induced by the anti-inflammatory cytokines IL-4 and 
IL-13, and produces protective factors such as IL-10 and Arginase1. The M2b phenotype is a 
phenotype brought about by IL-1, LPS and certain immune complexes, and is characterized by an 
increase in IL-10, IL-1, TNFα and IL-6. This phenotype is considered to be immunity regulating. 
Lastly, the M2c phenotype is induced with IL-10 and TGFβ treatment, and produces high levels 
of these two factors. M2c is considered to be the deactivated microglial phenotype associated with 
tissue repair (Martinez and Gordon 2014, Cherry, Olschowka and O'Banion 2014). Other 
microglial phenotypes have been discovered after introducing specific stimuli, such as the Mox 
phenotype seen with oxidative tissue damage (Kadl et al. 2010). The response pattern common to 
all M2 phenotypes is high expression of the anti-inflammatory cytokine IL-10 and low expression 
of the pro-inflammatory cytokine IL-12. M2 phenotypes, or ‘alternative’ activation states, reduce 
inflammation and promote neuronal survival. 
The redox state of microglia has been implicated to be important in determining the 
phenotype of the cell. Reactive oxygen species, ROS, are damaging molecules that lead to 
differential cell signaling in microglia. Normally, low levels of ROS are produced by microglia, 
but with classical activation, ROS levels increase due to a greater amount of the NADPH oxidase 
and nitric oxide synthase enzymes (Qin and Crews 2012). This increase in ROS acts as a second 
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messenger to activate downstream signaling, such as the ROS-sensitive NFκB pathway (Rojo et 
al. 2014). As stated above, most of the classical activation phenotypes of microglia are produced 
by activating of the NFκB pathway. Introduction of ROS also activates anti-oxidant pathways to 
counteract this toxic stimulus, and the main pathway that becomes activated is the Nrf2 
transcription factor and the Nrf2 target genes. Activation of the Nrf2 transcription factor and 
subsequent translocation to the nucleus increases the gene expression of anti-oxidant enzymes, 
such as the peroxiredoxins (Bae et al. 2009, Matte et al. 2015). Interestingly, the M2 markers 
decrease in Nrf2 knockout mice, thus indicating that Nrf2 is an important mediator of the 
alternative activation of microglia (Rojo et al. 2010). Mitochondrial dysfunction has also been 
implicated in classical activation of microglia, with LPS treatment reduction oxidative respiration 
(Orihuela, McPherson and Harry 2016). This information indicates that the redox state of the cell 
can determine the phenotype of the microglia, with increased ROS leading to a classically activated 
phenotype and an increased anti-oxidant response inducing an alternative activation phenotype. 
Similarly, attenuating mitochondrial dysfunction could protect against the production of these 
inflammatory mediators. 
 Reactive microglia have become a hallmark of PD, and have been found to be increased in 
the vicinity of the few remaining nigral dopaminergic neurons (Jyothi et al. 2015). However, 
knowing that there are multiple activation states, these reactive microglia could be either helpful 
or harmful in PD. Since microglia exist as a heterogeneous population of different activation 
phenotypes there is a complex interplay of stimuli that contribute to the overall status of microglia 
in the brain. There is a need for homeostasis of the microglial phenotypes, with the availability of 
both classical activation and alternative activation phenotypes. Interestingly, with aging there is 
an increase in inflammatory activation of microglia which skews the homeostasis towards a more 
15 
 
damaging phenotype (Raj et al. 2014, Holtman et al. 2015). This age-induced increase in 
inflammatory microglial activation could explain the increased prevalence of PD with increased 
age. Similarly, misfolded proteins that are seen in neurodegenerative diseases such as PD can illicit 
an inflammatory response in microglia. Aggregated, nitrated and oxidized forms of α-synuclein 
have been found to increase microglial inflammation (Reynolds et al. 2008, Zhang et al. 2005). 
Several environmental toxicants such as, the pesticides rotenone and paraquot, have been found to 
induce neurodegeneration through microglial ROS generation (Bonneh-Barkay et al. 2005, Gao et 
al. 2002). Microglia respond to various stimuli in a rapid fashion and can switch from classical 
activation phenotype to an alternative activation phenotype and vice versa. Since microglia can 
constantly switch phenotypes depending on their environment, it is thought that there is a mixture 
of different phenotypes throughout the brain at any one time. This would point to the hypothesis 
that there is a continuum of 
microglial phenotypes instead of 
the basic M1/M2, or pro- and anti-
inflammatory labels. This means 
that certain factors and cell 
signaling pathways that can induce 
microglia to shift towards a 
particular side of the continuum 
(pro- or anti-inflammatory) but that 
distinct polarizations probably do 
not occur. See figure 3 for an 
overview of the input signals and 
Figure 3. Input signals and signaling mechanisms that 
contribute to the shift in microglial phenotypes towards a 
M1 or M2 status 
Hu et al. Nat. Rev. Neurology, 2014 
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signaling mechanisms that go into the shift of microglia activation down both sides of the 
continuum of activation. Understanding the molecular mechanisms behind microglial activation 
and factors that can induce specific activation phenotypes would be beneficial in finding a therapy 
for PD.  
 
Astrocyte role in PD 
 
Astrocytes, or astroglia, are found throughout the brain and are the largest population of 
glial cells in the CNS. The exact ratio of neurons to glial cells throughout the brain is not known, 
however some reports have estimated that there could be up to 10-17 times as many glial cells than 
there are neurons in certain areas of the brain (Pakkenberg and Gundersen 1988). However, more 
recent evidence indicates that the neuron to glia ratio is closer to being 1:1 in the human brain 
(Herculano-Houzel 2009). Since microglia are only considered to be around 10-15% of the total 
cells in the brain, depending on the region, the majority of the glial cells in the brain would most 
likely be astrocytes (Carson 2002). This would indicate that astrocytes play an important role in 
the CNS and could be a powerful therapeutic option for neurodegenerative disease such as 
Parkinson’s disease.  
There are three known types of mature astrocytes, with diverse phenotypes and tissue 
localization. Two of the three forms are the protoplasmic astrocytes that are found in the grey 
matter, and the fibrous astrocytes found in the white matter of the brain. These cells are 
characterized by the spherical bushy morphology in the grey matter, and the process-bearing less 
bushy morphology in the white matter. The third type of astrocytes is the Bergmann glia of the 
cerebellum and the Muller cells of the retina, characterized by their elongated morphology 
(Kimelberg and Nedergaard 2010). There are several astrocyte-specific markers that identify these 
cells from other cell types in the brain. The most commonly used astrocyte markers currently are 
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glial fibrillary acidic protein, GFAP, and the glutamate transporters GLT-1/EAAT2 and 
GLAST/EAAT1.  Some of the newer markers include Aquaporin 4 and aldehyde dehydrogenase 
1 family member 1 (Aldh1L1) (Kimelberg 2004, Lovatt et al. 2007). All cells that robustly produce 
the GFAP protein are astrocytes, however, an astrocyte can be GFAP-negative and are defined as 
astrocytes by the expression of other proteins and physiological properties (Kimelberg 2004). The 
exact function of the GFAP protein in astrocytes is poorly understood, however, it is thought to 
promote mechanical strength and help maintain the shape of the cell (Cullen, Simon and LaPlaca 
2007). GFAP knockout studies have been immensely helpful in determining the functions of this 
protein in astrocytes. Liedtke et al. demonstrated that GFAP knockout led to abnormal 
myelination, deterioration in white matter structure, and impairment of the function and structure 
of the blood brain barrier (Liedtke et al. 1996). Along the same lines, the average process length 
of astrocytes lacking GFAP expression were found to be significantly smaller when cultured with 
neurons, compared to astrocytes normally expressing GFAP (Weinstein, Shelanski and Liem 
1991). Therefore, GFAP helps produce the astrocyte processes that could be used to contact 
neurons.  Interestingly, there is increased GFAP expression after any degenerative injury or insult 
including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. The reason for 
this increased GFAP is still not fully understood, however the second messenger nitric oxide (NO) 
has been implicated in increasing GFAP expression in astrocytes (Brahmachari, Fung and Pahan 
2006).  
Glia, which is from Greek for glue, no longer seems to be apt name for these cells. 
Astrocytes work very closely with neurons with intricate neuron-glia crosstalk. Astrocytes support 
neurons through multiple processes, including antioxidant protection, glutamate protection, 
maintenance of the blood brain barrier, and the production of neurotrophic factors and cytokines 
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(Volterra and Meldolesi 2005, Hamby and Sofroniew 2010, Barreto et al. 2011).  In the healthy 
CNS, astrocytes are arranged in non-overlapping domains that potentially contact around 160,000 
synapses. This allows the astrocytes to therefore control both neural activity and cerebral blood 
flow by enwrapping the neuronal synapses along with contacting the brain vasculature, and 
(Maragakis and Rothstein 2006, Zonta et al. 2003). The equal spacing of astrocytes in the healthy 
CNS is thought to allow these cells to perform their important support functions of potassium 
buffering (Leis, Bekar and Walz 2005), controlling extracellular pH (Deitmer and Rose 2010), 
glutamate and GABA uptake (Sattler and Rothstein 2006), and antioxidant functions (Aschner 
2000) to protect the neurons throughout the brain. Cui et al. found that inducible ablation of 
astrocytes in adult mice led to significant neurodegeneration, demonstrating the importance of 
these cells on neuronal survival (Cui et al. 2001). 
 
 
Astrocyte activation 
 
 
Reactive astrogliosis is the mechanism by which astrocytes respond to injury or toxic 
stimuli, such as infection, α-synuclein accumulation, ischemia, and neurodegenerative disease 
such as Parkinson’s disease. Astrocyte activation is a constitutive, graded, multi-stage, and 
evolutionary conserved reaction of astrocytes. This activation of astrocytes is characterized by 
both molecular and morphological 
changes, and is a hallmark of 
Parkinson’s disease along with 
microgliosis, or activated microglia. 
The morphological changes mainly 
include hypertrophy of the cell body 
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and major process branches, and reduction in the number of primary branches (Figure 4). The 
expression of several proteins increase with astrocyte activation, including GFAP, vimentin and 
nestin. The increase in GFAP expression leads to the assumption that there is an increase in 
astrocyte proliferation, however that is not always the case since most astrocytes only express 
GFAP at low levels under basal conditions. Astrocyte activation is much more complex than 
originally thought, and researchers are now realizing that astrocyte activation is a gradient process 
that is not as uniform as previously described. Understanding the mechanism behind astrocyte 
activation and the effects of this activation could be a key piece to the puzzle of solving 
neurodegenerative diseases such as Parkinson’s disease.  
Previously, it was thought that microglia were the only immune cells in the CNS. However, 
it has recently been determined that astrocytes are also immunocompetent cells, and express the 
MHCII protein which is crucial for antigen presentation. Similar to microglia, astrocytes activated 
by an inflammatory stimulus can also produce higher levels of pro-inflammatory cytokines, such 
as IL-1β and TNF-α, along with increased production of reactive oxygen species (ROS) (Hirsch et 
al. 2003). Animal models of PD have demonstrated that astrocyte activation is increased, along 
with an increase in inflammatory cytokines. MPTP, a selective dopaminergic neuronal toxicant, 
increased astrocyte activation most likely through neuronal damage (Yasuda et al. 2008). 
Similarly, lipopolysaccharide (LPS) is a bacterial endotoxin that has been found to be a potent 
activator of microglia and induces the production of inflammatory factors. LSP treatment both in 
cell culture and in animal models demonstrated the ability to activate astrocytes and cause them to 
produce inflammatory factors such as nitric oxide (Sola et al. 2002). However, evidence indicates 
that the increased inflammation from astrocyte cultures due to LPS treatment could be a secondary 
effect from contaminating microglia (Saura 2007, Sola et al. 2002). Along the same lines, 
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Tarassishin et al. demonstrated that human astrocytes do not respond to LPS, but strongly respond 
to the pro-inflammatory cytokine IL-1β (Tarassishin, Suh and Lee 2014). As it relates to 
Parkinson’s disease, excessive uptake of aggregated α-synuclein by astrocytes can induce the 
upregulation of IL-1α, IL-1β, IL-6, and TNFα (Rappold and Tieu 2010). The cell signaling 
responsible for the activation of astrocytes in neurodegenerative disease has yet to be uncovered, 
however the JAK-STAT pathway has been implicated. Interestingly, MPTP-induced activation of 
the JAK2-STAT3 in mice preceded the increase of GFAP in astrocytes. Similarly, LPS injection 
induced a similar activation of STAT3 in a mouse model. Both neuronal damage and inflammatory 
treatment induced this STAT3 activation, indicating that the JAK2-STAT3 pathway is important 
for astrocyte activation in neurodegenerative diseases (O'Callaghan et al. 2014). Therefore, 
blocking astrocyte activation under certain conditions could be beneficial by reducing the 
astrocyte-produced inflammation.   
On the other hand, several studies demonstrated that activated astrocytes increase 
neuroprotection by the increased uptake of glutamate, production of reduced glutathione (GSH), 
production of superoxide dismutases (SODs), release of adenosine, and formation of glial scars. 
The production of GSH is important in the protection of neurons because it can prevent the nitric 
oxide (NO)-induced inhibition of the mitochondrial complex I and therefore reduce the production 
of reactive oxygen species (ROS) (Dias, Junn and Mouradian 2013a). Increasing the glutathione 
peroxidase-containing cells could reduce the severity of neurodegeneration in cell culture from PD 
patients, indicating that production of glutathione could be a crucial protective factor against ROS 
produced in PD patients (Zeevalk, Razmpour and Bernard 2008). The transcription factor Nrf2 has 
been demonstrated to increase the production of GSH in astrocytes (Steele et al. 2013). Nrf2 
activation leads to the expression of several cytoprotective genes that reduce ROS levels and 
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directly protect neurons, including the peroxiredoxins (Dowell and Johnson 2013). Interestingly, 
astrocyte-specific Nrf2 overexpression was able to protect against α-synuclein-induced 
neurodegeneration through the increase in autophagy-lysosome degradation of the synuclein 
protein (Gan et al. 2012). Other protective factors, such as several astrocyte-produced chaperones 
have been implicated in neuroprotection. DJ-1 is an anti-apoptotic protein that serves as a redox-
sensitive chaperone, and is increased in reactive astrocytes (Mullett et al. 2013). Along with 
another chaperone Hsp70, DJ-1 can lead to increased degradation of α-synuclein aggregates 
(Batelli et al. 2008). Several astrocyte-derived neurotrophic factors have been found to protect 
dopaminergic neurons from cell death. For instance, glial-cell derived neurotrophic factor (GDNF) 
is secreted by astrocytes and is essential in dopaminergic neuronal survival (Arenas 1996). 
Implantation of GDNF overexpressing astrocytes into the Substantia Nigra of rats was able to 
significantly protect against 6-OHDA induced neurodegeneration (Ericson, Georgievska and 
Lundberg 2005).  Similarly, overexpression of brain-derived neurotrophic factor (BDNF) under 
the control of the GFAP promoter led to significant neuroprotection in a Huntington’s disease 
animal model (Giralt et al. 2010). Finding signaling pathways that can increase neuroprotective 
mechanisms in astrocytes is an important therapeutic approach for neurodegenerative diseases. 
Calcium is another important signaling mechanism for astrocytes, and it is proposed that calcium 
signaling regulates many of the astrocytic functions. Calcium signaling through the Inositol 1,4,5-
triphosphate (IP3) was found to be required in astrocyte activation and neuroprotection after brain 
injury (Kanemaru et al. 2013). Astrocytes have demonstrated the ability to be neuroprotective, so 
directing that neuroprotection could be a powerful approach to protecting against 
neurodegenerative diseases such as Parkinson’s disease. 
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Astrocyte activation is still poorly understood, and can be both protective and harmful to 
neurons. Interestingly, only protoplasmic astrocytes, and not fibrous astrocytes, have been found 
to contain an increase in aggregated α-synuclein (Halliday and Stevens 2011, Braak et al. 2006). 
This would indicate that the heterogeneous population of astrocytes can respond differently to 
certain signals. Similarly, a comparison in astrocyte gene expression in either an ischemic stroke 
model or endotoxin inflammatory model demonstrated that at least 50% of the injury-altered gene 
expression was disease specific (Zamanian et al. 2012). Therefore, it stands to reason that astrocyte 
activation is not a uniform mechanism, but dependent on factors such as area of the brain and 
activation stimuli (Rappold and Tieu 2010). This was confirmed by Jang et al. by treating primary 
astrocyte cultures with either the bacterial endotoxin lipopolysaccharide (LPS) along with the 
inflammatory cytokine IFNγ, or the anti-inflammatory cytokine IL-4. The LPS co-treated with 
IFNγ in these primary astrocytes led to an increase in the gene expression of pro-inflammatory 
factors such as iNOS, IL-1β, and TNFα. On the other hand, the IL-4 treatment induced the gene 
expression of protective factors such as IL-10 and Arginase1. Activation of STAT6 by the IL-4 
treatment is implicated in the shift of astrocyte phenotype towards a more anti-inflammatory and 
protective function, similar to that which is seen in microglial alternative activation (M2) (Jang et 
al. 2013b). The differential activation of astrocytes could be a key therapeutic option in 
neurodegenerative diseases such as AD and PD, where there is an increase in inflammation and 
the need for more neuroprotective factors.  
 
 
Neurotrophic factors in PD 
 
 
 One therapeutic avenue for research against PD is to find a protein or chemical that can 
protect the neurons from cell death. A family of biomolecules known to support the growth, 
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survival, and differentiation of developing and mature neurons are called neurotrophic factors 
(NTFs).  These biomolecules are mainly proteins, with the one exception being lactacystin which 
is produced from D-glucose (Corey and Li 1999). The implications of finding a neurotrophic 
compound would be immensely helpful in any neurodegenerative diseases and could have many 
other uses in development and maintenance of neurons throughout the body. Interestingly, 
lactacytin was originally found by screening thousands of culture samples to find something that 
could induce neuroblastoma differentiation in N2a cells (Omura et al. 1991). There are over 30 
proteins that are considered neurotrophic factors, and there are still new NTF proteins that are 
being discovered. These proteins are currently divided into 6 subfamilies depending on the 
receptors that they signal through or the overall structure of the protein. The major families of 
neurotrophic factors that have been studied in neurodegenerative diseases are the neurotrophins 
and glial cell-line derived neurotrophic factor (GDNF) family, along with the recently discovered 
cerebral dopaminer neurotrophic factor (CDNF)/mesencephalic astrocyte-derived neurotrophic 
factor (MANF) family.  
 The GDNF family of proteins all have seven conserved cysteine residues that are in the 
same spacing as member of the transforming growth factor-β (TGF-β) superfamily of proteins. 
Although the sequence homology between the GDNF family members that the other TGF-β family 
members is only about 20%, they all share a conformational similarity and are therefore grouped 
into the cysteine-knot family (Eigenbrot and Gerber 1997). However, the conformational similarity 
does not extend to functional similarity because the GDNF family signals through a receptor 
tyrosine kinase (Ret), whereas the other members of the TGF-β superfamily signal through 
receptor serine/threonine kinases (Trupp et al. 1996). There are currently four members of the 
GDNF family of neurotrophic factors, Glial-cell line derived neurotrophic factor (GDNF), 
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Artemin, Neuturin and Persephin. These four proteins share between 40-50% homology. The 
GDNF family of NTFs was first demonstrated to be a potent dopaminergic neuroprotective factor 
in 1993 when GDNF was able to protect cultured ventral midbrain dopaminergic neurons (Lin et 
al. 1993). GDNF was also able to promote the survival and cholinergic differentiation of cultured 
motor neuron, and could therefore be a potential treatment for Amylotropic sclerosis (ALS) 
(Henderson et al. 1994, Zurn et al. 1994). GDNF mRNA has been demonstrated to be expressed 
in multiple regions in the developing and mature brain, including in the striatum and substantia 
nigra of the mature rat brain (Pochon et al. 1997, Koo and Choi 2001). Interestingly, GDNF is 
depleted in the neurons and neuropil of the substantia nigra in PD patients compared to age-
matched controls, whereas other neurotrophic factors such as nerve growth factor (NGF) and brain 
derived neurotrophic factor (BDNF) were not decreased nearly as much as GDNF nor as 
consistently (Chauhan, Siegel and Lee 2001). This would indicate that GDNF is an important 
factor in the protection of dopaminergic neurons and the reduction in availability of this protein 
could lead to the progression of PD. Multiple reports have found that nervous tissue up-regulates 
protective mechanisms to repair damage from various injury (Benn and Woolf 2004). Where 
normally it is the neurons that produce GDNF for the adult brain, during injury the neurons have 
reduced GDNF production and glial cells become the predominant source of GDNF (Pochon et al. 
1997, Blum and Weickert 1995, Bresjanac and Antauer 2000). Interestingly, Saavedra et al found 
that mild damage to dopaminergic neurons in neuron-glia co-cultures induced up-regulation of 
GDNF production in astrocytes, whereas extensive damage did not (Saavedra et al. 2006). The 
authors went on to propose that GDNF induction in astrocytes requires signaling from injured 
dopaminergic neurons. This would imply that there is a neuronal factor that is produced with mild 
damage that can induce astrocytes to produce more GDNF, but these factors are currently 
25 
 
unknown. Finding a signaling molecule that is upregulated in neuronal injury that can signal to 
astrocytes and increase GDNF would be a promising therapeutic option. 
 One of the disadvantages of using GDNF as a therapeutic treatment for PD is that it does 
not cross the blood brain barrier and therefore has to be introduced directly into the brain. Multiple 
groups have demonstrated that infusion of GDNF protein directly into the brain is neuroprotective 
and could lead to function improvement in rodent and non-human primate models of PD (Grondin 
et al. 2002, Tomac et al. 1995, Gash et al. 1996, Bjorklund et al. 2000, Kordower et al. 2000). Two 
scientific trials showed positive effects in PD patients by direct infusion of GDNF protein into the 
brain, however, a placebo-controlled study did not show any improvements (Gill et al. 2003, Slevin 
et al. 2005, Lang et al. 2006b). However, rapid metabolism of this protein would lead to a PD 
patient needing constant delivery of the GDNF protein, which is not ideal when it has to be 
delivered directly to the brain. Also, it was found that the patients were developing antibodies 
directed to the foreign GDNF protein. Development of gene therapy techniques allowed 
researchers to get around this obstacle by being able to induce overexpression of GDNF with a 
one-time injection. These methods used viral delivery, with either recombinant Lentiviruses (LVs) 
or adeno associated viruses (AAVs), to incorporate the GDNF overexpression genes in the nigro-
striatal pathway for long-term production of the GDNF protein. Initial studies using both LV-
GDNF and AAV-GDNF injections into either the striatum or substantia nigra demonstrated there 
was effective GDNF delivery for over 3-6 months. These same studies found that both viral vector 
injections could promote regeneration and functional recovery in both 6-OHDA treated rats and 
MPTP treated monkeys (Bjorklund et al. 2000). Multiple clinical trials for both direct GDNF 
protein infusion and AAV-GDNF viral vectors with convection enhanced delivery (CED) are 
currently underway, with a phase II clinical trial in the UK started in the 2015(Sullivan and 
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O’Keeffe 2016). These results demonstrate that prolonged delivery of GDNF can protect 
dopaminergic neurons in animal models of PD and some human trials have shown improvements 
as well.  
 Finding a molecule that increases endogenous GDNF production has several benefits and 
is a plausible way to get increased GDNF levels to affected areas of the brain. Multiple studies 
have looked into increasing the endogenous GDNF levels to varying degrees. The pathways 
involved in activation of the 
GDNF gene expression are 
becoming more clear, however, 
finding specific transcription 
factors to drive GDNF 
production is still underway. 
Activation of the protein 
kindase A (PKA), protein 
kinase C (PKC), and mitogen 
activated protein kinase 
(MAPK) pathways have all 
been found to increase GDNF expression in particular cell types (Saavedra, Baltazar and Duarte 
2008). Similarly, the transcription factors NFκB, Sp1, Ap2, and cAMP response element-binding 
protein (CREB) can all bind to the GDNF promoter and have been implicated in the gene 
expression of GDNF. Activation of multiple receptors, such as the glutamate, dopamine, adenosine 
2B, estrogen, and MT1 receptors have also been identified to modulate GDNF gene expression 
(Ho et al. 1995, D'Astous et al. 2004). Figure 5 diagrams the cellular signaling pathways and 
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transcription factors that have been associated with GDNF gene expression. Several factors that 
have been found to increase GDNF expression, such as riluzole (a sodium channel blocker), 
amitriptyline (an anti-depressant drug), and melatonin, activate the MAPK pathway and then 
increase downstream transcription factors Sp1 and AP-2 (Caumont, Octave and Hermans 2006, 
Hisaoka et al. 2001, Armstrong and Niles 2002). Interestingly, activation of the transcription factor 
NFκB, which is normally seen to increase inflammatory factors, by the reactive oxygen species 
hydrogen peroxide (H2O2) also binds to the GDNF promoter and increased gene expression 
(Saavedra et al. 2006). The cell signaling involved in the expression of GDNF is still being 
investigated, however, several well-known signaling pathways lead to increased gene expression 
and therefore could be used as therapeutic targets to increase endogenous levels of GDNF. Finding 
a factor that can activate specific pathways or transcription factors to increase endogenous GDNF 
levels could be an immensely powerful tool as a therapeutic option in neurodegenerative diseases 
such as Parkinson’s disease.  
 Although direct GDNF infusion and GDNF overexpression has demonstrated positive 
improvements in both animal models and human PD patients, there are still concerns with GDNF 
treatments. The GDNF-induced cell signaling through the Ret receptor that leads to 
neuroprotection still remains unclear. It has been shown that GDNF can lead to activation of the 
MAPK and PIP3/Akt pathway, but nothing definitive has been found in animal models of PD (Li 
et al. 2013, Nicole et al. 2001). The use of NTF therapies has an advantage over current PD 
treatments, since these proteins can protect and possibly regenerate the dopaminergic neurons in 
the SN compared to the current drugs only treating the symptoms of the disease. However, results 
indicate that neurotrophic factors alone are not able to fully protect the dopaminergic neurons in 
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some animal models of PD, such as α-synuclein models (Decressac et al. 2011), and PD patients. 
Therefore, it would be beneficial to find a factor that can work with GDNF and improve 
neuroprotection.  
 
 
Background and Literature Review II 
 
 
AVIT proteins 
 
 A non-toxic protein in Mamba snake venom was isolated in 1990 and was titled protein A 
(Schweitz, Bidard and Lazdunski 1990). This ambiguous title was later changed to Mamba 
Intestinal Toxin-1 (MIT-1) due to the ablility of this protein to potently contract gastrointestinal 
muscles (Schweitz et al. 1999).  Subsequently, proteins homologous to MIT-1 were found in other 
species, such as frogs and mammals. The frog orthologues were termed Bv8 and Bm8 due to the 
species it was found in, Bombina variegate and Bombina maxima respectively (Ferrara et al. 2004).  
The human orthologues were originally isolated in 2001 by Zhou and colleagues and were termed 
Prokineticin-1 (PK1) and Prokineticin-2 (PK2) for their ability to contract gastrointestinal muscles 
(Li et al. 2001). PK1 was then isolated by a different method and also termed Endocrine Gland-
Vascular Endothelial Growth Factor (EG-VEGF) (LeCouter et al. 2001). These homologous 
proteins all share the same amino terminal amino acid signaling sequence of AVITGA. Therefore, 
this family of proteins became known as the AVIT family (Kaser et al. 2003). Substitution of any 
one of these animo acids will block any receptor signaling from these proteins (Bullock, Li and 
Zhou 2004). Along with the AVIT signaling sequence, the members of the AVIT family all contain 
about 80-90 amino acids and 10 cysteine residues with identical spacing. These 10 cysteine 
residues for 5 disulfide bonds, and disruption of any of the disulfide bonds prevents any 
29 
 
downstream signaling. Research into the AVIT family has steadily increased over the years (Figure 
6), and the diverse biological functions of these proteins continues to expand. For instance, 
researchers have found a crustacean Prokineticin-like protein, called Astakine, that regulates 
hematopoetic stem cell proliferation and 
differentiation, and circadian rhythms in 
the invertebrate crustaceans. 
Interestingly, Astakine does not contain 
the AVIT signal sequence and has 
demonstrated the ability to bind to 
different receptors. These results 
implicate an evolutionary conserved 
function for the prokineticin domain 
containing proteins (Watthanasurorot et al. 2011). There is a total of 478 manuscripts on PubMed 
that mention AVIT family of proteins up to the year 2015. As expected, there is a significant 
increase in publications starting around 2000, when the human homologues Prokineticin-1 and 
Prokineticin-2 were isolated. However, the number of publications have continued to increase over 
every five-year span. This indicates that the AVIT family of proteins is becoming more important 
as more diverse biological functions are found every year.   
 
 
Prokineticins 
 
Prokineticins are human proteins that obtained their name because they were first 
discovered to contract smooth muscle in the gut (Li et al. 2001). The two prokineticin proteins, 
Prokineticin-1 (PK1) and Prokineticin-2 (PK2), are members of the AVIT protein family due to 
Figure 6. Number of publications that 
mention AVIT family members on Pubmed 
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the presence of the particular amino acid signaling sequence AVITGA on the N-terminus and 
contain 86 and 81 amino acids, respectively. Both PK1 and PK2 share around 45% identity in their 
amino acid sequences and are expressed on different chromosomes. In humans, the PK1 gene is 
located on chromosome 1p21 while PK2 maps to 3p21.1. PK2 can also be alternatively spliced 
with an isoform containing 21 additional amino acids known as Prokineticin-2 long form, or PK2L, 
and is cleaved to create an active form, PK2β (Chen et al. 2005). PK2 has many physiological 
functions throughout the human body. For instance, prokineticin signaling modulates the 
physiological functions the reproductive organs including roles in the ovary, uterus, placenta, and 
testis. Dysfunction in prokineticin signaling can lead to reproductive pathological conditions such 
as recurrent pregnancy loss, preeclampsia, and male infertility (Traboulsi et al. 2015). 
  The prokineticins regulate physiological functions in various tissues including gut 
motility, circadian rhythms, angiogenesis, pain perception, hematopoiesis, energy expenditure and 
olfactory bulb biogenesis. Studies also suggests that prokineticins are linked to pathologies 
myocardial infraction, immune regulation and tissue-specific cancer initiation and propagation. 
Recently, the prokineticins and their receptors were found increased in the lungs of cystic fibrosis 
patients compared to control (Chauvet et al. 2015). Prokineticin signaling has been implicated in 
the induction of cancer cell proliferation and survival through STAT3 signaling (Xin et al. 2013). 
Interestingly, PKR2 expression could be a used as a prognostic tool for colorectal cancer, with 
human patients expressing PKR2 having a significantly lower 5-year survival rate (Goi et al. 
2015). Prokineticin signaling has been implicated to be an important factor in the development of 
several organs in the body, such as the reproductive organs, pituitary gland, placenta, and 
gastrointestinal tract. It is a signaling protein that has several characteristics of a pleiotropic 
cytokine or a chemokine. PK2 can promote cell survival and growth (LeCouter et al. 2004a), and 
31 
 
in other tissues PK2 can cause an increase in inflammation  and nociception (Negri et al. 2006b). 
Genetic studies looking into nociception showed that knockout of PK2 or PKR1 caused significant 
reduction of nociception(Negri et al. 2006a). Since these proteins potently contracted gut muscles 
they named them prokineticins (Li et al. 2001), and studies looked into function ex vivo (Schweitz 
et al. 1999) and in vivo (Wade et al. 2010). However, there are conflicting results that showed 
adding PK2 protein to gut muscles does not induce contraction, but could cause contraction 
through nerves from the brain (Bassil et al. 2005). Interestingly, Kallmann syndrome, in humans, 
has been linked to mutations in PK2 or PKR2 (Pitteloud et al. 2007a). Also, some studies have 
looked into a genetic knockout of one Prokineticin receptor (PKR1) and found heart and kidney 
defects, possibly due to mitochondrial defects (Boulberdaa, Urayama and Nebigil 2011b). Many 
research studies have demonstrated important roles for the prokineticins in the course of pregnancy 
and placental development, with modulation of disorders of both the female and male reproductive 
system (Alfaidy et al. 2014, Su et al. 2014, Karaer et al. 2014, Traboulsi et al. 2015). Along the 
same lines, PK1/EG-VEGF was shown to be an important factor produced in Leydig cells and can 
regulate proliferation of vascular endothelial cells in the testis  (LeCouter et al. 2003a, Beltrame, 
Cerri and Sasso-Cerri 2015). Recently, prokineticins were found to increase insulin sensitivity and 
reduce adipose tissue expansion, which go along with previous reports that prokineticin signaling 
to the Hypothalamus acts as an anorectic peptide (Von Hunolstein and Nebigil 2015, Beale et al. 
2013). Prokineticin signaling is important for many different functions throughout the body 
(Scheme 1) and elucidating the signaling mechanism in different areas of the body, and disease 
conditions, is important in understanding the significance of PK2 expression in different diseases. 
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Prokineticin structure 
The prokineticin gene and promoter structures are highly conserved in mammals such as 
humans and mice, indicative of their functional roles in important physiological processes. 
Mammalian prokineticin genes contain four exons with the third exon being a target for alternative 
splicing in Prokineticin-2. The prokineticin protein contains a 19-residue signal peptide that targets 
the proteins for constitutive secretion within the first exon. Six of the structurally important 
cysteine residues are coded in Exon-2 and Exon-4 encodes for the other four of the ten conserved 
cysteines. An alternative splice form of prokineticin-2 has been identified, which contains a 63 bp 
insertion between exon 2 and exon 4 resulting in a longer isoform of PK2 (PK2L) that has an 
additional 21 amino-acid residues (Kaser et al. 2003, Chen et al. 2005). In the mature PK2L 
isoform, the 21 lysine and arginine rich amino acid insertion occurs between Lys47 and Val48. 
Exon-3 insertion contains two putative furin protease cleavage sites. In vitro results from co-
expression of furin with PK2L demonstrated the production of a shorter cleaved form of the protein 
(PK2β) that could still functionally activate prokineticin receptors (Chen et al. 2005). Interestingly, 
the shorter PK2β fragment showed greater selectivity for PKR1 than PKR2 whereas both PK1 and 
PK2 show no significant selectivity for either prokineticin receptor. Although some evidence 
indicates that PK2L is differentially expressed from PK2 in certain tissues, such as the lung, the 
specific function of this protein is still relatively unknown (Chen et al. 2005).  Currently there have 
not been any alternative splice forms of PK1 detected. The pI of PK2 was determined to be around 
8.85 while that of PK2L was 10.68 due to the lysine and arginine rich exon-3 insertion indicating 
that these proteins are highly basic proteins. PK1 (EG-VEGF) has demonstrated the ability to bind 
to heparin-sepharose with high affinity and it has been suggested that their bioavailability and 
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activity may be further regulated by interactions with components of the extracellular matrix due 
to the highly basic nature of these secreted proteins (LeCouter et al. 2003a).  
The transcriptional regulatory elements for PK2 are highly conserved between the mouse 
and human promoters and have been characterized in detail (LeCouter et al. 2003a, Zhang et al. 
2007b). Several transcription factors have demonstrated the ability to regulate the expression of 
PK2, including CLOCK, BMAL1, Ngn1, MASH1 and HIF1α. These transcription factors are all 
in the basic Helix-Loop-Helix (bHLH) family and bind to the specific E-box sequence 
(CACGTG). The PK2 promoter sequence contains multiple E-box elements in both the mouse and 
human promoters (Cheng et al. 2002, Zhang et al. 2007b).  The CLOCK and BMAL transcription 
factors have been found to be responsible for the expression of PK2 in the suprachiasmatic nucleus 
(Cheng et al. 2005b, Cheng 
et al. 2002, Watanabe et al. 
2007). Whereas, PK2 
expression is regulated by 
Neurogenin 1 (Ngn1) and 
MASH1 during olfactory 
bulb biogenesis. Ngn1 and 
MASH1 mutant mice also 
showed significantly 
reduced PK2 expression (Zhang et al. 2007b). PK2 was shown to be highly induced by hypoxia 
both in vivo and in cell cultures (LeCouter et al. 2003a, Shojaei et al. 2007). The PK2 promoter 
contains two putative HIF1α binding sites. These HIF1α binding sites are less than 300 nucleotides 
upstream of the transcriptional start site at -115 and -248. Therefore, PK2 gene expression is 
Figure 7. Transcriptional regulation of PK2 by basic Helix 
Loop Helix (bHLH) transcription factors 
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regulated through intricate mechanisms involving several bHLH transcription factors in distinct 
biological processes. Figure 7 details the functions and bHLH transcription factors involved in 
PK2 transcription. However, STAT3 was demonstrated to be required for PK2 expression in 
mouse bone marrow cells, so there are other transcription factors that can control PK2 expression 
systemically and possibly in the CNS (Qu et al. 2012). Interestingly, PK2 and STAT3 form a feed-
forward loop where STAT3 can increase PK2 expression, and PK2 can activate the STAT3 
pathway and lead to increased tumor cell proliferation and survival (Xin et al. 2013). PPARγ is 
another transcription factor recently found to increase PK1 protein expression.  Garnier et al found 
that PK1 expression in placental development was at least partly controlled by PPARγ, and that 
PPARγ knockout mice produced significantly less PK1 (Garnier et al. 2015). 
The protein structure of the prokineticins is a result of the highly conserved cysteine 
residues that form five disulfide bridges. The N-terminal and C-terminal ends are exposed at the 
surface of the molecule and are believed to participate in receptor binding and activation. The 
folded protein is believed to have an approximately ellipsoid shape with a net positive charge on 
one side and a hydrophobic face on the other. The core of the protein contains many charged amino 
acids, whereas some of the hydrophobic residues are exposed on the surface of the protein. A 
potential signaling mechanism emerged from the detailed NMR structure of the amphibian 
prokineticin homolog where they identified two β-hairpins at the C and N terminus of the protein 
and a single turn of 310 helix at the N terminus (Kaser et al. 2003, Morales et al. 2010).  
Receptor binding and downstream signaling is dependent on the first six N-terminal amino 
acids (AVITGA) of both prokineticins and are completely conserved in all of their invertebrate 
homologs. Addition or substitution mutations in any of the six amino acids results in an inactive 
protein. However, synthetic peptides of the first 6 or 12 amino acid residues alone do not have any 
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significant functional activity even at high doses, indicating that the N-terminal AVITG segment 
alone appears to be insufficient for activity (Bullock et al. 2004). Deletion of the AVITG region 
did not induce a structural change in the Bv8 homologue but resulted in a complete loss of activity. 
Further, the addition of synthetic AVITG-OH or AVITG-NH2 peptides in solution could not 
compensate for the loss of activity in the N-terminal truncated AVIT-mutant. Peptides lacking the 
AVITG motif did not antagonize any functional activity of the native protein and demonstrated 
that this sequence is most likely required for both receptor binding and activation (Morales et al. 
2010). Studies have also looked into mutating the cysteine residues and C-terminal amino acids. 
These studies demonstrated that substituting any of the cysteine residues that it would abolish 
receptor activation, whereas domain swapping of PK1 and PK2 found that the sequences in the C-
terminus other than the cysteine residues could be variable and still lead to functional signaling 
(Bullock et al. 2004). Bullock et al. went on to perform intricate studies using prokineticins with 
N-terminal AVITG substitution mutants and found that specific mutations at the N-terminus can 
result in mutant proteins with antagonist activity. The activation of PKR1 and PKR2 by both PK1 
and PK2 was antagonized by mutant proteins with a substitution of the N-terminal alanine with 
methionine (A1MPK1) or the addition of a methionine at the N-terminus (MetPK1). Both in vitro 
cell culture assays and in vivo experiments demonstrated that the peptide antagonists could be 
functional antagonists (Cheng et al. 2002, Cottrell, Zhou and Ferguson 2004, Ng et al. 2005). More 
research into the protein structure of the Prokineticins could lead to better understanding of the 
receptor signaling and possibly lead to more directed therapeutic approaches.  
 
Prokineticin receptors 
 
 It is thought that PK2 has such a diverse range of functions due to the fact that it has two 
known receptors that it can signal through. However, prokineticin signaling is much more complex 
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than just the existence of two receptors. The prokineticin receptors, PKR1 and PKR2, are G-protein 
coupled receptors that can both bind PK2 and have the potential to signal through different 
cascades (Zhou 2006). The two prokineticin receptors belong to the Neuropeptide Y family and 
have an unusually high degree of similarity (~85% amino acid identity) with most of the variation 
around the N-terminal region. Human PKR1 is located on chromosome 2q14 and PKR2 on 20p13. 
Studies have shown mRNA expression of both receptors have been found in several areas of the 
body, including gastrointestinal organs (Lin et al. 2002b), ovaries, testes, adrenal glands, uterus. 
In the bone marrow and the blood, both PKR1 and PKR2 have been detected in mature blood cells 
and hematopoietic stem cells (Lin et al. 2002b, Soga et al. 2002a, LeCouter et al. 2003a, Battersby 
et al. 2004, Hoffmann, Feige and Alfaidy 2006, Hoffmann, Feige and Alfaidy 2007). However, 
the expression of PKR1 has been found more in peripheral areas such as the testis, and skin, 
whereas PKR2 is expressed higher in the CNS. Interestingly, Lin et al. shows that PKR1 is 
expressed much more than PKR2 in the gut (Lin et al. 2002b). Also, evidence points to the fact 
that PK2 activates the receptors at slightly different concentrations. PK2 can activate PKR1 at 
lower concentrations than PKR2(Soga et al. 2002a). PK2β also has a unique activation 
concentration, with it binding to PKR1 about the same as PK1 but needs ten times the 
concentration of PK2 or PK1 to activate PKR2 (Chen et al. 2005). Also, some researchers (Levit 
et al. 2011) have theorized that the receptors can be phosphorylated on certain intracellular 
domains and that could lead to differential binding or other signaling factors. To complicate 
matters further, PKR2 has the ability to dimerize, as either a homodimer or heterodimer, 
and undergo domain swapping (Marsango et al. 2011). The same group went on to demonstrate 
that the PKR2 receptor is dimerized in neutrophils, and therefore could exist in vivo as a dimer 
(Marsango et al. 2011). Truncated versions of the PKR2 receptor were used to determine that the 
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transmembrane domain 5 (TM5) is important for the dimerization of the receptor and could 
modulate the function of the receptor (Sposini et al. 2015). Dimerized receptors have shown 
differential binding affinities and could activate different signaling pathways (Munoz et al.).  
Multiple proteins have been identified to interact with the prokineticin receptors and 
modulate their activation and downstream signaling. Recently, Song et al. found that the Snapin 
protein can interact with the C-terminus of the PKR2 receptor. Snapin deficiency did not affect the 
calcium mobilization induced by the PKR2 receptor, but led to faster degradation of PKR2 after 
agonist stimulation. Therfore, Snapin could regulate receptor recycling or cellular trafficking of 
PKR2 (Song et al. 2016). PKR2 has also been found to associate with the extracellular matrix 
glycoprotein Anosmin 1, another protein associated with Kallmann’s syndrome. Anosmin 1 
directly binds to and increases Fibroblast Growth Factor receptor 1 (FGFR1) activation and leads 
to downstream functions such as neurite outgrowth and cytoskeletal rearrangements (Hu et al. 
2004, Murcia-Belmonte, Astillero-Lopez and Esteban 2016). Melanocortin Receptor Accessory 
Protein 2 (MRAP2) can inhibit PKR1 activation and therefore lead to increased food intake (Chaly 
et al. 2016). This interaction could be an important therapeutic avenue for patients with eating 
disorders, with MRAP2 leading to increased food intake whereas PKR1 leads to reduced food 
intake. Research into other proteins that associate with the prokineticin receptors could lead to new 
cell signaling pathways that the prokineticins can regulate. 
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The prokineticin receptors, 
especially PKR2, have been found to 
be mutated at several different sites 
(Figure 8), and that some of these 
mutations could lead to differential 
downstream signaling (Libri et al. 
2014). Levit et al. suggested that 
Thr178 in human PKR1 and Thr169 
in human PKR2 in the second intracellular loop along with Tyr365 in human PKR1 and Gln356 
in human PKR2 may represent subtype-specific phosphorylation-related sites in the cytoplasmic 
side of the receptors by using prediction tools for phosphorylation sites (Levit et al. 2011). The 
intracellular loop 3 of PKR2 has also been found to impact receptor trafficking and G-protein 
coupling (Zhou et al. 2013). Interestingly, four different mutations in PKR2 (R85C, R85H, R164Q, 
V331M) were found to have defective Gq signaling, however the receptor could still recruit β-
arrestins with PK2 treatment, which could lead to differential signaling from wild type PKR2 
receptor. In particular, the R268C mutation could only signal to Gs and Gq proteins, but not the 
Gi protein, and could have a protective effect (Sbai et al. 2014). Over 20 mutations PKR2 have 
been shown to result in either human Kallmann syndrome or hypogonadotropic hypogonadism 
(HH), with six such mutations affecting cell trafficking of the receptor. The amino acid Arg80 on 
the intracellular loop of PKR2 is important for the expression of this protein, and an R80C mutation 
in this intracellular loop 1 of PKR2 leads to a dominant negative effect on wild-type PKR2 (Abreu 
et al. 2012). Interestingly, the L173R mutation in the PKR2 protein is associated with the 
gonadotropin releasing hormone (GnRH) deficiency in humans and is estimated to have an age of 
Figure 8. Known mutations in the PKR2 gene 
that cause functional impairment and their 
location in the protein 
Zhang et al 2009 
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9000 years (Avbelj Stefanija et al. 2012). However, Su et al. found that there are two genetic 
variants of the prokineticin receptors, I379V in PKR1 and V331M in PKR2, could reduce the 
possibility of recurrent miscarriage (Su et al. 2013). Similary, the V67I variant of PKR1 could 
potentially downregulate PK1 expression and regulate human early pregnancy (Su et al. 2016). 
The differential expression of the prokineticin ligands and receptors throughout tissues in the body 
leads to differential cell signaling for distinct biological processes, and mutations in the 
prokineticin receptors have demonstrated the ability to change the signaling pathways. 
Prokineticin receptor mutations in humans could have diverse biological consequences in both 
health and disease, and require further study to investigate the functions of these mutations.  
The role of each prokineticin receptor is still not fully known in most physiological 
processes, however overexpression and knockout studies have provided insight into the potential 
roles for each prokineticin receptor in certain physiological processes. Chen et al. demonstrated 
that a PKR2 antagonist and glycerol could induce cellular trafficking of the PKR2 receptor to the 
cell surface and potentially treat patients with Kallmann’s syndrome with this trafficking issue 
(Chen et al. 2014). Along the same lines, PKR2 knockouts or null mutations could recapitulate 
Kallmann’s syndrome and HH in mouse models (Pitteloud et al. 2007a, Abreu et al. 2008). 
Similarly, PKR2 knockout mice demonstrate a dysfunction in olfactory bulb development to go 
along with hypoplasia and severe atrophy of the reproductive organs. PK2-PKR1 signaling has 
been studied using PKR1 knockout mice, and found impaired pain sensitization and nociceptive 
responses, similar to that which is found with PK2 knockout mice (Hu et al. 2006a, Negri et al. 
2006a, Giannini et al. 2009). The two Prokineticin receptors have drastically different roles in the 
cardiovascular system, where overexpression of PKR2 in the mouse heart induces hypertrophy 
and capillary vessel leakage without angiogenesis. However, the targeted overexpression of PKR1 
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induced neovascularization of the heart (Urayama et al. 2008). Similarly, Urayama et al. went on 
to demonstrate that signaling through PKR1 was able to protect cardiomyocytes from cell death, 
whereas signaling through PKR2 induced hypertrophy and impaired endothelial integrity 
(Urayama et al. 2007a, Urayama et al. 2009). An antibody directed to PK1/EG-VEGF found that 
reduction of PK1 signaling and demonstrated that PK1 induced angiogenesis in embryonic tissue 
(Feflea et al. 2012). Mitochondrial defects and increased apoptosis in both heart and kidney tissues 
were a result of PKR1 knockout (Boulberdaa et al. 2011a). These knockout and overexpression 
studies verify that differential expression and availability of the two prokineticin receptors regulate 
a broad range of physiological processes.  
The development of chemical agonists and antagonists to both of the prokineticin receptors 
would elucidate many of the unknown roles prokineticins play in health and disease, and allow the 
characterization of signaling pathways that are controlled by either of these receptors. Chemical 
antagonists of the prokineticin receptors were first developed in 2008 based on triazine and 
pyrimidindione derivatives (Balboni et al. 2008, Giannini et al. 2009, Ralbovsky et al. 2009). The 
trizaine-based compounds were found to be highly selective for PKR1 in functional assays with 
almost 70-fold less potency as a PKR2 antagonist. PC-1, the first generation of the triazine 
compounds, was used to inhibit PK2 signaling in the chronic constriction model, and found that 
PK2 increases peripheral nerve neuropathic pain (Lattanzi et al. 2015). Similarly, the next 
generation of traizine antagonists were tested in models of inflammatory pain and found to be 
highly effective as anti-hyperalgesic drugs (Giannini et al. 2009). The newest generation of triazine 
compounds (PC-27) actually has an IC50 that is 100 times more potent than the first generation of 
triazine compounds (PC-1) (Congiu et al. 2014). Another antagonist was produced as a brain 
permeant 3-pyrrolidine carboxamide, with an IC50 of 5nM and 8nM for PKR1 and PKR2, 
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respectively (Curtis et al. 2013). Gasser et al. then formulated a chemical non-peptide agonist to 
the PKR1 receptor, and found that this agonist was able to protect cardiomyocytes from cell death 
through the MAPK and Akt pathways (Gasser et al. 2015). Currently there are no specific PKR2 
agonists, and all of the chemical antagonists inhibit both of the prokineticin receptors. Genetic 
knockdown of the two receptors using siRNA were useful in demonstrated that the signaling is 
more dominantly through PKR1 (Guilini et al. 2010). Therefore, more research into separating the 
functions of the two prokineticin receptors could elucidate how to control prokineticin signaling 
in different tissues and disease models.  
 
Prokineticin signaling pathways 
The two prokineticin receptors belong to the neuropeptide Y (NPY) receptor class of 
GPCRs which can promote intracellular calcium mobilization, cAMP accumulation and 
phosphoinositol turnover (Lin et al. 2002b, Masuda et al. 2002a). GTPγS displacement 
experiments were the first findings to demonstrate that prokineticins signaled through GPCRs (Li 
et al. 2001). Since the receptors are GPCRs, signaling also depends on the G-protein that is 
activated by the receptor. The prokineticin receptors signal through the Gi, Gq, and Gs 
proteins(Chen et al. 2005). The signaling pathways downstream of the receptors have begun to 
be elucidated in recent years and have been shown to depend on the G-protein involved. The 
majority of the known cell signaling pathways and functions of prokineticin signaling are shown 
in Figure 9. Prokineticins activate the MAP kinase pathway most likely through Gi signaling, 
calcium mobilization through Gq signaling, and increased Akt and cAMP levels through Gs 
signaling (Chen et al. 2005). Different tissues can therefore express the 3 ligands, 2 receptors, or 
3 G-proteins in distinct manners along with receptor phosphorylation and therefore lead to tissue 
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specific functions. Specific downstream pathways activated however remain to be elucidated, 
particularly the transcription factors activated by prokineticin signaling to mediate their functional 
effects have not been defined. Both ligands activate the two receptors almost equally, therefore 
indicating that signaling studies can be related to both proteins. Li et al. performed the first study 
to characterize the prokineticins and found that recombinant PK1 and PK2, even in the nanomolar 
ranges, induced calcium influx into the cell. They went on to find that this calcium influx was 
required for prokineticin-induced contraction of the gastrointestinal smooth muscle (Li et al. 
2001). Several common signaling pathways are activated by prokineticin signaling in different cell 
types and areas of the body.  
Several studies have characterized a similar downstream pathway leading to cell survival 
and proliferation. Lin et al. used a treatment with Prokineticin-1 in adrenal cortex-derived 
endothelial (ACE) cells which led to a dose and time-dependent increase in cell proliferation and 
migration through the activation of p44/42 MAPK pathway. The same group went on to 
demonstrated that PK1 treatment also activated the Akt pathway, which is a known survival signal 
for these cells. The Akt activation then led to increased endothelial nitric-oxide synthase (eNOS) 
(Lin et al. 2002b). The Akt pathway is also activated by PK1 treatment and similarly induces 
proliferation and survival of neuroblastoma cells. The cell survival induced in these neuroblastoma 
cells by PK1 treatment was mediated by PKR2, whereas the cell proliferation needed the 
expression of both prokineticin receptors. Similarly, the Mitogen-activated protein kinase (MAPK) 
and Akt pathways were activated by PK1 treatment in enteric neural crest cells, which also led to 
an increase in cell proliferation and differentiation (Ngan et al. 2007). Phosphorylation of the 
MAPK, Akt pathways was also demonstrated with PK1 treatment in multiple myeloma cells. Li et 
al. found that multiple survival signaling pathways could be activated downstream of the 
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prokineticin receptors. PK1 signaling also caused the activation of STAT3 and upregulated 
Sphingosine kinase (SphK) along with the potent anti-apoptotic Bcl-2 family member Mcl-1 in 
myeloma cells (Li et al. 2010).  Similarly, prokineticins act as autocrine mitogenic factor in 
endocrine endothelial cells, 
which was demonstrated with 
PK1 treatment resulting in 
phosphorylation and activation 
of the extracellular signal-
regulated kinase 1 and 2 
(ERK1/2) (Keramidas et al. 
2008). PK1 also acts as a survival 
factor by activating the Akt and 
MAPK pathways in placental cell 
extracts and umbilical vein-
derived macrovascular endothelial cells (HUVEC) (Brouillet et al. 2010). Interestingly, PK2-
PKR1 signaling activated Akt in cardiomyocytes to protect against oxidative stress and promote 
angiogenesis (Urayama et al. 2007a). These results were confirmed with in vivo studies using a 
selective PKR1 agonist, that demonstrated cardiomyocyte protection from a myocardial infarction 
through the MAPK and Akt pathways (Gasser et al. 2015).  
Prokineticin treatment has been found to activate signaling pathways other than MAPK 
and Akt, leading to an expanded physiological role throughout the body. In endometrial epithelial 
Ishikawa cells, PK1 signaling went through the calcineurin/NFAT pathway to induce the 
expression and secretion of IL-8 and IL-11 cytokines (Maldonado-Perez et al. 2009, Cook et al. 
Figure 9. Cell signaling pathways involved for 
prokineticin signaling through PKR1 and PKR2, and 
the functions/disease this signaling modulates 
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2010). Waddell et al. found that PK1 treatment in these same cells increased CTGF, or connective 
tissue growth factor, via Gq, phospholipase C (PLC), cSrc, growth factor (EGFR), and the MAPK 
signaling pathways (Waddell et al. 2011).  Nitric oxide release was increased with PK1 treatment 
in longitudinal muscle-myenteric plexus cultures, which then inhibits spontaneous giant 
contractions in the circular muscle of the mouse proximal colon (Hoogerwerf 2006). Prokineticin-
1 signaling is important for normal angiogenesis of the placenta and could modulate placental 
pathologies (Alfaidy et al. 2014). Interestingly, PK1 is highly expressed and was defined as a novel 
mediator of the inflammatory response in the third-trimester placenta, based on the induction in 
the expression of IL-8 and COX-2 (Denison et al. 2008). Seidmann et al. demonstrate that a 
balance between PK1 expression and FGF is necessary to prevent fetal hypoxia, and that PK1 
modulates functional capillarization in late pregnancy (Seidmann et al. 2013). Another function of 
prokineticin signaling is the down regulation of B7-1, CD-14, CC chemokine receptor 5 and CXC 
chemokine receptor 4 in human peripheral blood monocytes induced by PK1 treatment and induces 
morphological changes in these cells (Dorsch et al. 2005).  
Prokineticin signaling has also been studied some in the CNS, with the presumed signaling 
through the more dominantly expressed PKR2 receptor. For instance, PK2 is able to induce a dose-
dependent depolarization of subfornical organ neurons and can regulate voltage-activated 
potassium channels through the MAPK signaling pathway and sodium channels (Cottrell et al. 
2004, Fry, Cottrell and Ferguson 2008). PK2 is also able to increase the activity of acid-sensing 
ion channels, which is dependent on the PKC signaling pathway in rat primary sensory neurons. 
This indicates that PK2 increases pain sensation from acidosis through acid sensing ion channels 
(Qiu et al. 2012). Similarly, through a PKC-epsilon dependent signaling pathway, Bv8 was able 
to increase in the inward currents caused by heat and the transient receptor potential vanilloid 1 
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(TRPV1) capsaicin receptor (Vellani et al. 2006). Another PKC-dependent role for prokineticin 
signaling was demonstrated in rat trigeminal ganglion neurons, where PK2 treatment reduced 
inward currents produced upon GABA(A) receptor activation involved in pain perception. This 
effect was blocked with a pan PKC inhibitor bur the PKA inhibitor H89 was not able to inhibit the 
inward current reduction.   
The current information about prokineticin signaling is not very detailed. The majority of 
the cell signaling studies for downstream pathways of the prokineticin receptor involve the 
commonly activated MAPK and Akt pathways. However, detailed signaling mechanisms have yet 
to be elucidated for many cell types and tissues. Collectively, the current information related to 
prokineticin signaling demonstrate that there is a potential for diverse signaling pathways 
activation downstream of the prokineticin receptors. Cell survival, differentiation, migration, and 
cell excitability are the main cellular functions controlled by prokineticin signaling, depending on 
the cell type and physiological function of the tissue. Several cell types, including cardiomyocytes, 
endothelial cells, neural crest cells and myeloid cells have increased cell survival from 
prokineticin-induced activation of Akt and ERK1/2. More research into the signaling pathways for 
the prokineticin receptors could elucidate many of the physiological roles that these signaling 
peptides play throughout the body.  
 
Prokineticin-2 in inflammation 
 
 Prokineticin-2 expression has been found to be increased with tissue inflammation in 
different areas throughout the body. Recently, the prokineticins have been found to be increased 
with tissue inflammation in lung (Chauvet et al. 2015), gut (Watson et al. 2012), bladder (Chen et 
al. 2015a), testis (Chen et al. 2016), spinal cord (Abou-Hamdan et al. 2015), and brain (Cheng et 
al. 2012). The role of prokineticin signaling in the propagation of inflammation has been studied 
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by several groups that demonstrate blockage of PK2 signaling can reduce the level of inflammation 
in the tissue.  Martucci et al. demonstrated that sub-nanomolar ranges of PK2 could induce 
chemotaxis of macrophages and potentiate LPS-induced IL-1 and IL-12 proinflammatory 
cytokines, while reducing the anti-inflammatory cytokine IL-10 (Martucci et al. 2006). The Gq 
proteins seem to be responsible for the effects of PK2 on macrophages, due to the fact that the 
phospholipase inhibitor U73122 blocked the signaling. In primary mouse splenocytes, PK2-PKR1 
signaling was demonstrated in vitro and in vivo using receptor knockout mice. Amphibious Bv8 
treatment induced the production of IL-1beta and treatment at levels between picomolar and low 
nanomolar decreased IL-4 and IL-10 levels in these cultured mouse splenocytes. A PKR1 
knockout mouse was unable to elicit this PK2-induced effect, therefore pointing to the PKR1 
receptor as being responsible for skewing the cell towards the production of proinflammatory 
factors (Franchi et al. 2008). Interestingly, granulocyte colony-stimulating factor (G-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) increased the expression of PK2 in 
isolated neutrophils.  PK2 was also demonstrated to be a potent chemotactic factor for neutrophils 
most likely via PKR2 signal transduction since PKR1 mRNA was not detected in these cells. PK2 
was highly expressed in tumor-infiltrating neutrophils and isolated PK2 from neutrophils was 
found to be fully active in vitro. The involvement of Gi proteins in prokineticin GPCR signal 
transduction in haematopoietic cells was further demonstrated by the discovery that PK2-induced 
hematopoiesis and mobilization of hematopoietic cells were found to be pertussis toxin sensitive 
(LeCouter et al. 2004a, Zhong et al. 2009). Dorsch et al. found that monocytes treated with PK1 
had increased levels of IL-12 and TNFα and decreased IL-10 production in response to LPS 
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stimulation. Whereas other groups demonstrated an increase in  CCL4, CXCL1 and CXCL8  with 
PK1 treatment in monocytes but not macrophages or dendritic cells (Dorsch et al. 2005, Monnier 
et al. 2008). 
There have been many studies on the effects of prokineticin signaling in the different cell 
types of the blood. However, there have not been any extensive studies to detail signaling pathways 
downstream of the prokineticin receptor that would lead to an increase in inflammation. 
Additionally, the studies that have implicated prokineticin signaling in the induction of 
inflammation use the recombinant proteins mainly in the picomolar range or with amphibious Bv8 
in mammalian cells. Due to the fact that there are two receptors and that the signaling of this 
molecule is highly regulated at the receptor level, with heterodimerization and phosphorylation 
leading to differential signaling, studies into higher doses and more intricate cell signaling would 
be appropriate. 
 
 
Prokineticin-2 in the CNS 
 
Prokineticin 2 signaling has been studied in several areas of the brain, and the prokineticin 
receptors are expressed in many areas of the central nervous system. Interestingly, PK1 has only 
been found expressed in low levels throughout the CNS except in the nucleus tractus solitarus and 
lateral reticular nucleus of the hindbrain, and therefore PK2 is the dominant prokineticin signaling 
molecule in the CNS. In situ hybridization experiments performed by Cheng et al. detailed the 
regional expression of PK2 and its two prokineticin receptors across the entire mouse brain (Cheng 
et al. 2002). PK2 expression was also determined using the GENSAT EGFP-PK2 transgenic 
mouse in which the expression of the EGFP reporter protein is driven by the PK2 promoter (Zhang, 
Truong and Zhou 2009). Images from the olfactory bulb and superchiasmatic nucleus from eGFP-
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PK2 transgenic mice is shown in Figure 10. PKR2 is expressed higher in the CNS than PKR1, 
however, studies have indicated that PKR1 is expressed at a higher rate in immune cells such as 
microglia (Zhou 2006). Olfactory bulb neurogenesis is an important function that has been 
attributed to PK2 signaling in the CNS. Ng et al. demonstrated that if you remove PK2 using 
knockout mice, that there was a reduction in the size and architecture of the olfactory lobe (Ng et 
al. 2005). The transcription of PK2 in this region of the brain was found to be under the regulation 
of the proneural transcription factors Neurogenin 1 and MASH1 which bind at conserved E-box 
sites on the PK2 promoter to activate transcription (Zhang et al. 2007b). Interestingly, migrating 
neuroblasts and subventricular zone transient-amplifying progenitors in the adult mouse brain were 
found to express PKR2 (Puverel et al. 2009). PK2 expression was also identified to be associated 
with areas of active neuronal migration and proliferation in the adult zebrafish brain during normal 
development and during post-injury telencephalon regeneration (Ayari et al. 2010). This research 
indicates that PK2 acts as a chemoattractant that causes neural progenitor cells to migrate through 
the rostral migratory stream towards the olfactory bulb and possibly induce neuronal 
differentiation. Recent studies have indicated that PK2 is an important factor in the 
superchiasmatic nucleus regulating circadian rhythms (Zhou and Cheng 2005, Li, Hu and Zhou 
2009, Li et al. 2006b, Burton et al. 2016). In response to light there is an induction of PK2 within 
the superchiasmatic nucleus possibly in AVP-positive cells, and circadian rhythms become 
dysfunctional when either PK2 or PKR2 is knocked out (Mieda et al. 2015). PK2 also has the 
ability to induce its own transcription in the SCN through PKR2 signaling in a positive feedback 
loop. The PKR2 receptor is expressed in various SCN output areas including the paraventricular 
hypothalamic nucleus (PVN), dorsal medial hypothalamic nucleus (DMH), paraventricular 
thalamic nuclei (PVT). Therefore, PK2 is increased in the SCN and could potentiate signaling in 
49 
 
output areas through PKR2 signaling. Along the same lines, PK2 signaling has also been 
demonstrated to modulate the excitability of certain subsets of subfornical neurons, which would 
suggest a potential role for regulating autonomic function (Yuill et al. 2007). Collectively these 
studies indicate that PK2 is an important mediator for circadian rhythms and the autonomic 
functions associated with them. Zhou et al. also used PK2 knockout mice to show that PK2 is 
involved in thermo-regulation and energy expenditure (Zhou et al. 2012). This study demonstrated 
that PK2 expression was increased in the paraventricular nucleus (PVN) after fasting, and then 
returned to normal after the addition of food. This research indicates that PK2 is at least partly 
responsible for energy uptake and expenditure and that PK2 increase in the PVN could help 
animals survive better when there is little food uptake. Interestingly, PK2 expression in the 
hypothalamus was reduced when an animal was fasting, and acute or chronic administration of 
PK2 caused the animals to 
eat less food (Gardiner et 
al. 2010). Along the same 
lines, exogenously added 
PK2 signals through the 
PKR1 receptor in the 
brainstem and leads to 
reduced food intake and 
body weight in mice (Beale et al. 2013). Therefore, PK2 can signal in several areas of the brain 
that can lead to reduced food intake and weight loss, indicating that it is an anorectic peptide. PK2 
signaling has been widely studied in the different areas of the brain and they have demonstrated a 
wide range of important functions throughout the CNS.  
Figure 10. Immunofluorescent images of GFP-positive cells 
in the mouse olfactory bulb and suprachiasmatic nucleus of 
untreated PK2-eGFP mice 
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There have been mixed results with PK2 in diseases of the CNS, with neuroprotection seen 
in some models and neurodegeneration seen in others. The first results of PK2 signaling in 
neurodegeneration were reported in 2001 by Melchiorri et al., demonstrating that mouse Bv8 could 
support neuronal survival against NMDA excitotoxicity in the mouse cortex and cerebellum 
through the MAPK/PI3K pathway (Melchiorri et al. 2001). The neuroprotection conferred by 
mouse Bv8 was seen in a mouse co-culture of cortical neurons and astrocytes. However, it took 
another decade before more research went into prokineticin signaling in neurodegeneration. 
Interestingly, Cheng et al. found that Prokineticin-2 is increased in a model of stroke. While 
picomolar concentrations of PK2 increased the infarct volume, a prokineticin receptor antagonist 
was able to reduce the infarct volume (Cheng et al. 2012). However, in 2016 Landucci et al. 
demonstrated that prokineticin signaling could be neuroprotective in a cell culture model of 
ischemia through the ERK1/2 and Akt pathways (Landucci et al. 2016). These results are more in 
line with the cell signaling that has been seen with prokineticin receptor activation. The largest 
difference in the two studies is the dose of Prokineticin-2 or Bv8 used, with Cheng et al. looking 
at a picomolar dose and Landucci et al. with a nanomolar concentration. There has only been one 
study on prokineticin signaling in Alzheimer’s disease (AD) that came out in 2015. They found 
that PK2 expression was increased in animal models of AD and that using a prokineticin receptor 
antagonist there was a reduction in Amyloidβ-induced cell death of cortical neurons (Severini et 
al. 2015). Recently, a study found that PK2 expression is increased in CNS autoimmunity animal 
models and that blocking this increased PK2 in the spinal cord of animals led to a reduction in 
inflammation and demyelination. However, the study also points out that using the prokineticin 
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receptor antagonist reducted production of IL-6, which is normally pro-inflammatory (Abou-
Hamdan et al. 2015). Prokineticin signaling is a very complicated mechanism and has shown 
differing disease outcomes depending on the situation and dose of PK2. Severini et al. went on to 
discuss that their results could be due to the use of low (picomolar) ranges of PK2. Currently, there 
has been no research into overexpressing PK2 in the healthy or diseased CNS (Severini et al. 
2015).  
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Abstract 
Prokineticin-2 (PK2), a recently discovered secreted protein, regulates important 
physiological functions including olfactory biogenesis and circadian rhythms in the CNS. 
Interestingly, although PK2 expression is low in the nigral system, its receptors are constitutively 
expressed on nigrostriatal neurons. Herein, we demonstrate that PK2 expression is highly induced 
in nigral dopaminergic neurons during early stages of degeneration in multiple models of 
Parkinson’s disease (PD), including PK2 reporter mice and MitoPark mice. Functional studies 
demonstrate that PK2 promotes mitochondrial biogenesis and activates ERK and Akt survival 
signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression is 
protective whereas PK2 receptor antagonism exacerbates dopaminergic degeneration in 
experimental PD.  Furthermore, PK2 expression increased in surviving nigral dopaminergic 
neurons from PD brains, indicating that PK2 upregulation is clinically relevant to human PD. 
Collectively, our results identify a paradigm of compensatory neuroprotective PK2 signaling in 
nigral dopaminergic neurons that could have important therapeutic implications for PD.  
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Introduction 
Prokineticin-2 (PK2), of the AVIT protein family, regulates diverse physiological 
processes including hematopoiesis, angiogenesis, reproductive functions, and pain perception 
(Cheng et al. 2002, Hu et al. 2006b, Li et al. 2006a, Lin et al. 2002a, Ng et al. 2005, Pitteloud et 
al. 2007b). In the brain, PK2 regulates circadian rhythms by functioning as an output molecule 
from the suprachiasmatic nucleus (SCN) and neurogenesis by directing the migration of progenitor 
cells from the subventricular zone during olfactory bulb biogenesis (Ng et al. 2005, Cheng et al. 
2002, Cheng et al. 2005b). Recent evidence also links PK2 signaling to thermoregulation and 
energy expenditure via the hypothalamus (Zhou et al. 2012). Constitutive expression of PK2 is 
largely restricted to these aforementioned regions, however, its two highly similar G-protein-
coupled receptors (GPCR), PKR1 and PKR2, are ubiquitously and differentially expressed across 
the central nervous system (CNS), reflecting PK2’s distinct functions throughout the brain (Cheng, 
Leslie and Zhou 2006a).  
While investigating changes in gene expression during dopaminergic cell death via PCR-
array, we surprisingly found that PK2 mRNA was highly induced during dopaminergic (DAergic) 
cell death triggered by tumor necrosis factor alpha (TNFα) (Gordon et al. 2012). We therefore 
hypothesized that PK2 is a novel signaling mediator secreted during dopaminergic degeneration. 
Supporting this notion, our mouse models of PD revealed that PK2 is induced in nigral 
dopaminergic neurons early during degeneration, prior to the onset of motor deficits. We also 
found that PK2 expression is elevated in the substantia nigra (SN) of PD patients, corroborating 
PK2’s clinical relevance in human PD. PK2 activates PKR1 and PKR2, both of which are 
differentially expressed in the CNS (Lin et al. 2002a, Soga et al. 2002b, LeCouter et al. 2003b, 
Shojaei et al. 2007). We found that PKR2 is constitutively expressed in dopaminergic neurons of 
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the nigrostriatal system in mice and human PD cases, suggesting that PK2 signaling via PKR2 
could be relevant during dopaminergic degeneration. Indeed, our functional studies using PK2 
overexpression and recombinant PK2 (rPK2) demonstrated that PK2 signaling protects against 
oxidative stress, mitochondrial dysfunction and dopaminergic degeneration induced by the 
Parkinsonian neurotoxicant MPP+. Blocking PK2 signaling using a PK2 receptor antagonist 
augmented dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by 
AAV gene delivery was neuroprotective. Given that prokineticin GPCRs are druggable targets and 
that PK2 signaling is neuroprotective against dopaminergic degeneration, our results have 
potential therapeutic implications for mitigating dopaminergic neuron loss in PD using 
prokineticin receptor agonists.  
 
 
Results 
PK2 is induced during MPP+- and TNFα-induced N27 cell death  
Using qPCR-array, we serendipitously discovered that PK2 mRNA expression is highly 
induced (~7-fold over control) early during dopaminergic cell death (Supplementary Table. 1). 
Thus, we hypothesized that PK2 is likely a compensatory bioactive signaling mediator secreted 
early during dopaminergic degeneration. To validate this hypothesis, we determined both TNFα 
(30 ng/ml) and the Parkinsonian toxicant MPP+ (200 μM) increased PK2 protein expression in 
N27 cells (Fig. 1A). PK2 supernatant levels also increased, demonstrating that PK2 is both 
upregulated and secreted by dopaminergic neuronal cells following neurotoxic stress. A rabbit 
polyclonal antibody that recognizes an epitope within the internal region of PK2 was used for 
immunofluorescence detection of PK2 expression and localization in N27 dopaminergic cells (Fig. 
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1B). Typical of a secreted protein, PK2 accumulated prominently around the perinuclear zone 
(arrow heads). Indeed, PK2 contains a signal peptide at its N-terminus targeting it for constitutive 
secretion (LeCouter et al. 2003b, Li et al. 2001). Our results identify PK2 as an inducible secreted 
mediator during early stages of neurotoxic stress.   
  
PK2 is induced in nigral DAergic neurons in experimental PD  
Previous studies characterizing PK2 expression in the adult mouse brain reported it either 
absent or sparse in the ventral midbrain, including the SN (Cheng et al. 2006a, Zhang et al. 2009). 
Since PK2 receptors were constitutively expressed mostly on neurons, it’s possible that PK2 ligand 
expression could mediate specific signaling functions via its cognate receptors. Initially, using the 
standard acute (4 x 18 mg/kg, 2-h intervals) MPTP model of PD, we verified, in concordance with 
our in vitro results, that MPTP significantly increased PK2 levels in nigral tissue lysates. Western 
blot (Fig. 2A) and densitometric analysis (Fig. 2B) revealed that upregulation occurred as early as 
3 h after MPTP treatment and peaked at 24 h in MPTP-treated mice. Reduced nigral levels of 
tyrosine hydroxylase (TH), a marker of dopaminergic neurons, was not observed until 3 days post-
treatment, suggesting MPTP-induced PK2 upregulation precedes dopaminergic degeneration (Fig. 
2A). No significant difference in PKR2 expression existed between MPTP-treated and saline-
injected control mice (Fig. 2A). We confirmed that PK2 staining co-localized largely with TH-
positive (TH+) dopaminergic neurons (Fig. 2C). PK2 upregulation was not observed in the striatum 
or cortex (Supplementary Fig. 1). In saline-treated mice, we observed little to no PK2 expression, 
and no distinct cellular staining patterns, which supports Cheng et al. (Cheng, Leslie and Zhou 
2006b), who characterized PK2 expression throughout the entire adult mouse brain by in situ 
hybridization without finding significant expression in the SN pars compacta (SNpc). We also 
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confirmed PK2 mRNA upregulation in the nigra (Fig. 2D). Two GPCRs for PK2, prokineticin 
receptors 1 and 2 (PKR1/2), have been identified and cloned by independent groups (Lin et al. 
2002a, Masuda et al. 2002b, Soga et al. 2002b). We determined their expression in the SN of both 
saline- and MPTP-treated mice. Cellular PKR2 was highly expressed on dopaminergic neurons 
and colocalized with TH staining revealing a punctate pattern of PKR2 staining evident at higher 
magnification (Fig. 2E). Unlike the PK2 ligand, MPTP did not alter the constitutive expression of 
PKR2 in the SN (Fig. 2E).  
To further confirm PK2 upregulation in dopaminergic nigral neurons, we used GENSAT 
BAC PK2 eGFP transgenic mice [Tg (Prok2-eGFP) FH64Gsat]. This transgenic mouse contains 
an eGFP reporter transgene and a polyadenylation sequence introduced between the PK2 promoter 
and the first coding exon of the PK2 gene (Heintz 2004, Gong et al. 2003). Transcription of the 
eGFP reporter is driven by PK2 promoter activation, and is terminated at the polyadenylation site, 
so that reporter expression occurs without any changes in native PK2 expression. Consistent with 
reported constitutive PK2 expression in the SCN and olfactory bulb (Cheng et al. 2002, Cheng et 
al. 2005b), we observed high eGFP fluorescence in these regions in the adult PK2-eGFP mouse 
brain (Supplementary Fig. 2A), confirming the utility of this model for our studies. PK2-eGFP 
mice were treated with MPTP (4 x 20 mg/kg, 2-h intervals). In nigral sections from saline-treated 
mice, eGFP fluorescence was undetectable (Fig. 2F). However, in MPTP-treated mice at 24 h, 
strong eGFP fluorescence was evident along the nigral tract with most of the eGFP-positive cells 
being TH-positive dopaminergic neurons. Some TH-negative cells in the nigral tract were also 
labelled with eGFP (Fig. 2F), representing less than 5% of the PK2-positive cells in the SN; 
however, the identity of these PK2-positive cells is unclear. We also confirmed our IHC findings 
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by Western blotting PK2 and GFP (Supplementary Fig. 2B). Together, these results demonstrate 
that PK2 is highly expressed in nigral dopaminergic neurons of PK2-eGFP mice following MPTP-
induced degeneration.  
The acute MPTP model exhibits rapid dopaminergic degeneration. To verify if PK2 is 
upregulated in a more gradual and progressive model of dopaminergic degeneration, we utilized 
the MitoPark mouse, which is an L-DOPA-responsive transgenic model of PD generated by 
targeted inactivation of the mitochondrial transcription factor A (Tfam) gene in dopaminergic 
neurons. Thus, mitochondrial dysfunction drives progressive dopaminergic degeneration in 
MitoPark mice over a period of 32 weeks and is accompanied by behavioral motor deficits 
(Ekstrand and Galter 2009, Ekstrand et al. 2007). We investigated whether PK2 upregulation 
occurred at time points preceding the onset of motor deficits in MitoPark mice, which have been 
reported to begin at around age 12 weeks (Ekstrand and Galter 2009, Ekstrand et al. 2007). First, 
we confirmed the time course of MitoPark motor deficits and found no significant motor 
impairments at 8 weeks compared to age-matched wild-type C57 controls (Fig. 2G-H, and 
Supplementary Fig. 3). PK2 expression increased significantly at 8 and 12 wk (Fig. 2I). Consistent 
with our observation that PK2 upregulation precedes dopaminergic neurodegeneration, no 
significant loss of nigral TH protein was evident in MitoPark mice at 8 weeks (Fig. 2I). We also 
confirmed that PK2 was localized to TH+ nigral dopaminergic neurons in 12-wk-old MitoPark 
mice (Fig. 2J). Overall, these results demonstrate that PK2 is upregulated specifically in nigral 
dopaminergic neurons following both acute and progressive dopaminergic degeneration. 
Constitutive PK2 receptor expression on adjacent nigral dopaminergic neurons suggests that PK2 
has autocrine/paracrine signaling roles as a compensatory response following dopaminergic 
neuron injury and degeneration.    
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PK2 is elevated in the substantia nigra of PD brains 
Nigral tissue lysates from the postmortem brains of PD patients (Supplementary Table 2) 
and age-matched controls were probed for PK2 protein expression by Western blotting. Increased 
PK2 expression was evident in PD brains with significantly lower expression in age-matched 
control subjects (Fig. 3A and Supplementary Fig. 4A). Densitometric analysis of PK2 band 
intensities from 10 controls and 10 PD samples indicated that PK2 levels in PD brain lysates were 
about 2-fold higher (Fig. 3B). For reasons not clear at present, in contrast to mouse brains, we 
observed a small amount of PK2 in control human brains. Perhaps a higher basal level of PK2 
expression occurs in human brains compared to mice, or the effect is age-related. We also 
confirmed increased neuronal PK2 expression in DAB-stained postmortem nigral tissue sections 
obtained from PD patients relative to age-matched controls (Fig. 3C). PK2 and TH co-labeling 
(Fig. 3D) revealed that PK2 was largely absent on TH+ dopaminergic neurons in control brain 
sections. However, in PD brain sections, intense and specific PK2 staining was localized to 
surviving TH+ dopaminergic neurons. Together, these results demonstrate for the first time that 
PK2 expression is elevated in PD patients, providing clinical relevance to our findings from 
experimental PD models.  
We also confirmed that the PKR2 receptor is expressed on dopaminergic neurons in the 
human brain (Fig. 3E and Supplementary Fig. 4B) using nigral samples from control and PD cases. 
Again, constitutive PKR2 expression showed no significant difference between control and 
diseased patient samples. Although PKR2 is constitutively expressed on neurons across different 
brain regions (Li et al. 2001, Zhang et al. 2009), a significant decrease in PKR2 expression is not 
evident in nigral lysates of PD brains perhaps because it would still be expressed in other neuronal 
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populations at substantial levels. Supplementary Fig. 5 shows that PKR2 is expressed in many 
MAP2-positive neurons in human SN samples. These results confirm that secreted PK2 can act 
directly on dopaminergic neurons via the constitutively expressed PKR2 receptor. 
 
PK2 reduces MPP+-induced dopaminergic neuronal cell death 
We next identified the functional role of secreted PK2 during dopaminergic cell death. We 
found that PKR2 was highly expressed on N27 dopaminergic cells, and consistent with our in vivo 
findings, its expression did not change with MPP+-induced degeneration (Fig. 4A). We also 
confirmed that rPK2 treatment mobilized calcium in these cells (Fig. 4B), indicating that functional 
PK2 receptors are present on dopaminergic neuronal cells. When we treated N27 dopaminergic 
cells with 200 μM MPP+ in the presence or absence of nanomolar doses of rPK2, the rPK2 (25 
nM) co-treatment significantly reduced MPP+-induced activation of caspase-3 and DNA 
fragmentation measured at 8-h and 16-h time points, respectively (Fig. 4C-D), suggesting that PK2 
is protective in dopaminergic cells during neuronal cell death. Furthermore, co-treatment with a 
specific PK2 receptor antagonist, PKRA7 (Curtis et al. 2013) effectively blocked the 
neuroprotective action of rPK2 (Fig. 4E-F). We then showed that co-treatment with 5-50 nM rPK2 
mitigated MPP+-induced intracellular ROS levels in a dose-dependent manner (Fig. 5A). Next, we 
visualized mitochondrial integrity by using MitoTracker Red fluorescent dye in MPP+-treated N27 
cells in the presence and absence of rPK2. MPP+ caused considerable fragmentation of 
mitochondria compared to untreated controls, whereas in rPK2 co-treated cells, mitochondrial 
fragmentation was significantly reduced (Fig. 5B, top panel). These changes were further 
evidenced by quantifying key morphometric parameters including mitochondrial circularity and 
solidity (Fig. 5B, bottom panels). To understand the mechanism by which PK2 signaling reduces 
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mitochondrial dysfunction in dopaminergic cells, we examined the relevant protective signaling 
pathways. Both rPK2 co-treatment with MPP+ and rPK2-alone significantly increased mRNA and 
protein levels of the mitochondrial anti-apoptotic protein Bcl-2 in N27 cells (Fig. 5C-E). To further 
investigate PK2’s neuroprotection in greater mechanistic detail, we evaluated the contribution of 
key downstream effectors of PK2 signaling in other systems, including ERKs (p44/42) and Akt 
(Guilini et al. 2010, Lin et al. 2002b, Ngan and Tam 2008, Martin et al. 2011). In N27 
dopaminergic cells, phosphorylation of Akt and ERKs was observed 3 h after rPK2 stimulation 
(Fig. 6A-B), confirming that these pathways are activated downstream of PK2 signaling. The PK2-
stimulated Akt and ERK activations were both completely blocked by the PK2 receptor antagonist 
PKRA7 (Curtis et al. 2013), indicating the specificity of PK2 signaling in activating these kinases. 
The ERK-specific inhibitor PD98059 (Crews, Alessandrini and Erikson 1992) significantly 
attenuated the protection from MPP+-induced cell death afforded by rPK2 treatment (Fig. 6C), 
whereas PD98059-alone had no effect on cell viability. Similar results were obtained with the Akt 
inhibitor API-1 (Kim et al. 2010) (Fig. 6C). These results indicate that the neuroprotective effect 
of rPK2 was mediated, at least in part, by activating Akt and ERK/MAPK signaling pathways. 
Finally, we tested whether a genetic knockdown of endogenous PK2 sensitizes N27 cells to MPP+-
induced toxicity. Transduction of N27 cells with the CRISPR/Cas9-based PK2 KO lentivirus 
almost completely abolished PK2 protein and mRNA expression in N27 cells (Fig. 6D-E). Our 
cytotoxicity results demonstrated that PK2 deficiency via CRISPR/Cas9 indeed sensitized the cells 
to MPP+ toxicity, and that the addition of 25 nM rPK2 reversed this sensitivity (Fig. 6F). 
Knockdown of PK2 significantly reduced Akt activity in both untreated and MPP+-treated N27 
cells (Fig. 6G). Together, these results demonstrate for the first time that PK2 signaling protects 
dopaminergic cells against MPP+-mediated oxidative stress, mitochondrial dysfunction and cell 
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death by activating ERK and Akt signaling pathways, implying that PK2 secreted from 
dopaminergic neurons is a compensatory protective factor acting locally against neuronal death.  
 
PK2 overexpression promotes mitochondrial biogenesis 
Having confirmed that exogenous rPK2 is neuroprotective, we next tested endogenous PK2 
overexpression. We engineered dopaminergic MN9D cells to express human wild-type PK2 by 
stably transfecting them with pCMV6-PK2-myc expression plasmid or control vector. Stable PK2 
overexpression was validated by Western blotting using the PK2 antibody (Supplementary Fig. 
6A) and immunostaining for PK2-myc using a myc-tag antibody (Supplementary Fig. 6B). Basal 
levels of its PKR2 receptor in these cells were unaffected (Supplementary Fig. 6A). After vector 
and PK2-overexpressing cells were treated with MPP+ (300 µM), we confirmed that, similar to 
rPK2 treatment, PK2-expressing cells were significantly protected against MPP+ neurotoxicity 
compared to vector control cells (Supplementary Fig. 6C-E). This protective effect of PK2 was 
attenuated by co-treating with 2 µM PKRA7. To investigate whether stable PK2 expression 
protects against MPP+-induced mitochondrial dysfunction, we first performed MitoTracker Red 
imaging in an N27 cell line stably expressing human PK2, established by a lentivirus-based gene 
delivery method. MPP+ caused mitochondrial fragmentation in N27 vector control cells, as 
evidenced by donut-shaped morphology (Fig. 7A). However, in MPP+-treated PK2-expressing 
cells, longer strand-like mitochondria were preserved. Quantification of mitochondrial circularity, 
solidity and length confirmed these findings (Fig. 7B-D). The fluorescent signals from 
MitoTracker Red (Fig. 7E) revealed a larger mitochondria area in PK2-expressing cells relative to 
vector cells, suggesting a role for PK2 in regulating mitochondrial biogenesis. We also examined 
whether PK2 protected against MPP+-induced cellular ATP depletion, which could result from 
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mitochondrial dysfunction. PK2-expressing and vector control cells were treated with or without 
MPP+ for 16 h. PK2 overexpression increased basal levels of ATP production; however no 
significant differences were observed between MPP+-treated PK2-expressing and vector control 
cells (Fig. 7F). Consistent with our rPK2 treatment results, stable PK2 overexpression also 
increased basal levels of Bcl-2 mRNA, and it mitigated the loss of Bcl-2 caused by MPP+ treatment 
relative to vector control cells (Fig. 7G). Furthermore, the transcription of PGC1α (Fig. 7H) and 
TFAM (Fig. 7I), key genes controlling mitochondrial biogenesis, were both markedly upregulated 
in PK2-expressing cells compared to vector cells. In line with these results, stably expressing PK2 
increased protein levels of TFAM as well as a mitochondria marker, mitochondrial import receptor 
subunit TOM20 (Fig. 7J and Supplementary Fig. 7). Finally, PK2 signaling increased the 
mitochondrial DNA copy number in both control and MPP+-treated N27 cells (Fig. 7K). Together, 
these data demonstrate for the first time that PK2 protects dopaminergic cells by activating 
mitochondrial biogenesis pathways. These findings also establish an exciting new link between 
PK2 signaling and the PGC1α pathway as the mechanism by which PK2 mediates protection 
against mitochondrial dysfunction and death in dopaminergic cells.   
 
PK2 reduces primary DAergic neurons from MPP+-induced loss  
Prior to testing if PK2 protects primary dopaminergic neurons from MPP+-induced 
neurodegeneration, we verified that primary dopaminergic neurons expressed both PKR1 and 
PKR2 (Fig. 8A), and rPK2-induced calcium mobilization confirmed that these receptors were 
functionally active (Fig. 8B). Given the constitutive expression of PKR2 in various neuronal sub-
populations, the observed calcium changes are not specific for dopaminergic cells, which compose 
about 5% of the total cells in this population. We then treated primary mesencephalic neuronal 
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cultures for 48 h with 5 μM MPP+-alone or co-treated with 25 nM rPK2, which was added again 
24 h later. MPP+ reduced the number of TH+ dopaminergic neurons to almost 30% of the vehicle-
treated group, indicating extensive dopaminergic degeneration. PK2 treatment significantly (#, 
p<0.05 vs MPP+-alone) mitigated MPP+-induced dopaminergic degeneration (Fig. 8C-D). MPP+ 
induced a dramatic decrease (~85%) in neurite length of TH-immunoreactive neurons, which was 
significantly improved by rPK2 treatment (Fig. 8C and 8E). The functional activity of surviving 
primary dopaminergic neurons was confirmed by dopamine uptake assays. PK2 significantly 
ameliorated the MPP+-induced loss of dopamine uptake activity (Fig. 8F). Together, these results 
further corroborate a novel neuroprotective role for PK2 in dopaminergic neurons in vitro.  
 
PKRA7 increases susceptibility to MPTP toxicity in mice   
We utilized the small-molecule PK2 receptor antagonist PKRA7 (Curtis et al. 2013) to 
block PK2 signaling in the MPTP model of PD because knockout mice for PK2 and its receptors 
show significant defects in brain development and architecture, potentially involving dopamine 
pathways which would confound our studies (Cheng et al. 2002, Li et al. 2006a, Ng et al. 2005, 
Pitteloud et al. 2007b). Since the acute MPTP treatment paradigm causes severe loss of 
dopaminergic neurons, it is not amenable to testing the effect of PK2 receptor antagonists, which 
we anticipated would exacerbate neuronal loss. Therefore, we adopted a subacute MPTP treatment 
paradigm that results in partial nigral dopaminergic degeneration (Ghosh et al. 2012, Ghosh et al. 
2013, Thomas et al. 2011). Furthermore, the time course of neurodegeneration in the sub-acute 
model is linear and well characterized, therefore the dose and treatment regimen can be tailored to 
achieve the partial dopaminergic degeneration required to study the effect of blocking PK2 
signaling. Once-daily injections of MPTP (18 mg/kg/day, i.p.) were administered for three 
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consecutive days to induce moderate neurochemical and behavioral deficits. One day before the 
first MPTP treatment, we initiated once-daily i.p. injections of PKRA7 (20 mg/kg/day) for 10 days. 
TH immunostaining of coronal sections from the SN and striatum showed that while PKRA7-
alone had no effect on the nigrostriatal dopaminergic system, it augmented MPTP-induced 
neurodegeneration in both the striatum and SN (Fig. 9A). These findings were confirmed by 
stereological quantification of TH+ neurons and Nissl-positive cells in the SN as well as 
densitometry of the striatal TH innervation (Fig. 9B-D). We found that the number of Nissl-
positive total neurons did not significantly differ from that of TH+ neurons, which is consistent 
with previous findings (De Miranda et al. 2015, St-Amour et al. 2012). Western blotting of nigral 
tissue lysates showed moderately reduced TH expression in the SN of MPTP-treated mice when 
compared to control mice, whereas PKRA7 significantly enhanced nigral TH loss in MPTP-treated 
mice (Fig. 9E). In addition, PKRA7 did not alter PK2 and PKR2 levels in the SN of either PKRA7-
alone- or PKRA7/MPTP-treated mice compared to saline and MPTP-treated mice (Fig. 9F). Nigral 
PK2 levels did not differ significantly between vehicle- or MPTP-injected mice after 7 days (Fig. 
9F). This result is not surprising since we have observed that the MPTP-induced PK2 expression 
started to decrease by the third day post-MPTP injection (Fig. 2A). As expected, three doses of 
MPTP produced a ~51% loss of striatal dopamine compared to vehicle-treated control mice as 
measured by HPLC at day 7 after last administration of saline or MPTP, a more sensitive and 
precise measure of MPTP-induced dopaminergic degeneration. However, PKRA7 treatment 
significantly exacerbated MPTP-induced dopamine depletion by ~75%, whereas PKRA7-alone 
had no effect on striatal dopamine levels (Fig. 9G). In line with the histological, biochemical and 
neurochemical evidence, both the representative locomotor activity maps of individual open-field 
movements (Fig. 9J) and the group averages of horizontal activity and total number of movements 
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(Fig. 9H-I) indicated that PKRA7 worsens the behavioral deficits of MPTP-treated mice. Together, 
our results from a preclinical model of PD further support that blocking endogenous PK2 signaling 
exacerbates dopaminergic degeneration, resulting in increased neuropathology and behavioral 
deficits.  
 
rAAV-mediated PK2 overexpression is neuroprotective in mice  
To further demonstrate the neuroprotective action of PK2 in vivo, we investigated whether 
recombinant adeno-associated virus (rAAV) 2/5-mediated PK2 overexpression confers MPTP 
resistance in mice. Recombinant AAVs encoding GFP-tagged human PK2 or GFP-alone were 
stereotaxically injected into the striatum of C57BL/6 mice. Striatal delivery of neuroprotective 
growth factors with rAAV gene delivery system has been more effective than nigral delivery (Kirik 
et al. 2000, Klein et al. 1999). Four weeks after the virus injection, we performed GFP/PK2 double 
IHC, confirming that rAAV-mediated delivery of GFP-PK2 or GFP resulted in widespread and 
efficient transgene expression in the striatum (Fig. 10A). Consistent with the initial observation of 
low basal PK2 expression in the striatum, only marginal endogenous PK2 immunoreactivity was 
observed in the striatum of AAV-GFP-transduced mice. We confirmed GFP-PK2 or GFP 
transgene expression in AAV-injected mice by Western blotting striatal lysates with a hamster 
monoclonal anti-PK2 (top panel) or anti-GFP (middle panel) antibody (Fig. 10B). GFP-PK2-AAV 
expression was lower than that of GFP-AAV (Fig. 10B), possibly because PK2 is a secreted 
protein, and therefore, GFP-tagged PK2 can be released from GFP-PK2-AAV-infected cells. To 
confirm the retrograde transport of PK2 from the striatum to the SN, we determined PK2 
expression in the SN from animals that received viral gene delivery in the striatum. IHC revealed 
GFP-PK2 co-labeled in TH+ neurons of the SN, indicating retrograde transport of the GFP-PK2 
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transgene from the striatum to the SN (Supplementary Fig. 8). Four weeks after virus injection, 
mice were exposed to a sub-acute MPTP paradigm, treating mice with 20 mg/kg MPTP daily for 
four days to produce significant dopaminergic neurodegeneration in the SN and striatum; the 
subacute paradigm is routinely used to assess the efficacy of putative neuroprotective agents (Chen 
et al. 2015b, Carta et al. 2009).  Saline- and MPTP-alone groups were also included. Spontaneous 
open-field movements lasting 10 min were recorded 24 h after the last MPTP dose and individual 
track plots were generated for each mouse (e.g., Fig. 10C). The locomotor activity of AAV-PK2-
transduced mice treated with MPTP was much improved relative to MPTP-alone and AAV-
GFP/MPTP groups (Fig. 10D-E). Similarly, AAV-PK2 transduction significantly restored the 20-
rpm rotarod performance of MPTP-treated mice (Fig. 10F). Based on these results, we conclude 
that AAV-mediated PK2 overexpression reverses MPTP-induced motor deficits. Furthermore, 
PK2 overexpression protected against MPTP-induced dopaminergic terminal loss in the striatum 
(Fig. 10G-H).  TH+ DAB staining (Fig. 10I) and stereological counts of TH+ and Nissl+ neurons 
(Fig. 10J-K) revealed a severe loss of nigral dopaminergic neurons (72% in MPTP-alone group 
and 74% in AAV-GFP/MPTP group compared with saline controls; p<0.001 for both groups) and 
total neurons (56% in MPTP-alone group and 55% in AAV-GFP/MPTP group compared with 
saline controls;  p<0.001 for both groups) in both MPTP-alone and AAV-GFP/MPTP groups. In 
contrast, AAV-mediated delivery of PK2 significantly prevented the loss of nigral dopamine 
neurons and total neurons after MPTP treatment (Fig. 10J-K), with only 36% of dopamine neurons 
and 23% of total neurons degenerated compared to saline controls, further supporting the 
neuroprotective efficacy of PK2 overexpression (p<0.001 compared with MPTP-alone group; 
p<0.001 compared with AAV-GFP/MPTP group). The difference between TH+ and total neuronal 
loss is consistent with other reports from Przedborski and colleagues (Jackson-Lewis et al. 1995) 
68 
 
using the same dose (80 mg/kg of total MPTP) that we have used in an acute treatment paradigm, 
and could be due to the fact that TH protein levels can be transiently decreased after MPTP toxicity 
without directly causing neuronal death (Meredith and Rademacher 2011a). Combined with the 
abovementioned observation that blocking PK2 signaling  in vivo potentiates MPTP toxicity, these 
results convincingly demonstrate a protective role for PK2 signaling in the nigrostriatal 
dopaminergic system and suggest that modulating PK2 levels may be a novel therapeutic strategy 
for PD. 
 
Discussion 
PD is a progressive neurodegenerative disorder with a complex multifactorial etiology that 
makes therapeutic intervention a major challenge. Therapeutic approaches that can slow or halt 
disease progression are urgently needed. This study uncovers a novel neuroprotective role for the 
AVIT protein family member PK2 in nigral dopaminergic neurons with clinical relevance to PD 
pathophysiology. We demonstrate for the first time that PK2 is rapidly induced following neuronal 
injury in cell culture and preclinical mouse models of PD. We also confirmed elevated PK2 levels 
in nigral tissues of postmortem PD patients, thereby establishing the clinical importance of these 
findings. Since the PKR2 receptor for PK2 is constitutively expressed on nigral dopaminergic 
neurons, pharmacological targeting of PK2 signaling could be explored for therapeutic 
development in PD. Our mechanistic studies demonstrate that both endogenous PK2 
overexpression and soluble rPK2 protect dopaminergic neurons against mitochondrial dysfunction 
and cell death by promoting mitochondrial biogenesis through PGC1α- and TFAM-dependent 
mechanisms and by activating ERK and Akt signaling pathways. AAV-mediated PK2 gene 
delivery significantly protects mice against MPTP-induced behavioral deficits and dopaminergic 
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degeneration in the nigrostriatal system, indicating that modulating PK2 activity may benefit the 
treatment of PD. We show that blocking the endogenous protective function of PK2 with the PK2 
receptor antagonist PKRA7 worsens MPTP-induced histological, neurochemical and behavioral 
deficits, further demonstrating the neuroprotective function of PK2 in the dopaminergic system.   
Our in vivo data from preclinical mouse models suggest that PK2 upregulation occurs 
during the early phase of dopaminergic degeneration prior to the onset of motor deficits. In the 
MPTP model, PK2 protein levels in nigral dopaminergic neurons increased 3 h post-MPTP 
administration and remained elevated for up to 3 days when nigral TH protein began declining 
(Fig. 2A). In the MitoPark transgenic mouse model of PD, PK2 increased by 8 weeks (Fig. 2I), 
prior to the onset of motor symptoms and remained elevated until 12 weeks when significant motor 
deficits are evident (Fig. 2G-H). Basal PK2 levels were either low or undetectable in the nigral 
brain region of healthy control mice. This is in agreement with previous reports showing little or 
no PK2 expression in regions of the midbrain (Zhang et al. 2009, Cheng et al. 2006a). Our finding 
that PK2 expression is upregulated early during the disease course prior to the onset of motor 
symptoms, together with our clinical data demonstrating that PK2 is elevated in PD patients, 
suggests that soluble circulating PK2 could serve as a potential marker of disease onset or 
progression. Understanding the transcriptional mechanisms underlying PK2 upregulation in 
dopaminergic neurons is crucial for targeting this pathway to achieve neuroprotection. Previous 
studies have shown that constitutive PK2 expression in the CNS is controlled by the circadian 
regulatory genes CLOCK/BMAL1 in the SCN and by Ngn1/MASH1 during olfactory bulb 
biogenesis (Cheng et al. 2002, Cheng et al. 2005a, Zhang et al. 2007a). The PK2 promoter is replete 
with multiple E-box sequences (CACGTG) that bind basic helix-loop-helix (bHLH) transcription 
factors such as HIF1α, which regulates PK2 expression during angiogenesis (LeCouter et al. 
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2003b). Others have reported HIF1α activation following MPTP-induced oxidative stress in nigral 
dopaminergic neurons and also in cell culture models of PD, making it a likely candidate for 
transcriptional upregulation of PK2 as a protective response (Lee et al. 2009, Correia and Moreira 
2010, Sharp and Bernaudin 2004). Our laboratory is currently studying the transcriptional 
mechanisms regulating PK2 upregulation in dopaminergic neurons.  
PK2 signaling supports the survival and proliferation of specific cell types outside the CNS 
(LeCouter et al. 2003b, LeCouter et al. 2004b, Shojaei et al. 2007). For example, PK2 is required 
for angiogenesis and hematopoiesis and regulates the survival of cardiomyocytes and myeloid cells 
via the AKT and STAT3 signaling pathways, respectively (Urayama et al. 2007b, Xin et al. 2013). 
Also, MAPK/ERK activation is involved in PK2-mediated angiogenesis (Guilini et al. 2010, Lin 
et al. 2002b). Biphasic PK2 expression has been demonstrated in the ischemic striatum (Cheng et 
al. 2012).  In agreement with these findings, we provide the first evidence that PK2 protects 
dopaminergic neuronal cells by activating ERK and Akt signaling pathways (Fig. 6). Additionally, 
our results demonstrate for the first time that PK2 signaling via PKR2 on dopaminergic neurons 
upregulates neuroprotective antioxidant response pathways, particularly PGC-1α and TFAM (Fig. 
7). Recent large-scale genome-wide association studies (GWAS) have shown that PGC-1α-
responsive genes, which regulate cellular bioenergetics, are specifically down-regulated in early 
PD patients (Zheng et al. 2010, Mudo et al. 2012). Also, PGC-1α overexpression protects against 
dopaminergic degeneration in PD models (Mudo et al. 2012, O'Donnell et al. 2014). The loss of 
functional TFAM signaling also results in dopaminergic degeneration and underlies the recently 
developed MitoPark genetic mouse model of PD. Our results suggest that PK2 is an upstream 
positive regulator of PGC-1α, and thus PK2 receptor agonists could have therapeutic potential in 
restoring mitochondrial dysfunction and mitigating progressive dopaminergic neuron loss in PD.  
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Overall, our results have important implications for understanding dopaminergic 
degeneration in PD and PK2 biology. To our knowledge, this is the first report showing that PK2 
is induced early during dopaminergic neuronal injury in the adult brain and that recovery of PK2 
levels translates into dopaminergic neuronal protection through activation of cell survival signaling 
events and restoration of mitochondrial function in preclinical models of PD.  Thus, developing 
agonists for PK2 GPCRs could be a novel therapeutic strategy for slowing or arresting the 
progression of dopaminergic neuronal degeneration in PD.   
 
 
Methods 
Chemicals and Reagents  
DMEM/F-12, RPMI, neurobasal medium, B27 supplement, fetal bovine serum (FBS), L-
glutamine, Lipofectamine 2000, G418, IR-dye tagged secondary antibodies, Hoechst nuclear stain, 
penicillin, streptomycin, MitoTracker Red dye and other cell culture reagents were purchased from 
Life Technologies (Gaithersburg, MD). Recombinant TNFα was purchased from Peprotech. 
Antibodies for rabbit (Cat# sc-67176) and goat (Cat# sc-48069) PK2, BCl-2 (Cat# sc-7382), 
TFAM (Cat# sc-23588), TOM20 (Cat# sc-11021) and c-Myc (Cat# sc-40X) were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Specificity of the PK2 rabbit antibody was 
confirmed by pre-absorption of antibody with rPK2 peptide (Supplementary Fig. 9). Mouse TH 
(Cat# MAB318) and Tubulin (Cat# MAB1637) antibodies were purchased from Millipore 
(Temecula, CA). Prokineticin receptor R2 antibody (Cat# CVL-PAB0638-0) was obtained from 
Covalab (Villeurbanne, France). Antibodies for p44/42 (Cat# 9102), phospho-p44/42 
(Thr202/Tyr204) (Cat# 4370s), Akt (Cat# 4691s) and phospho-Akt (Ser473) (Cat# 4060s) were 
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purchased from Cell Signaling (Danvers, MA), and goat polyclonal GFP antibody (Cat# ab6673) 
was obtained from Abcam (Cambridge, MA). The Bradford protein assay kit was purchased from 
Bio-Rad Laboratories (Hercules, CA). The Cell Titer Glo Luminescent Cell Viability assay kit was 
purchased from Promega. Caspase-3 assay substrate was purchased from MP Biomedicals (Solon, 
OH). The DNA fragmentation assay kit was purchased from Roche Applied Science. The PK2 
antagonist PKRA7 (Curtis et al. 2013) and hamster monoclonal PK2 antibody were kindly 
provided by Dr. Qun-Yong Zhou (University of California, Irvine). The ROS generation 
determinant DCF-DA was purchased from Calbiochem (San Diego, CA). Mouse β-actin antibody 
(Cat# A5441) and MPTP were obtained from Sigma (St. Louis, MO).  
 
Animal studies 
All animal procedures were approved by Iowa State University’s Institutional Animal Care 
and Use Committee (IACUC). All mice were housed under a 12-h light cycle in a climate-
controlled mouse facility (22 ± 1°C) with food and water available ad libitum. Based upon the 
outcomes of preliminary studies, we estimated error variances of 15% for biochemical and 
neurochemical endpoints and 20% for histological measures.  Setting alpha=0.05, we calculated 
sample sizes (n) of 8-10 animals per group, which has worked well for us in previous animal 
studies conducted in our laboratory (Ghosh et al. 2012, Ghosh et al. 2013). We used all male 
animals for all studies. All mice were pre-screened for normal baseline performance during 
behavioral assessments conducted prior to randomly assigning animals to experimental groups. 
Investigators involved with data collection and analysis were not blinded to group allocation. 
MPTP studies were performed as previously described (Zhang et al. 2007c), using C57BL/6NCrl 
mice (8-10 weeks of age) to determine levels of PK2 in the mouse brain. Over an 8 h period, one 
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i.p. injection of 18 mg/kg MPTP or equal volumes of saline (vehicle) was administered every 2 h. 
Mice were euthanized at the indicated time points and samples processed for either IHC, qRT-
PCR or Western blotting. For PKRA7 experiments, C57BL/6 mice were injected i.p. with 18 
mg/kg MPTP, or equal volumes of saline (vehicle), once daily for three consecutive days. PKRA7 
(20 mg/kg/day) was given i.p. 24 h before MPTP treatment and continued once daily for 10 
consecutive days until sacrifice. For the PK2 rAAV neuroprotection experiments, C57BL/6NCrl 
mice were injected i.p. with 20 mg/kg MPTP, or equal volumes of saline (vehicle), once daily for 
four consecutive days and sacrificed 24 h after the last MPTP injection. 
 
PK2-eGFP transgenic mice 
The PK2-eGFP transgenic FVB/N-Swiss mice were originally generated at Rockefeller 
University by the GENSAT project using bacterial artificial chromosome (BAC) clone RP23-
12A18, as described previously (Gong et al. 2003). The eGFP reporter cassette included a 
polyadenylation site that prevents PK2 overexpression. The PK2-eGFP male mice (8-10 weeks of 
age) were obtained from NIH-supported Mutant Mouse Regional Resource Center, UC Davis, CA, 
and bred at Iowa State University’s animal facility.  Mice were housed under a 12-h light cycle in 
a climate-controlled mouse facility (22 ± 1°C) with food and water available ad libitum. 
Intraperitoneal injections of either 20 mg/kg MPTP or saline (vehicle) were administered every 2 
h with a total of four injections.   
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MitoPark transgenic mice 
MitoPark transgenic mice were kindly provided by Dr. Nils-Göran Larsson of Karolinska 
Institute, Stockholm, and was originally generated in his laboratory at the Max Planck Institute for 
Biology of Ageing by conditionally knocking out the mitochondrial transcription factor TFAM 
through control of the dopamine transporter (DAT) promoter as previously described (Ekstrand 
and Galter 2009, Ekstrand et al. 2007). All mice used for this study were from the MitoPark 
breeding colony at Iowa State University. Housing was under a 12-h light cycle in a climate-
controlled facility with food and water provided ad libitum. After behavioral experiments were 
performed at the indicated ages, mice were perfused for IHC or euthanized and dissected for 
Western blot analysis. All animal procedures were approved by Iowa State University’s 
Institutional Animal Care and Use Committee (IACUC). 
 
Human post-mortem PD brain samples 
We obtained freshly frozen SN tissue samples and cryostat sections from the brains of 
confirmed post-mortem human PD patients and age-matched neurologically normal individuals 
from the brain banks at the Miller School of Medicine, University of Miami, FL, the Australian 
Brain Bank Network and at the Banner Sun Health Research Institute, AZ.  Case details of human 
post-mortem tissues are shown in Table S1. For Western blot experiments, tissue homogenates 
from freshly frozen tissue were prepared at a final concentration of 1 mg/ml total protein from 
which 40 µg of total protein was used. Nigral tissue blocks were fixed with 4% paraformaldehyde 
(PFA) solution (in 0.1 M phosphate-buffered saline, pH 7.4). Cryostat sections were used for IHC 
experiments. All human post-mortem samples were procured, stored, and distributed according to 
applicable regulations and guidelines involving consent, protection of human subjects and donor 
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anonymity. For samples obtained from the Australian Brain Bank Network, Institutional Human 
Research Ethics Approval was obtained from the Medical Research Ethics Committee at the 
University of Queensland, Brisbane, Australia. Since the post-mortem human brain tissues were 
obtained from approved national brain banks, Institutional Review Board (IRB) approval from 
Iowa State University was not required. 
 
Fluorescent Western blotting 
Cells and micro-dissected brain tissues were collected at the end of treatment and lysed 
using a modified RIPA buffer as previously described (Kanthasamy et al. 2006, 
Latchoumycandane et al. 2011). Proteins were separated by Sodium Dodecyl Sulfate (SDS) gel 
electrophoresis. Normalized protein samples were loaded into each well and first separated in a 
4% stacking gel and then through a 12-18% resolving gel. Proteins were then transferred to a 
nitrocellulose membrane and blocked using fluorescent Western blocking buffer (Rockland 
Immunochemicals). Membranes were washed several times in wash buffers comprising either PBS 
containing 0.05% Tween (PBST) or Tris-buffered saline containing 0.05% Tween (TBST). 
Primary antibodies, in either blocking buffer or 5% bovine serum albumin (BSA) solution, were 
then added to the membranes and incubated overnight at 4°C. After another 4-5 washes, an infra-
red (IR) dye-tagged secondary antibody was added for 1 h. Actin or α-tubulin was used as a loading 
control. Membranes were scanned using the Odyssey IR imaging system (LI-COR). 
 
SYBR Green qRT-PCR 
Total RNA was isolated from fresh cell pellets or animal tissues using the Absolutely RNA 
Miniprep kit from Agilent Technologies. First strand cDNA synthesis was performed using an 
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Affinity Script qPCR cDNA synthesis system (Agilent Technologies). Real-time PCR was 
performed with the RT2 SYBR Green master mix (Qiagen) and pre-validated qPCR mouse primer 
sets purchased from Qiagen. For normalization of each sample, the 18S rRNA gene (mouse and 
rat) was used as the housekeeping gene. The amount of each template was optimized empirically 
to maximize efficiency without inhibiting the PCR reaction. According to manufacturer’s 
guidelines, dissociation curves were run to ensure a single amplicon peak was obtained. The results 
are reported as fold change in gene expression, which was determined via the ΔΔCt method using 
the threshold cycle (Ct) value for the housekeeping gene and for the respective gene of interest in 
each sample. 
 
Mitochondrial fragmentation analysis 
For Mitochondrial dysfunction experiments, cells were plated onto glass-bottom dishes 
coated with 0.1% Poly-D-Lysine in RPMI with 10% FBS, penicillin (100 U/ml), streptomycin 
(100 μg/ml), and 2 mM L-glutamine. Cells were treated in RPMI with 2% FBS, penicillin (100 
U/ml), streptomycin (100 μg/ml), and 2 mM L-glutamine for 16 h. After treatment, MitoTracker 
Red dye was added to each dish at a concentration of 1:2000 l from a stock of 1 mM. The cells 
were incubated with the dye for 15-20 min at 37°C. After incubation, cells were fixed with 4% 
PFA for 1 h and then washed several times with PBS. High resolution confocal images were 
obtained using a Leica SP5 X confocal microscope system at the Confocal Microscopy and Image 
Analysis Facility at Iowa State University. Quantification of mitochondrial morphology was 
performed using a custom Image J macro program as described previously (Dagda et al. 2009, 
Merrill et al. 2011).  To determine the mitochondria/cell ratio, mitochondrial area was measured 
by thresholding the MitoTracker fluorescence in ImageJ and dividing by the whole cell area.   
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Mitochondrial DNA copy number 
Total DNA containing both nuclear and mitochondrial DNA was isolated from N27 cells 
using the DNeasy Blood & Tissue kit (Qiagene). DNA concentrations were measured using 
Nanodrop UV absorbance spectrophotometry. Real-time PCR primers for mitochondrially 
encoded NADH dehydrogenase 1 (ND1) (forward, TGACCAACTAATGCACCTCCTA; reverse, 
GAAAATTGGCAGGGAAATGT) and nuclear-encoded glyceraldehyde phosphate 
dehydrogenase (GAPDH) (forward, AAACCCATCACCATCTTCCA; reverse, 
CCTCGAAGTACCCTGTGCAT) were synthesized as previously described (McInerny, Brown 
and Smith 2009). For qPCR assay, each reaction contained 200 nM each of forward and reverse 
primers and 20 ng of sample DNA, plus appropriate amounts of Universal Master Mix (Qiagene). 
The standard cycling conditions were 95°C for 5 min, followed by 40 cycles of 95°C for 30 s, and 
60°C for 30 s. The mtDNA levels were expressed as relative ND1 levels (ND1/GAPDH). 
 
 
CRISPR/Cas-based knockdown of PK2 in N27 cells  
The lentivirus-based CRISPR/Cas9 KO plasmid, pLV-U6gRNA-Ef1aPuroCas9GFP-PK2, 
with the PK2 gRNA target sequence CTGTTCACACCGCCCGCCGGGG, was purchased from 
Sigma-Aldrich. To make lentivirus, the lenti-CRISPR/Cas9 PK2 KO plasmid and control plasmid 
were transfected into 293FT cells using the Mission Lentiviral Packaging Mix from Sigma-Aldrich 
according to manufacturer’s instructions. The lentivirus was harvested 48 h post-transfection and 
titers were measured using the Lenti-X™ p24 Rapid Titer Kit (Clontech). For stable knockdown 
of PK2 in N27 cells, cells were grown in 6-well plates with a seeding density of 0.1 x 106 cells/well 
78 
 
in growth media, and lentivirus was added to the media at an MOI of 100 the following morning. 
After 24 h, fresh media supplemented with puromycin (50 µg/mL) was added to the cells for stable 
cell selection.  
 
Plasmid construction, generation and purification of rAAV 
PK2 mRNA sequence was obtained from NCBI and codon-optimized for expression in the 
mouse using the GeneArt Gene Synthesis service at Life Technologies. The finished plasmid was 
sent to the Viral Vector Core Facility at the University of Iowa for cloning. Briefly, Kpn1 and 
Xho1 restriction enzymes were used to subclone the codon-optimized PK2 sequence into the 
pFBAAV2/5CMVmcsBgHpA viral vector. To generate rAAV, the pFBAAV2/5CMV-PK2-
eGFP-BgHpA or AAV2/5CMVeGFP control viral plasmid was transfected into SF-9 insect cells 
along with the helper plasmid pAAV-RC containing Rep/Cap sequences for viral packaging. The 
resulting packaged cis-acting AAV baculovirus carries the AAV expression cassette flanked by 
the AAV inverted terminal repeats (ITR). P1 baculovirus stock was used to amplify the P2 virus. 
For production of the virus, SF-9 cells were grown in bioreactors and infected with the P2 virus. 
Cells were harvested after signs of infection and collected in 50 mL tubes. Cells were pelleted and 
mechanically lysed with glass beads and a bead blender to release the virus. The lysate was treated 
with detergent to further lyse cells and dissociate virus from membranes and proteins. Benzonase 
was added to digest genomic, proviral, and plasmid DNA while leaving packaged viral DNA 
intact. The lysate was then clarified by centrifugation to obtain viral particles. Viral particles were 
purified using Iodixanol step gradients of 25%, 40%, and 60%, and full viral particles were then 
collected at the 40-60% interface. The viral particles were further purified using a Mustang Q 
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Anion Exchange disk as per manufacturer’s instructions. A qPCR assay verified AAV2/5CMV-
PK2-eGFP-BgHpa viral genome titer of 2.98 x 1012.  
 
Stereotaxic surgery 
C57BL/6NCrl mice (8-10 weeks of age) were anesthetized using a ketamine/xylazine 
mixture. The Angle 2 stereotaxic instrument was used with a 10-mL Hamilton syringe to inject the 
rAAV directly into the striatum at the following stereotaxic coordinates in relation to Bregma 
(mm): -2 ML, 0.5 AP, -4 DV. After drilling a hole in the skull, 3 μl of rAAV viral particles (~9 x 
1012 total viral particles) were injected into the brain.  The animal was allowed to recover for four 
weeks to maximize viral gene expression before behavioral testing, sacrificing or any treatment 
paradigm. 
 
Behavioral measurements 
The automated VersaMax Monitor (model RXYZCM-16, AccuScan, Columbus, OH) was 
used to measure the spontaneous open-field locomotor activity of mice in an activity chamber 
made of clear Plexiglas and covered with a ventilated Plexiglas lid, as described previously (Ngwa 
et al. 2013, Harischandra et al. 2014). Horizontal and vertical activity data were collected and 
analyzed by a VersaMax Analyzer (model CDA-8, AccuScan). Locomotor activities were 
monitored during a 10-min test session following a 2-min acclimation period. For rotarod 
experiments, mice were placed on the rod as it rotated at a constant speed of 20 rpm and latency 
to fall was recorded during 20-min sessions. 
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HPLC analysis of striatal dopamine levels 
HPLC samples were prepared and processed as described previously (Ghosh et al. 2013). 
Briefly, mice were sacrificed, striata were collected, and neurotransmitters were extracted in 0.2 
M perchloric acid solution containing 0.05% Na2EDTA, 0.1% Na2S2O5, and isoproterenol (internal 
standard). Dopamine and metabolites were separated isocratically by a reversed-phase column 
with a flow rate of 0.6 ml/min using a Dionex Ultimate 3000 HPLC system (pump ISO-3100SD, 
Thermo Scientific, Bannockburn, IL) equipped with a refrigerated automatic sampler (model 
WPS-3000TSL). The electrochemical detection system included a CoulArray model 5600A 
coupled with an analytical cell (microdialysis cell 5014B) and a guard cell (model 5020). Data 
acquisition and analysis were performed using Chromeleon 7 and ESA Coularray 3.10 HPLC 
Software. 
 
Immunocytochemistry and histology  
For immunocytochemistry, cells were plated onto coverslips in 24-well plates coated with 
0.1% poly-D-lysine. After treatment, 4% formaldehyde was used to fix the cells for 30 min. The 
cells were washed 4-5 times with PBS. Blocking buffer containing 2% BSA, 0.1 % Triton X-100, 
and 0.05% Tween 20 was added to the wells for 1 h to permeabilize the cells. The cells were 
incubated with primary PK2 (Rabbit polyclonal, 1:500 dilution), Bcl-2 (Mouse polyclonal, 1:500 
dilution) or c-Myc (mouse monoclonal, 1:2000) antibodies in 2% BSA at 4°C overnight. After 4-
5 washes, an Alexa dye-conjugated secondary antibody in 2% BSA was added and incubated at 
room temperature on a shaker for 1 h. Cells were then washed 4-5 times before adding Hoechst 
counterstain for 15-20 min to label nuclei. Coverslips were mounted onto slides with Fluoromount 
mounting media (Sigma). Cells were imaged under an Eclipse TE2000-U microscope (Nikon, 
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Tokyo, Japan) with a SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI), and all 
photomicrographs were processed in MetaMorph 5.7 (Universal Imaging, Downingtown, PA). 
For histology, mice were perfused with saline and 4% PFA after being anesthetized using 
a ketamine-xylazine mixture. Extracted brains were then post-fixed in PFA for 24 h and 
cryoprotected in 30% sucrose before being embedded in OCT compound, frozen, and sectioned 
on a Cryostat (CryoStar NX70, Thermo Scientific) at -20°C. Antigen retrieval was performed 
using citrate buffer (10 mM sodium citrate, pH 8.5) at 90°C for 30 min. Sections were then washed 
with PBS and permeabilized with blocking buffer (2% BSA, 0.1% Triton X-100, and 0.05% 
Tween 20 in PBS) for 1 h at room temperature. Antibodies directed against PK2 (rabbit polyclonal, 
1:500), PKR1 (goat polyclonal, 1:1000), PKR2 (rabbit polyclonal, 1:1000), and TH (mouse 
monoclonal, 1:2000) were incubated with the sections overnight at 4°C. After several washes with 
PBS, sections were incubated with Alexa dye-conjugated secondary antibodies for 1 h at room 
temperature. Hoechst stain was added to the sections for 20 min at room temperature to label 
nuclei. Sections were then mounted on slides using the ProLong® Gold antifade mounting medium 
(Molecular probes) according to the manufacturer’s instructions. A SPOT digital camera attached 
to an inverted fluorescence microscope (Nikon TE2000-U) was used to capture photomicrographs 
of sections. 
DAB immunostaining was performed on striatal and SN sections, as described 
previously (Ghosh et al. 2013, Roy et al. 2012). Briefly, 30-μm sections were incubated with either 
anti-TH antibody (Calbiochem, Billerica, MA, USA; rabbit anti-mouse, 1:1800 dilution) or anti-
PK2  followed by incubation with biotinylated anti-rabbit or goat or mouse secondary antibody. 
Separate sections were stained with cresyl violet to count the total number of Nissl-positive 
neurons in the same animals. Total numbers of TH+  and Nissl+ neurons in every 6th section of the 
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SN were counted stereologically with Stereo Investigator software (MBF Bioscience, Williston, 
VT, USA) using an optical fractionator as described previously (Ghosh et al. 2010).  
 
DAergic cell cultures and generation of stable cell lines 
A rat mesencephalic dopaminergic clonal neural cell model (N27 neuronal cells) was a 
kind gift from Dr. Kedar N. Prasad (University of Colorado Health Sciences Center, Denver, CO) 
and grown in RPMI 1640 media supplemented with 10% FBS, penicillin (100 U/ml), streptomycin 
(100 μg/ml), and 2 mM L-glutamine in 175-mm3 flasks, as previously described (Clarkson et al. 
1998, Kaul et al. 2003, Zhang et al. 2007c). N27 cells were maintained in an incubator at 37°C 
with 5% CO2. To generate N27 cell lines stably overexpressing human PK2, N27 cells were stably 
infected with lentiviral particles encoding human PK2-GFP or GFP-alone. For the production of 
lentiviruses, lentiviral constructs (pLenti-PK2-mGFP and pLenti-C-mGFP, Origene, Rockville, 
MD) were packaged into viruses via transient transfection of the 293FT packaging cells 
(Invitrogen) using Lipofectamine 2000 reagent and a Lentiviral packaging kit from Systems 
Biosciences (SBI), as previously described (Jin et al. 2011b). The viruses were collected by 
centrifuging 48-72 h post-transfection. Transduction of N27 cells was performed at a multiplicity 
of infection (MOI) of 1 in the presence of polybrene (6 µg/ml). Two days after transduction, GFP-
expressing cells were sorted once per week for three weeks by flow cytometry, each time taking 
the brightest 1% of GFP-expressing cells to guarantee that 100% of the cells were GFP-positive. 
The mouse dopaminergic MN9D cell line was kindly obtained from Dr. Syed Ali (National 
Center for Toxicological Research, Food and Drug Administration, Jefferson, AR) and cultured as 
described previously (Jin et al. 2011a). MN9D cells stably expressing human PK2 were created by 
stable transfection with the pCMV6-PK2-myc plasmid or empty vector control (Origene) using 
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Lipofectamine 2000 reagent according to manufacturer’s recommendations. The stable 
transfectants were selected in 400 μg/ml G418 and further maintained in 200 μg/ml G418 added 
to MN9D growth media. We used ciprofloxacin for mycoplasma elimination (GenHunter, 
Nashville, TN). The widely used N27 and MN9D neuronal cell models both represent a 
homogeneous population of TH-positive dopaminergic cells and are highly useful for studying 
degenerative mechanisms in PD (Zhang et al. 2007d, Jin et al. 2011a). Primary neurons were 
obtained from the ventral mesencephalon of gestational 14-day-old (E14) mouse embryos as 
described previously (Jin et al. 2011b). Quantification of TH+ cell counts and neuronal processes 
in primary neuronal cultures was performed as described previously (Ghosh et al. 2013). TH+ 
neurons and their processes were counted from three experiments in which over 8 fields were 
imaged in each well per group.  
 
Caspase-3 activity, DNA fragmentation and ATP production  
Enzymatic assays for caspase-3 activity were performed using acetyl-DEVD-amino-4-
trifluoromethylcoumarin (Ac-DEVD-AFC, 25 μm) as the fluorometric substrate for the reaction, 
as described previously (Anantharam et al. 2002, Kaul et al. 2003). A Synergy-2 multi-mode 
microplate reader (BioTek Instruments, Inc) was used to detect fluorescent signals generated upon 
cleavage of the AFC peptide substrate by caspase-3 with excitation at 510 nm and emission at 400 
nm. Caspase-3 activity was normalized by determining protein concentrations with the Bradford 
assay. For the DNA fragmentation assay, N27 cells were plated in 6-well plates at 0.8 x 106 
cells/well and treated the next day. At the end of treatment, cells were gently lysed using the lysis 
buffer provided with the kit. Lysates were then spun down at 200 x g for 10 min to collect 
supernatants. The extent of DNA fragmentation was then quantified using the Cell Death Detection 
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ELISA Plus assay kit (Roche Applied Science) according to previously published methods 
(Anantharam et al. 2002, Kaul et al. 2003, Zhang et al. 2007c). The plates were read by a Synergy-
2 multi-mode microplate reader with absorbance at 405 nm and an ABTS solution (reference 
wavelength at ~490 nm) as a blank. The amount of protein in each sample lysate was used to 
normalize the raw absorbance values. For measurement of ATP production, cells were plated onto 
black-walled clear-bottom plates at 0.7 x 104 cells/well and exposed to 300 µM of MPP+ for 16 h 
in 2% FBS medium. Following treatment, the plates were equilibrated for 15 min at room 
temperature. After equilibration, Cell Titer-Glo Luminescent reagent was added and then 
incubated at room temperature for 30 min to get a steady luminescence signal. Luminescence 
readout was recorded using the Synergy-2 multi-mode microplate reader. 
 
Intracellular ROS generation 
The fluorescent probe 2’,7’-dichlorodi-hydrofluorescein diacetate (DCFH-DA) 
(Calbiochem) was used to determine the level of intracellular reactive oxygen species (iROS). N27 
cells were treated with 200 µM MPP+ in RPMI media with 2% FBS or co-treated with different 
doses of recombinant PK2 (rPK2), ranging from 5 to 50 nM, along with the MPP+ treatment. After 
treatment for 8 h, the cells were washed with warm HBSS media, and then incubated with 100 µl 
of 40 µM DCFH-DA in HBSS for 1 h. The fluorescence intensity of the signal was determined 
using a Synergy-2 multi-mode microplate reader at an excitation of 485 nm and an emission of 
530 nm. After subtracting the control fluorescent signal as background, an increase in fluorescence 
intensity of treatments was expressed as an increase in iROS, as previously described (Qian et al. 
2007, Zhang et al. 2005). 
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Fluo-4 calcium mobilization assays 
A Fluo-4 NW assay kit (Molecular probes) was used to test calcium mobilization in N27 
cells and primary neurons resulting from nanomolar concentrations of rPK2. Cells were plated 
overnight into 96-well plates with their respective growth media. Cells were then washed with 
HBSS and incubated with the Fluo-4 NW dye. Each plate was then read kinetically using a 
Synergy-2 multi-mode microplate reader. After obtaining background readings by reading each 
plate every 50 ms for 20 sec, rPK2 was injected at the indicated nanomolar concentrations. The 
net change in fluorescent signal (Dt), read every 50 ms for 3 min, was obtained after subtracting 
the background from the maximum signal for each sample. 
 
Data analysis and statistics 
All in vitro data were determined from at least two biologically independent experiments, 
each done with a minimum of three biological replicates. Data analysis was performed using Prism 
4.0 software (GraphPad Software, San Diego, CA). Data were analyzed using one-way ANOVA 
and then Bonferroni's post-tests or two-way ANOVA to compare all treatment groups. Because 
our simple one-way and two-way ANOVAs were performed on completely balanced data sets, we 
ignored group variance inequalities which were all generated by large treatment effects. Where the 
normality assumption was violated we conducted nonparametric tests, however, in no case did the 
nonparametric results change the overall interpretation of our parametric results. Differences with 
p<0.05 were considered statistically significant. Student's t-test (two-tailed) was used when two 
groups were being compared.  
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Figure 1. Prokineticin-2 is upregulated and secreted following neurotoxic stress in N27 
dopaminergic neuronal cells.  (A) Upregulation and release of PK2 in dopaminergic N27 cells. 
Representative (left) Western blot analysis of intracellular and secreted PK2 protein following 
treatment of N27 cells with TNFα (30 ng/ml) and MPP+ (300 μM) for 12 h. At the end of treatment, 
supernatants were collected and concentrated using a Vivaspin centrifugal concentrator with a 3-
kDa molecular weight cutoff. Experiments were repeated twice with a total n = 3. Data represented 
as mean ± SEM and asterisks denote a significant (* p<0.05 and ** p<0.01) difference between 
control and TNFα- or MPP+-treated groups using one-way ANOVA. (B) Localization of PK2 
(green) in N27 cells was determined via IHC after exposure to TNFα and MPP+ for 12 h. Hoechst 
dye stained the nuclei (blue). Cytosolic expression of PK2 was localized to the peri-nuclear region 
(white arrows). Scale bar, 10 µm.  
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Figure 2. Prokineticin-2 is highly induced in nigral dopaminergic neurons in animal models of 
Parkinson’s disease. (A-D) Mice were injected with 4 MPTP doses (18 mg/kg, i.p.) at 2-h 
intervals. (A-B) Representative Western blots (A) of PK2, PKR2 and TH expression in nigral 
lysates. Mice were sacrificed at 3, 12, 24 and 72 h post-MPTP. Experiments were repeated three 
times with three mice/group and quantified by densitometric analysis after normalization to β-actin 
(B). (C) Double-labeling IHC for PK2 and TH in mouse nigral sections stained for TH (red) and 
PK2 (green). Strong PK2 expression occurred in TH+ neurons along the nigral tract. Scale bar, 40 
µm. (D) Real-time PCR for PK2 mRNA expression in the SN, 24 h post-MPTP treatment, with 
18s as the internal standard for normalization. Data represented by group mean ± SEM from 
experiments repeated twice with a total n = 4. Asterisks denote a significant difference between 
control and MPTP treatment (*** p<0.001) using Student’s t-test. (E) Top: Double-labeling IHC 
shows expression of PKR2 (green) on TH+ neurons. Image magnification, 60X. Scale bar, 10 µm. 
Bottom: Western blot for PKR2 in mouse nigral lysates. Mice receiving 4 doses of MPTP (18 
mg/kg, i.p.) were sacrificed at the indicated time points. Tubulin was used as the loading control. 
Representative blots indicate that PKR2 is constitutively expressed. (F) Visualization of PK2 using 
GENSAT Prok2-eGFP reporter transgenic mice. Coronal sections from saline- or MPTP-treated 
transgenic mice were stained for TH (red) with eGFP directly imaged at 488nm excitation. Image 
magnification, 20X. Scale bar, 40 µm. Representative images are shown and experiments were 
repeated at least three times. (G-J) PK2 induced in nigral dopaminergic neurons in transgenic 
MitoPark mice. Horizontal activity (G) and rotarod performance (H) showing no significant 
differences in motor function at 8 wk and onset of motor deficits at 12 wk (n = 7-10 mice/group). 
Data represented as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001) using Two-way ANOVA. (I) 
Western blot of PK2 and TH expression revealed significantly elevated PK2 in 8- and 12-wk 
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MitoPark mice. Quantification of PK2 band is shown on the right. (J) IHC staining for TH (green) 
and PK2 (red) showing increased PK2 expression in nigral dopaminergic neurons at 12 wk. Scale 
bar, 40 µm. Data represented as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001) with an n = 2-8 
using one-way ANOVA with Bonferroni post test. 
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Figure 3. PK2 is elevated in the substantia nigra of human PD patients. (A) Representative 
Western blot for PK2 expression in nigral lysates from PD patients and age-matched controls 
probed using a rabbit polyclonal antibody directed against the human PK2 protein. Increased levels 
of PK2 were evident in PD patient samples compared to control subjects. A representative TH 
Western blot is also shown. (B) Densitometric band intensities for PK2, determined from 10 
control and 10 PD samples normalized using β-actin as the internal control. Data represented as 
mean ± SEM and expressed as fold change over control with a total n = 10. Asterisks denote a 
significant (** p<0.01) difference between control and PD samples using Student’s t-test. (C) IHC 
for PK2 in human nigral sections using DAB immunostaining showed increased neuronal PK2 
expression in PD brains. Scale bar, 40 µm. (D) Double-labeling immunofluorescence for PK2 
(Green), TH (Red) and nuclei (blue). Scale bar, 40 µm. Representative images from one of three 
experiments are shown. (E) Top: Double-labeling IHC shows expression of PKR2 (green) on 
human nigral TH+ (red) neurons. The top panel is 60X magnification to show PKR2 merging with 
several TH positive neurons (scale bar, 20 µm), and the bottom panel is 63X magnification with 
2.5X zoom to get a high magnification image of PKR2 in one TH-positive cell (scale bar, 10 µm). 
Bottom: Western blots for PKR2 expression in nigral lysates from control and PD brains (3 cases 
each) revealed that PKR2 was highly expressed in control brains and its expression levels did not 
change in PD patients. A representative TH Western blot is also shown.   
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Figure 4. Recombinant PK2 protects dopaminergic N27 cells against MPP+-induced 
dopaminergic neuronal cell death. (A) Representative Western blot from one of three experiments 
showing no changes in PKR2 expression during MPP+-induced cell death in N27 dopaminergic 
cells. (B) Calcium mobilization (flux) induced by rPK2 in N27 cells. Calcium-free HBSS was used 
on the control group (One-way ANOVA with Bonferroni post test and total n = 3). (C-D) 
Exogenously-stimulated PK2 signaling attenuated caspase-3 activation induced by MPP+ at 8 h 
(C) and DNA fragmentation at 16 h after MPP+ treatment (D). N27 cells were treated with MPP+ 
(200 μM) or co-treated with PK2 (25 nM) and cells were collected for assays of caspase-3 activity 
at 8 h and DNA fragmentation at 16 h. The data were expressed as fluorescence units (FU) per mg 
of protein for caspase-3 activity and absorbance units (AU) per mg protein for DNA fragmentation 
(One-way ANOVA with Bonferroni post test and total n = 3). (E-F) Co-treatment with the specific 
PK2 receptor antagonist PKRA7 blocked PK2’s neuroprotection in MTS (E) (One-way ANOVA 
with Bonferroni post test and total n = 4-8) and caspase-3 activity (F) (One-way ANOVA with 
Bonferroni post test and total n = 3) assays. N27 cells were treated with 200 μM MPP+ for 24 h in 
the presence or absence of 25 nM PK2 and 2 µM PKRA7. Data represented by group mean ± SEM 
(* p<0.05, ** p<0.01 and *** p<0.001; ## p<0.01 and ### p<0.001 comparing MPP+ and 
MPP+/PK2 co-treatment groups). 
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Figure 5. Recombinant PK2 protects dopaminergic N27 cells against MPP+-mediated oxidative 
stress and mitochondrial dysfunction. (A) Co-treatment with nanomolar doses of rPK2 attenuated 
MPP+-induced ROS generation in a dose-dependent manner. N27 cells were treated with 300 μM 
MPP+ for 8 h and total iROS was determined by quantifying the DCF-DA dye fluorescence using 
a plate reader with a total n = 3. “ns” = non-significant with an exact p-value = 0.4939. (B) PK2 
signaling blocked MPP+-induced mitochondrial fragmentation. Top: N27 cells were treated with 
MPP+ (300 μM) for 16 h and incubated with MitoTracker Red dye to visualize mitochondria. Scale 
bar, 20µm. Bottom: Morphometric analysis (ImageJ plug-in (Dagda et al. 2009)) of mitochondrial 
structures showed that PK2 co-treatment significantly reduced MPP+-induced mitochondrial 
circularity (left) and solidity (right) with a total n = 8-10. (C-E) PK2 upregulates anti-apoptotic 
protein Bcl2. Bcl-2 protein (C) (n = 2-3) and mRNA expression (D) (n = 3-15) was determined by 
Western blotting and qPCR, respectively. PK2 treatment upregulated the basal level of Bcl-2 
expression, which remained elevated during treatment with MPP+.  Bcl-2 expression was also 
visualized by immunofluorescence (E) with a total n = 3. Scale bar, 10 µm. Data represented by 
group mean ± SEM (* p<0.05 and *** p<0.001; ## p<0.01 and ### p<0.001 comparing MPP+ and 
MPP+/PK2 co-treatment groups). All statistics for this figure were determined using one-way 
ANOVA with Bonferroni post test.   
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Figure 6. Recombinant PK2 (rPK2) activates Akt and ERK (p44/42) signaling pathways to protect 
N27 cells from MPP+ toxicity. (A-B) N27 cells were untreated or treated with 25 nM rPK2 in the 
absence or presence of 2 µM PKRA7 for 3 h. Cells were collected and subjected to Western blot 
analysis of ERK (A) and Akt (B) activation. (C) N27 cells were untreated or treated with 300 µM 
MPP+ in the absence or presence of 25 nM rPK2, 100 nM Akt inhibitor API1 or 50 μM ERK 
inhibitor PD98059 for 24 h. Cell viability was then measured by MTS assay. Data are expressed 
as the mean ± SEM of three independent experiments using one-way ANOVA with Bonferroni 
post test with a total n = 7-22. (D-E) CRISPR/Cas9-based knockdown of PK2 in N27 cells infected 
with CRISPR/Cas9 PK2 KO lentivirus or CRISPR/Cas9 control scrambled lentivirus. PK2 
expression was analyzed by Western blot (D) and real time RT-PCR (E) (Student’s t-test with total 
n = 6). (F-G) CRISPR/Cas9 PK2 KO or CRISPR/Cas9 control lentivirus-infected N27 cells were 
treated with or without 300 µM MPP+ in the presence or absence of 25 nM rPK2. Cell viability 
was analyzed by MTS assay (F) (one-way ANOVA with Bonferroni post test and total n = 8, ns 
stands for non-significant with an exact p-value = 0.9065) and Akt activation was measured by 
Western blot (G) 24 h after MPP+ treatment. Asterisks denote statistical significance (*, p< 0.05, 
**, p< 0.01 and ***, p< 0.001. ns, non-significant).  
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Figure 7. Stable expression of PK2 protects against MPP+-mediated mitochondrial dysfunction 
and promotes mitochondrial biogenesis. (A-D) Reduced mitochondrial fragmentation in PK2-
overexpressing cells. Mitochondrial fragmentation was visualized using MitoTracker Red in 
vector and PK2-overexpressing cells treated with MPP+ (300 μM) for 16 h. Scale bar, 10µm. 
Reduced mitochondrial circularity (B), solidity (C) and increased mitochondrial length (D) were 
evident in cells overexpressing PK2 (Student’s t-test with a total n = 3, ns stands for non-significant 
with an exact p-value = 0.0767). (E) Increased mitochondrial area in PK2 overexpressing cells. 
Mitochondrial area was measured by thresholding the MitoTracker Red images to compare to the 
total area of the cell. PK2 overexpressing cells had significantly more mitochondrial area/total cell 
area compared to vector cells (Student’s t-test with total n = 6-7). (F) Overexpression of PK2 
increased ATP levels. PK2-overexpressing and vector cells were exposed to 300 μM MPP+ for 16 
h, and the amount of cellular ATP produced was measured using the Luminescent Cell Viability 
assay kit (One-way ANOVA with Bonferroni post test and total n = 4). (G-K) Overexpression of 
PK2 upregulated mitochondrial biogenesis pathways. Real-time qPCR analysis of Bcl-2 (G) 
(Student’s t-test with total n = 3), PGC1α (H) (One-way ANOVA with Bonferroni post test and 
total n = 3) and TFAM (I) (One-way ANOVA with Bonferroni post test and total n = 3-6) shows 
increased mRNA expression of Bcl-2, PGC1α and TFAM in PK2 cells compared to vector cells 
24 h post-MPP+ (300 μM). Increased TFAM and TOM20 protein levels were found in PK2 cells 
compared to vector cells 24 h post-MPP+ (300 μM) (J). Analysis of mitochondrial ND1 as a marker 
of mitochondrial DNA content shows increased mitochondrial DNA copy number (K) in PK2 cells 
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compared to vector cells 24 h after 300-μM MPP+ (One-way ANOVA with Bonferroni post test 
and total n = 6). Data represented by group mean ± SEM (* p<0.05, ** p<0.01 and *** p<0.001, 
relative to relevant control or MPP+-treatment groups). 
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Figure 8. Recombinant PK2 protects primary dopaminergic neurons from MPP+ neurotoxicity. 
(A) Expression of prokineticin receptors on primary dopaminergic neurons. Primary 
mesencephalic neuron cultures were stained for PKR1 and PKR2 (red) and TH (green). Both PKR1 
and PKR2 were expressed on TH+ dopaminergic neurons. Scale bar, 10 µm. (B) Calcium 
mobilization by rPK2 in primary mesencephalic neuron cultures. Primary neuron cultures were 
treated with nanomolar doses of rPK2 and the calcium flux was quantified via Fluo-4 NW calcium 
assay. Control cells were treated with calcium-free HBSS containing PK2. Calcium-flux was 
expressed as the net change in fluorescence signal (Df) represented as the maximum signal after 
baseline subtraction for each dose of PK2. Calcium was mobilized by PK2 in a dose-dependent 
manner. Data represented by group mean ± SEM. Asterisks denote significant (*** p<0.001) 
differences between HBSS-treated controls and PK2-treated groups. (C) Immunocytochemistry 
for TH+ dopaminergic neurons in EVM cultures treated with MPP+ and PK2. The PK2-treated 
cultures significantly improved dopaminergic neuron survival and function compared to MPP+-
alone, showing less degeneration of dopaminergic cell bodies and neurites. Representative images 
of dopaminergic neurons in primary EVM cultures were acquired at 20X using a Nikon TE2000-
U fluorescence microscope. MPP+ caused extensive degeneration of dopaminergic neurons, which 
was attenuated by rPK2. Scale bar, 10 µm. (D-F) TH+ neuron counts (D) (One-way ANOVA with 
Bonferroni post test and total n = 4), TH+ neurite length measurements (E) (One-way ANOVA 
with Bonferroni post test and total n = 3) and dopamine uptake functional assay (F) (Student’s t-
test with total n = 3) in primary EVM neuronal cultures. Primary EVM cultures were treated with 
MPP+ (5 μM) for 48 h or co-treated with rPK2 (25 nM), which was added initially and again 24 h 
later. Data represented by group mean ± SEM. Asterisks denote significant (*** p<0.001) 
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differences between the control and MPP+-treated groups. # and ### denotes p<0.05 and p<0.001 
between the MPP+ and MPP+/PK2 co-treatment groups. 
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Figure 9 Inhibition of endogenous PK2 signaling by a receptor blocker exacerbates MPTP-
induced toxicity in mice. Mice were intraperitoneally injected with 18 mg/kg MPTP or equal 
volumes of saline (vehicle), once daily for three consecutive days. PKRA7 (20 mg/kg/day) was 
given i.p. 24 h before MPTP treatment and continued once daily for 10 consecutive days until 
sacrifice. (A) TH-DAB immunostaining in the substantia nigra (SN) and striatum (2X 
magnification). Scale bar, 200 µm. (B-C) Stereological counts of TH-positive (B) and Nissl-
positive (C) neurons in the SN of ventral midbrain. (D) Integrated density quantification of DAB 
immunostaining in the striatum. Data represented by group mean ± SEM of 3 mice per group using 
one-way ANOVA with Bonferroni post test and total n = 3 (** p<0.01 and *** p<0.001, relative 
to relevant control or MPTP-treatment groups). (E) Western blot analysis of SN samples probed 
for TH and its quantification (right panel) show reduced TH levels when PKRA7 is administered 
along with MPTP. Data represented by group mean ± SEM using one-way ANOVA with 
Bonferroni post test and 5-7 mice per group (* p<0.05, ** p<0.01 and *** p<0.001, relative to 
control or MPTP-treated groups). (F) Western blot analysis of SN samples demonstrates that 
PKRA7 treatment does not change PK2 or PKR2 levels. Data represented by group mean ± SEM 
using one-way ANOVA with Bonferroni post test and 4 mice per group. (G) Compared to MPTP-
alone, PKRA7 treatment significantly reduced striatal dopamine levels, as measured using high-
performance liquid chromatography (HPLC). Data represented by group mean ± SEM using 
Student’s t-test and a total n = 2-3  mice per group (* p<0.05, ** p<0.01, and *** p<0.001, relative 
to relevant control or MPTP-treatment groups). (H-J) Mice were tested for motor activities 7 days 
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after the last dose of MPTP. (J) Representative movement tracks of mice are shown. Behavior 
analysis showing horizontal activity (H) (Student’s t-test with total n = 7) and number of 
movements (I). Data represented as the mean ± SEM using one-way ANOVA with Bonferroni 
post test and total n = 7-8 mice per group (* p<0.05, ** p<0.01). 
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Figure 10. PK2 overexpression protects against MPTP-induced neurotoxicity in mice. Mice were 
stereotaxically injected in the striatum with either GFP-AAV or GFP tagged PK2-AAV and 
allowed to reach maximal viral expression for four weeks. The mice were then intraperitoneally 
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injected with 20 mg/kg MPTP or equal volumes of saline (vehicle), once daily for four consecutive 
days and sacrificed 24 h after the last injection. (A) Expression of PK2 virus in the striatum by 
immunofluorescence microscopy. Brain sections were probed with anti-GFP (Green) and anti-PK2 
(Red) antibodies and imaged to show that the two proteins co-localize together (2X and 20X 
images). Scale bar, 200 µm (2 X images); 40 µm (20 X images). (B) PK2 overexpression levels 
by Western blotting. Striatal protein lysates probed for either GFP or PK2 show that the PK2 virus 
was able to overexpress PK2 in the striatum. Since GFP was directly fused to PK2, we observed 
only one band corresponding to the tagged PK2-GFP fusion protein and did not detect a separate 
25-kDa GFP band in the GFP tagged PK2-AAV samples. (C-F) Mice were tested for motor 
activities 1 day after the last dose of MPTP. (C) Representative VersaPlot movement tracks of 
mice are shown. Behavioral data showing horizontal activity (D), number of movements (E) and 
rotarod activity (F). Data represented by group mean ± SEM using one-way ANOVA with 
Bonferroni post test and a total n = 12-24 mice per group (** p<0.01 and *** p<0.001, relative to 
relevant control or MPTP-treatment groups). “ns” stands for non-significant with an exact p-value 
= 0.0912 (D), 0.1048 (E), 0.55 (F), and 0.054 (H). (G-J) PK2-AAV protects against MPTP-
induced loss of dopaminergic neurons. (G) TH-DAB immunostaining in the striatum (2X 
magnification). Scale bar, 200µm. (H) Integrated density quantification of DAB immunostaining 
in the striatum (One-way ANOVA with Bonferroni post test and a total n = 12-16). (I) TH-DAB 
immunostaining (2X magnification) in the substantia nigra (SN). Scale bar, 100µm. (J-K) 
Stereological counts of TH-positive (J) and Nissl-positive (K) neurons in the SN of the ventral 
midbrain. Data represented by group mean ± SEM using one-way ANOVA with Bonferroni post 
test and a total n = 3 mice per group (*** p<0.001, relative to relevant control or MPTP-treatment 
groups). 
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Supplemental Figures 
 
 
 
Supplementary Figure 1. Prokineticin-2 is induced in the substantia nigra, but not in the striatum, 
in MPTP-treated mice. C57BL/6 mice were injected with 4 doses of MPTP (18 mg/kg, i.p.) each 
separated by 2-h intervals. Representative Western blots of PK2 expression in nigral, striatal and 
cortical lysates. 
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Supplementary Figure 2. (A) Direct visualization of eGFP-PK2 in the olfactory bulb and 
suprachiasmatic nucleus where PK2 is known to be constitutively expressed at high levels in the 
adult PK2-eGFP reporter transgenic mouse brain. Representative images are shown. Scale bars, 
40 µm. (B) Saline- or MPTP-treated transgenic mice were sacrificed 24 h after the last injection 
and subjected to immunoblotting analysis of eGFP and PK2 expression in substantia nigra; β-
Actin was used as a loading control.  
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Supplementary Figure 3. Spontaneous locomotor activity plots of MitoPark mice and age-
matched controls at 8 weeks (presymptomatic) and 12 weeks (onset) showing decreased activity 
in MitoPark mice with disease onset at 12 weeks. 
 
 
Supplementary Figure 4. Additional Western blots of PK2 (A) and PKR2 (B) expression in nigral 
lysates PD patients and age-matched controls.   
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Supplementary Figure 5. PKR2 is expressed ubiquitously in MAP2-positive neurons in the 
substantia nigra of human brains. Double-labeling immunofluorescence for PKR2 (Red), MAP2 
(Green) and nuclei (blue) in substantial nigra of human brains. Scale bar, 10 µm. Representative 
images are shown.  
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Supplementary Figure 6. Stable expression of PK2 protects against dopaminergic cell death. 
(A) Stable expression of PK2 in dopaminergic MN9D cells was confirmed by Western blot. 
Overexpression of PK2 did not affect PK2 receptor expression. Densitometric analysis of PK2 
band intensity is shown in right panel with a total n = 2 and analyzed using student’s t-test. (B) 
Immunofluorescence staining for PK2-myc expression in vector and PK2 stable cells using an 
myc-antibody. Scale bar, 10µm. (C-D) MN9D cells expressing PK2 were partially protected from 
MPP+-induced neurotoxic insult as assessed by MTS (C) (student’s t-test; n = 3-5) and caspase-
3 activity assays (D) (one-way ANOVA with Bonferroni post-test; n = 3). The protective effect of 
PK2 overexpression was abolished using the specific PK2 receptor antagonist PKRA7 (2 μM).  
(E) The number of late-apoptotic cells following MPP+ treatment was abolished in PK2-
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overexpressing cells at 24 h, as quantified by flow cytometric analysis of Annexin V staining (one-
way ANOVA with Bonferroni post-test; n = 3). Data represented by group mean ± SEM and 
asterisks denote statistical significance (* p<0.05 and *** p<0.001, relative to relevant control or 
MPP+-treatment groups). 
 
 
 
 
 
V
e
c
to
r
P
K
2
V
e
c
to
r
P
K
2
V
e
c
to
r
P
K
2
V
e
c
to
r
P
K
2
0
100
200
300
*
TFAM                           TOM20
Control MPP
+
Control MPP
+
*
*
ns
P
ro
te
in
 l
e
v
e
l
(%
 v
e
c
to
r 
c
o
n
tr
o
l)
 
 
Supplementary Figure 7. Densitometric analysis of the Western blots in Figure 7J.  Data are 
representative of at least three independent experiments (Means ± SEMs of three samples) (* 
p<0.05, relative to Vector control or MPP+-treatment groups, ns, non-significant p = 0.1618).  
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Supplementary Figure 8. Mice were intraperitoneally injected with 18 mg/kg MPTP or equal 
volumes of saline (vehicle), once daily for three consecutive days. PKRA7 (20 mg/kg/day) was 
given i.p. 24 h before MPTP treatment and continued once daily for 10 consecutive days until 
sacrifice. Western blot analysis of SN samples demonstrates that PKRA7 treatment does not 
change PK2 or PKR2 levels. Data represented by group mean ± SEM using one-way ANOVA 
with Bonferroni post-test and 4 mice per group. 
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Supplementary Figure 9. Expression of GFP-PK2 in the substantia nigra following PK2-AAV 
injection into the striatum at 4 weeks post injection (white arrows). Double labeling 
immunofluorescence for GFP (Green) and TH (Red) in substantia nigra region of mouse brains 
stereotaxically injected with Saline, PK2-AAV, or GFP-AAV in the striatum. Scale bar, 40 µm.  
 
 
 
Supplementary Figure 10. Rabbit PK2 polyclonal antibody was pre-absorbed by incubating 5 µg 
of antibody together with 25 µg of recombinant PK2 protein overnight and Western blot was run 
with N27 cell lysates and incubated overnight with either pre-absorbed antibody (left) or normal 
antibody (right).  
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Supplementary Table 1. TNFα-induced PK2 gene upregulation in N27 dopaminergic cells in 
qPCR array 
 
Gene Fold change (TNFα/Control) 
Prok2 6.81 
Ripk2 3.80 
Tnfrsf5 2.86 
 
PK2 was discovered as a candidate in a Qiagen mouse apoptosis qPCR array study of 84 
apoptosis-related genes. The three most upregulated genes are shown with PK2 mRNA 
expression induced by over 6-fold. 
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Supplementary Table 2. Human post-mortem tissues used for immunoblot and IHC in Fig. 3 
and supplementary Fig. 4. (N/A= not available) 
 
  
Sample 
Code 
Gender Age 
(yrs) 
Post-mortem 
intervals 
Braak Score Neuropathological 
Diagnosis 
      
454 M 69 40 I-II Parkinson’s disease 
580 M 65 27 III-IV Parkinson’s disease 
588 M 72 12 III-IV Parkinson’s disease 
582 F 76  36 N/A Parkinson’s disease 
      
526 F 54 23  Normal control 
540 M 64 28  Normal control 
562 M 42 13  Normal control 
560 F 56 5.42  Normal control 
Code Gender Age 
(yrs) 
Race Post-mortem 
intervals 
Braak 
Score 
Neuropathological 
Diagnosis 
       
AK-2013-1 M 83 C 10.5 N/A Parkinson’s disease 
AK-2013-2 F 88 C 3.8 N/A Parkinson’s disease 
AK-2013-3 M 81 C 6 N/A Parkinson’s disease 
AK-12-03 F 87  C 2.08 IV Parkinson’s disease 
AK-11-54 F 76 C 3.5 III Parkinson’s disease 
AK-11-90 M 78 C 2.75 III Parkinson’s disease 
       
AK-2013-4 F 87 C 12  Normal control 
AK-2013-5 F 72 C 7.5  Normal control 
AK-2013-6 F 87 C 8  Normal control 
AK-00-14 M 90 C 4  Normal control 
AK-05-12 M 88 C 2  Normal control 
AK-11-11 M 93 C 2.15  Normal control 
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CHAPTER III 
PROKINETICIN-2 PROMOTES ALTERANATIVE ACTIVATION OF MICROGLIA 
THROUGH THE JMJD3-IRF4 PATHWAY 
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2School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.  
 
Abstract 
 Microglial activation has been implicated in the progression of Parkinson’s disease (PD), 
and anti-inflammatories have demonstrated the ability to protect against dopaminergic 
degeneration in animal models of PD. Alternative activation of microglia towards an anti-
inflammatory phenotype can resolve the increased inflammation and lead to neuronal protection. 
Prokineticin-2 (PK2) is a small, secreted chemokine-like signaling protein with wide-ranging 
biological functions throughout the body. Microglia express the prokineticin receptors and 
recombinant PK2 [rPK2] can activate downstream pathways in microglia. In the present study, we 
demonstrate that rPK2, PK2 overexpression and a PKR1 agonist induces basal levels of alternative 
activation markers such as Jmjd3 and Arginase-1, while decreasing classical activation markers 
such as reactive oxygen species (ROS), nitric oxide and pro-inflammatory cytokines. Recombinant 
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PK2 can also attenuate LPS-induced production of reactive oxygen, nitric oxide, pro-inflammatory 
cytokines and mitochondrial bioenergetics dysfunction. Overexpression studies with PK2-AAV 
2/5 in the mouse striatum induces alternative activation in microglia, with increased ramification 
of branches. PK2-AAV 2/5 injection rescues MPTP-induced microglial deramification, whereas 
the prokineticin receptor antagonist PKRA7 exacerbates this effect. Collectively, our results 
establish a novel paradigm of neuron-microglia signaling leading to alternative activation of 
microglia that could be an important therapeutic avenue for PD. 
 
Introduction 
 Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease that is 
characterized by the loss of dopamine producing neurons in the substantia nigra region of the brain. 
The exact cause of this neuronal death is not known, however, several factors have been implicated 
in the progression of the disease. These factors include mitochondrial dysfunction, oxidative stress, 
and neuroinflammation. Several studies have demonstrated that neuroinflammation is major part 
of PD progression (Hirsch and Hunot 2009), but the initial cause of the inflammation is not well 
understood. The hallmark of neuroinflammation includes increased number of activated microglia 
in the nigrostriatal pathway and the production of proinflammatory cytokines such as TNFα and 
IL-1β. Interestingly, several animal models of PD, including the neurotoxin MPTP that can cause 
Parkinsonian symptoms, has also been shown to increase inflammation and proinflammatory 
cytokines (Lofrumento et al.). Recently, our group discovered that a chemokine-like protein, 
Prokineticin-2 or PK-2, is upregulated in dopaminergic neurons on stimulation with inflammatory 
factors or neurotoxicants.  
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 Prokineticins are proteins that obtained their name because they were first discovered to 
contract smooth muscle in the gut (Li et al. 2001). The two prokineticin proteins, Prokineticin-1 
and Prokineticin-2, are members of the AVIT protein family due to the presence of the 
particular amino acid signaling sequence AVITGA on the N-terminus. PK2 mediates diverse 
physiological functions throughout the human body, from the testis, ovaries, heart, to the brain. It 
is a signaling protein that has several characteristics of a pleiotropic cytokine or a chemokine. This 
is because PK2 has been demonstrated to promote cell survival and growth (LeCouter et al. 2004a), 
however in other systemic tissues PK2 can cause an increase in inflammation (Martucci et al. 
2006) and nociception (Negri et al. 2006a). Prokineticins activate the ERK p44/42 kinase in the 
MAPK pathway most likely through Gi signaling, calcium mobilization through Gq signaling, and 
increased Akt and cAMP levels through Gs signaling (Lin et al. 2002b). In the central nervous 
system (CNS), PK2 plays a role in regulating circadian rhythms (Zhou and Cheng 2005), olfactory 
bulb biogenesis (Ng et al. 2005), thermoregulation, and energy expenditure (Zhou et al. 2012). 
Most importantly to Parkinson’s disease though, Prokineticin-2 has demonstrated the ability to 
protect dopaminergic neurons from neurotoxic insult in vitro (OUR PAPER). 
 Tissue inflammation can induce increased PK2 levels in different tissues, including the 
brain (Gordon and Neal et al., unpublished) (Cheng et al.). However, very little is known of the 
role that PK2 plays in neuroinflammation of the CNS. Microglial cells are the resident immune 
cells in the central nervous system and have the ability to fight off infections. These microglial 
cells are constantly surveying their surroundings to check for infection, but can be polarized into 
an activated state to produce inflammation in order to suppress the infection. This activated 
inflammatory state has been labeled M1, or classical activation, and is characterized by an increase 
in inflammatory cytokines such as TNFα and IL-1β along with damaging reactive oxygen and 
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reactive nitrogen species (ROS and RNS, respectively) (Lull and Block, 2010). This M1 phenotype 
can be brought about by the bacterial endotoxin lipopolysaccharide (LPS) or Th1 cytokines such 
as interferon, IFNγ. Interestingly, activated microglial cells have been detected in the substantia 
nigra region of the brain in PD patients (Langston et al. 1999, Whitton 2007, McGeer et al. 1988). 
Evidence indicates that the activated microglia are polarized to a classical activation state due to 
the increase in inflammatory cytokines TNFα and IL-1β. Recently, it was discovered that microglia 
can be alternatively activated, labeled M2, by the Th2 cytokines IL-4, IL-13 and IL-10 (Olah et al. 
2011, Mills et al. 2000). IL-4 and IL-13 can activate signal transducer and activators of 
transcription 6 (STAT6), which can then regulate the transcription of M2 related genes (Li et al. 
2014, Wang, Liang and Zen 2014). This M2-like alternative activation leads to the expression of 
anti-inflammatory factors such as PPARγ, Arginase1 and IL-10. These genes are involved in tissue 
repair and regeneration, such as the reduction of reactive nitrogen species by Arginase1. Recent 
results from Tang et al. demonstrated that reduced microglial alternative activation, by knocking 
out the demethylase Jmjd3, led to more toxicant-induced neuronal death. It has been determined 
that microglia, unlike T helper cells, do not polarize, and continually shift their phenotype 
depending on their environment. Similarly, there are not a distinct populations of microglia that 
are either classically or alternatively activated, instead these cells are in a mixed state with no 
discernible phenotype. However, specific stimuli can elicit a phenotypic response in microglia and 
could shift the entire populations phenotype towards more of a pro- or anti-inflammatory status. 
Therefore, it is important to elucidate mechanisms that could lead to the promotion of microglia 
towards an alternative activation phenotype (Tang et al. 2014). Switching microglia phenotypes 
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from a pro-inflammatory activation towards more of an anti-inflammatory activation could be a 
potential treatment option for the therapy of neuroinflammatory diseases, such as Alzheimer’s and 
Parkinson’s disease. 
 Most importantly in association to PD, PK2 has demonstrated the ability to protect 
dopaminergic neurons from neurotoxic insult in vitro. Our lab previously found that PK2 
expression is induced in Parkinson’s disease patients when compared to age-matched controls, and 
this increase is localized to the remaining dopaminergic neurons. We went on to demonstrate that 
dopaminergic neurons in vitro secreted increased levels of PK2 with neurotoxic insult (Gordon 
and Neal et al., unpublished). Both astrocytes and microglia express both prokineticin receptors, 
PKR1 and PKR2, and PK2 is able to signal through these receptors in both of these cell types 
(Koyama et al. 2006). However, there is currently no research published regarding microglial 
prokineticin signaling in neurodegenerative disease models. With the knowledge that PK2 can 
protect neurons, the current study went on to investigate the role of PK2 in microglial cells and its 
role in alternative activation. 
 
Results 
Prokineticin receptors R1 and R2 are expressed in microglial cells 
 PK2 is a small chemokine-like protein that signals through two G protein-coupled 
receptors, PKR1 and PKR2. PKR1 and R2 can both bind PK2 and have the potential to signal 
through different cascades (Zhou 2006). Studies have shown mRNA expression of both receptors 
in several areas of the body, including the brain (Lin et al. 2002b). However, the expression of 
PKR1 has been found more in peripheral areas such as the testis and skin, whereas PKR2 is 
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expressed higher in the CNS. Also, evidence points to the fact that PK2 activates the receptors at 
slightly different concentrations. PK2 can activate PKR1 at lower concentrations than PKR2 (Soga 
et al. 2002a). Although PKR2 has been seen at a higher level than PKR1 in the CNS, Koyama et 
al. demonstrated that PKR1 is expressed higher in the glial cells of the brain, including astrocytes 
and microglia (Koyama et al. 2006). Since PK2 had previously been demonstrated to modulate 
systemic inflammation and is increased in PD, we therefore wanted to determine the effect of PK2 
on the resident immune cells of the CNS, microglial cells. To begin with, we wanted to confirm 
that our cultured primary mouse microglia expressed the prokineticin receptors and that 
recombinant PK2 can signal to these cells. We found that both receptors were expressed in the 
primary mouse microglia by ICC (Figure 1A) and Western blotting (Figure 1B). The microscopy 
showed a differential cellular localization of R1 and R2, with R1 localized more around the 
periphery and R2 more throughout the cytoplasm. Consistent with previous results, the Western 
blots showed more PKR1 expression compared to PKR2. To verify these results we ran qPCR to 
determine the gene expression levels of both receptors in both mouse astrocytes and microglia 
(Figure 1C). These results indicate that the prokineticin receptors are expressed on our cultured 
mouse microglial cells. PK2 signaling in mouse astrocytes has been demonstrated to result in an 
increase in intracellular calcium, cell proliferation, and MAPK pathway activation (Koyama et al. 
2006). Since we confirmed that our cultured glial cells express the prokineticin receptors, the next 
step was to confirm that the human recombinant PK2 (Peprotech) could elicit the functional 
signaling in primary mouse microglial cells. Previous groups measured the increase in intracellular 
calcium to determine that PK2 activated one of the receptors in a particular cell type (Ngan and 
Tam 2008). Therefore, we used the Fluo4 fluorescent calcium dye to determine intracellular 
calcium levels as an experiment to test PK2 signaling in the microglial culture. We found that there 
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was a dose-dependent increase in intracellular calcium levels with PK-2 treatment in a primary 
mouse microglial cell culture (Figure 1D). Together, these results demonstrate that human 
recombinant PK2 can signal in our primary mouse microglial cells and cause functional changes 
such as increased intracellular calcium mobilization.  
Prokineticin-2 promotes alternative activation of mouse microglia 
 It was previously thought that activation of microglia would always lead to a pro-
inflammatory phenotype, known as classical activation, or M1. It is now known that certain stimuli 
can induce microglia to become activated but have an anti-inflammatory or protective phenotype, 
this is called alternative activation of microglia, or M2 (Boche et al. 2013). However, the 
mechanism underlying microglial polarity is not completely understood and seems to be more of 
a spectrum of phenotypes, with many different levels between classical activation, ‘resting’ 
(surveillant) and alternative activation. Certain factors, such as the IL-4 and IL-13 cytokines can 
polarize microglia towards an M2-like phenotype through STAT6 signaling (Li et al. 2014). Jmjd3 
is a histone demethylase that is mediated by STAT6 signaling and has previously been implicated 
in the induction of genes that are important for alternative activation in microglia. Jmjd3 is able to 
protect dopaminergic neurons from toxicant-induced cell death (Tang et al. 2014) through 
polarizing microglia. The demethylase activity of Jmjd3 leads to activation of M2 related genes, 
such as Arginase1 and mannose receptor, through the induction of the Irf4 transcription factor 
(Satoh et al. 2010). PK2 has demonstrated the ability to mediate inflammatory responses 
systemically, including macrophages (Martucci et al. 2006, Monnier and Samson 2008). We 
wanted to characterize the effect of exogenous PK2 on microglial activation states. Interestingly, 
we found that with exogenously added recombinant human PK2 (rPK2) on isolated primary mouse 
microglial cells significantly induced Jmjd3 gene expression (Figure 2A). This increase was also 
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attenuated with co-treatment with PC-7, a PK2 receptor antagonist, therefore showing that the 
increase of Jmjd3 expression was due to PK2 signaling. Following the discovery that PK2 can 
increase Jmjd3 expression, we wanted to measure several alternative activation marker genes to 
confirm that the increased Jmjd3 led to an alternative activation phenotype, such as what has been 
previously classified as M2. Gene expression studies of Irf4, Arginase-1 and mannose receptor c 
type-1 (Mrc1) showed a significant increase in the expression of these genes with rPK2 treatment, 
similar to the effect of IL-4, that was attenuated with co-treatment with PC7 (Figure 2B-  2D, 
respectively). Following the gene expression results, we wanted to examine the protein level of 
Jmjd3 and an important M2-associated marker, Arginase-1, using by Western blotting techniques. 
Consistent with the qPCR results we found that PK2 increases both Jmjd3 and Arginase-1 protein 
level compared to control, and PC-7 is able to significantly reduce this increase (Figure 2E). 
Similarly, immunocytochemistry (ICC) of Jmjd3 and Arginase-1 in primary mouse microglia 
allows the visual representation of the PK2-induced increase in these proteins that can be 
attenuated with PC-7 (Figure 2F). By quantifying the fluorescent signal, we were able to show 
consistency with the previous results of PK2 significantly increasing (~2 fold) Jmjd3 (Figure 2G) 
and Arginase-1 (Figure 2H). Collectively, this data demonstrated that exogenously added rPK2 
can induce an alternative activation, or M2-like, phenotype of mouse primary microglial cell 
cultures through the STAT6-Jmjd3-Irf4 signaling pathway.  
 
Prokineticin-2 attenuates toxicant-induced ROS and RNS in microglial cells 
 Neuroinflammation seen in PD includes increases in proinflammatory cytokines, such as 
TNFα, and IL-1β, along with ROS and RNS (Imamura et al. 2003, Panicker et al. 2015). The main 
sources of these inflammatory factors are the glial cells, and more specifically microglia. Previous 
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studies have demonstrated that anti-oxidant drugs can actually protect dopaminergic neurons from 
apoptosis (Jin et al. 2014a). Similar results were seen by reducing nitric oxide (NO) levels (Wong 
and Lerner 2015). Our previous results with PK2 signaling in neurons demonstrated that 
recombinant PK2 treatment could protect neurons by increasing Bcl2 and protecting the 
mitochondria (Gordon and Neal et al., unpublished). In that study we have shown that PK2 can 
attenuate toxin-induced ROS production in dopaminergic neurons. In this study, we wanted to 
investigate whether PK2 could have a similar reduction of ROS on microglial cells, and also look 
into microglial-derived RNS production. First, we used the endotoxin LPS to activate cultured 
primary microglial cells. After measuring intracellular ROS (iROS) levels using DCFDA 
fluorescent dye, we found that LPS significantly increased iROS production in these primary 
microglial cells and that cotreatment with 25nM of PK2 completely attenuated this increase 
(Figure 3A). These results are consistent with what we found in neurons, in that PK-2 cotreatment 
can reduce toxin-induced iROS levels. Nrf2 is the transcription factor mainly seen for anti-oxidant 
response genes, and an increase in Nrf2 activity leads to a reduction in ROS damage. Interestingly, 
we found that the gene expression for Nrf2 and one of the target genes of Nrf2, Prdx2, is 
significantly increased with rPK2 treatment (Figure 3B). Similarly, Nrf2 protein levels, measured 
by Western blot, also increased with rPK2 treatment, and using the receptor antagonist PC7 we 
were able to attenuate the PK2-induced increase of the Nrf2 protein (Figure 3C). Therefore, rPK2 
treatment in cultured primary microglial cells attenuated LPS-induced iROS levels, possibly 
through the upregulation of Nrf2 and its target gene Prdx2. We previously found that PK2 
treatment in dopaminergic neurons led to an increased expression of the anti-apoptotic 
mitochondrial protein Bcl2. We found similar results with rPK2 treatment in cultured primary 
microglia, with a significant increase in Bcl2 gene expression that can be attenuated with co-
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treatment with the PK2 receptor antagonist PC-7 (Figure 3D). Some reports have found that Bcl2 
acts as an anti-inflammatory mediator through inhibition of NFκB (Badrichani et al. 1999). 
Therefore, PK2 can induce several factors that can reduce or protect against oxidative stress.  
 Increased Bcl2 has been implicated in protecting the cell against mitochondrial dysfunction 
(Thomenius and Distelhorst 2003). Therefore, the increase in these anti-oxidant and mitochondrial 
protective proteins led us to examine the effect of rPK2 treatment on mitochondrial bioenergetics 
in microglia. Previous studies found that LPS treatment could reduce oxidative respiration in 
microglial cell cultures using the Seahorse XFe24 instrument(Orihuela et al. 2016). We found 
similar results with an 8 hour LPS treatment in primary microglia (Figure 3E), where basal 
respiration (Figure 3F, left panel) and ATP production (Figure 3F, right panel) were both 
significantly reduced compared to control. Interestingly, rPK2 co-treatment with LPS significantly 
attenuated the reduction in both basal respiration and ATP production and brought these 
parameters back to control levels. Recombinant PK2 treatment alone did not change either 
parameter compared to control. These results are the first to indicate that PK2 signaling can 
attenuate LPS-induced mitochondrial dysfunction in primary mouse microglia. 
We then went on to measure the reactive nitrogen species (RNS), nitric oxide (NO) levels 
produced in primary microglial cells treated with either LPS alone or co-treated with rPK2. 
Recombinant PK2 co-treatment was able to significantly attenuate LPS-induced NO production in 
primary microglial cells (Figure 3E). This reduction was not specific to LPS treatment, because 
we found that PK-2 also significantly attenuated TNFα-induced NO production in BV2 cells (not 
shown). The enzyme responsible for the production of nitric oxide in microglial cells is inducible 
nitric oxide synthase, or iNOS. Using qPCR to determine gene expression, we found that rPK2 
treatment was able to significantly reduce basal levels of NOS2 gene expression that was 
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attenuated with co-treatment with PC-7 (Figure 3F). Oxidative stress has been implicated in the 
progression of Parkinson’s disease, and reduction of these damaging molecules has demonstrated 
the ability to have a positive impact in fighting the disease progression. Herein, we found that 
cotreatment with recombinant human PK2 is able to significantly attenuate LPS-induced ROS and 
NO production, and mitochondrial energetics dysfunction in microglial cells.  
 
Prokineticin-2 reduces inflammatory cytokines production in primary microglial cells 
 Microglial cells are able to fight off infections using inflammatory molecules such as ROS, 
RNS and cytokines. It is normal for microglia to become classically activated and secrete 
inflammatory cytokines for short periods of time, but when this activation persists into chronic 
activation then it can lead to neurodegenerative diseases such as Parkinson’s disease (Castano et 
al. 1998, Herrera et al. 2000, Qin et al. 2007). It is also known that as ageing occurs, microglial 
cells are more prone to become classically activated into an inflammatory state (Perry and Holmes 
2014). If there were a way to reduce inflammatory cytokine production from these microglial cells, 
then it could help to slow the progression of a number of neurodegenerative diseases. Since rPK2 
was able to increase M2-associated markers in these microglial cultures, we wanted to determine 
if rPK2 treatment could also reduce M1-associated inflammatory markers. Surprisingly, we found 
that rPK2 treatment on primary mouse microglial cell cultures lead to a significant decrease in the 
gene expression of TNFα, IL-6 and IL-12 (Figure 4 A,B,and C).  Consistent with this data, after a 
12-hour treatment with rPK2 there was a significant reduction in the secreted protein level pro-
inflammatory cytokines TNFα, IL-12, and IL-6 (Figure 4D). Age is the major factor that increases 
likelihood of having Parkinson’s disease and microglial cells change to a more pro-inflammatory 
activation state with an increase in age, which this leads to more pro-inflammatory cytokines. 
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These are the first reported results indicating that human rPK2 can reduce pro-inflammatory 
cytokines in primary microglial cells. Therefore, this further indicates that PK2 can have an impact 
in polarizing microglia towards an alternative or anti-inflammatory phenotype and could have a 
positive impact on ageing and neurodegenerative disease such as Parkinson’s disease. Studies into 
PK2 reveal that it is produced higher in inflamed systemic tissues compared to healthy tissues 
(Chauvet et al. 2015, Chen et al. 2015a, Chen et al. 2016, Abou-Hamdan et al. 2015, Watson et al. 
2012). With this in mind, we wanted to investigate what role PK2 treatment would play in primary 
mouse microglia in an inflammatory setting. LPS is a powerful endotoxin that has been 
demonstrated to cause a significant increase in M1-associated pro-inflammatory cytokines in 
microglia (Castano et al. 1998, Herrera et al. 2000). Therefore, we treated primary mouse microglia 
with LPS and co-treated with rPK2, then measured secreted cytokine levels. Interestingly, we 
found that co-treatment with PK2 significantly reduced the production of several LPS-induced 
M1-associated pro-inflammatory cytokines, such as TNFα, IL-6, and IL-12 (Figure 4E-4G, 
respectively). This is the first study to show that Prokineticin-2 can significantly reduce toxin-
induced pro-inflammatory cytokines in primary mouse microglial cells. Therefore, PK2 could play 
a role in reversing the neuroinflammation seen in neurodegenerative diseases such as Parkinson’s 
disease by polarizing the microglia away from a pro-inflammatory and towards a more anti-
inflammatory phenotype. 
PK2 overexpression in vitro induces an alternative activation microglial phenotype 
 Since microglial activation is important in health and disease, understanding the pathways 
involved in the switch from one phenotype to another would be beneficial to understanding how 
to protect against many inflammatory diseases. Following our cell culture results that showed rPK2 
treatment can induce an alternative activation phenotype and reduce production of pro-
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inflammatory factors, we wanted to determine if PK2 overexpression (PK2 OE) would have the 
same effect both in vitro and in vivo. We used a lenti-viral delivery system to induce PK2 OE in 
primary mouse microglial cultures. Microglia were infected with the lenti-virus for 24 hours, cells 
were washed and kept in growth media for 24 hours and then collected. We confirmed PK2 OE in 
the microglial cells by using Western blotting techniques to show increased GFP protein level 
(Figure 5A). Similar to what was seen with rPK2 treatment, PK2 OE significantly increased the 
protein level of microglial alternative activation phenotype markers Jmjd3, Arginase1 and Nrf2 
(Figure 5B, 5C and 5D respectively) compared to control and GFP overexpression (GFP OE).  
Classical activation of primary microglial cell culture induces morphological changes 
towards a more amoeboid phenotype (Kettenmann et al. 2011, Stence, Waite and Dailey 2001). 
Interestingly, IL-4 anti-inflammatory cytokine treatment leads to a re-ramification of these 
activated microglia, indicating that morphology can be a determinant of the microglial activation 
states. Therefore, we wanted to characterize any microglial morphological changes that might be 
induced by PK2 OE in cell culture. Iba1 immunofluorescent images (Figure 5E top panel) were 
converted to binary in ImageJ and then skeletonized (Figure 5E middle panel). The skeletonized 
images were then analyzed using a specific ImageJ plugin called Analyze Skeleton (Arganda-
Carreras et al. 2010), according to previous literature that used it to measure microglial 
morphology (Morrison and Filosa 2013). This plugin analyzes the skeleton image to count the 
number of branches, junction, endpoints and determine process length (Figure 5E bottom panel). 
Using these morphological measurements, we were able to find that PK2 overexpression 
significantly increased the number of microglial branches, junctions and endpoints (Figure 5F, 5G 
and 5H respectively) compared to control and GFP OE. The overall length of the microglial 
branches was also significantly increased with PK2 overexpression compared to control and GFP 
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overexpression by looking at the longest/shortest branch, which gives the diameter of the cell’s 
branch reach. This is a way to calculate the length from the endpoint of one branch to the furthest 
endpoint on the opposite side of the cell, therefore measuring the entire breadth of the microglial 
branches. The longest/short path calculation and applications come from a previous source (Fraas, 
Niehoff and Luthen 2014). These morphological results are another indication of PK2 inducing 
alternative activation of microglia. This is because the morphology seen with PK2 OE leads to an 
increase in branches length, unlike what is seen with classical activation of microglia which leads 
to a more amoeboid morphology with less process branches. Together, this data demonstrates that 
PK2 OE, similar to recombinant PK2, can lead to an increase in alternative activation of microglia. 
PK2-AAV 2/5 induced an alternative activation microglial phenotype in vivo 
We developed an Adeno associated virus (AAV) viral expression system that can 
overexpress PK2 tagged to GFP. We injected the PK2-AAV into the mouse striatum 
stereotaxically, and were able to get PK2 overexpression stably for at least 2 months (data not 
shown). Once we determined that the PK2-AAV injection was successful in vivo, we wanted to 
determine if the PK2-AAV could induce alternative activation of microglia in the mouse striatum. 
Interestingly, using qPCR gene expression studies we found that the PK2-AAV was able to 
significantly increase the expression of multiple alternative activation genes, such as Jmjd3, Irf4, 
Arginase1, Mrc1 (CD206), Nrf2, and Bcl2 (Figure 6A), when compared to control animals injected 
with GFP AAV in same site of the striatum. Next, we wanted to determine if PK2-AAV can reduce 
classical activation markers, such as pro-inflammatory cytokines. We found PK2-AAV 
significantly reduced basal TNFα, IL-1β, IL-6, IL-12 and NOS2 (Figure 6A) when compared to 
GFP-AAV injected animals. This data indicates that PK2 overexpression can lead to alternative 
activation of microglia in vivo by increasing alternative activation markers while reducing classical 
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activation markers. Next, we analyzed used Western blotting techniques to measure the protein 
level of microglial activation markers in the mouse striatum. We found a significant increase in 
both Jmjd3 (Figure 6B left panel) and Arginase1 (Figure 6B right panel) protein level in the mouse 
striatum with PK2-AAV when compared to control and GFP-AAV. To show that this increase in 
Jmjd3 and Arginase1 were coming from microglia, we used triple-label immunofluorescence in 
striatum sections to visualize the protein levels. As expected, we found that PK2-AAV was able 
to increase both Jmjd3 (Figure 6C) and Arginase1 (Figure 6D) in Iba1-positive cells in the striatum 
compared to GFP-AAV injected animals. Therefore, the increases in Jmjd3 and Arginase1 are seen 
specifically in microglial cells, although these proteins might also be increased in other cell types. 
Overall, these results demonstrate for the first time that PK2 overexpression is able to induce 
alternative activation of microglial cells in vivo.  
 Classical activation of microglia leads to well characterized morphological changes in vivo. 
These changes include the de-ramification of the microglial branches and cell soma hypertrophy. 
Therefore, measuring microglial morphological parameters can give insight into the activation 
state of microglia in the brain. We wanted to investigate the effects of PK2-AAV injection in the 
mouse striatum on microglial morphology to give an indication of the microglial activation states. 
We used Iba1 DAB immunostaining to label the microglia in the striatum, and this staining gave 
a clear image of the microglia all the way down to the fine processes. The DAB phase contrast 
images (Figure 6E top inset) were then converted to binary and skeletonized (Figure 6E middle 
inset). The Analyze skeleton plugin then converted the skeletonized image to count the number of 
branches, junctions, endpoints and length of branches (Figure 6E bottom inset). Analyzing over 
200 microglia across at least three animals for each treatment showed us that PK2-AAV increased 
the number of branches, junctions and endpoints per cell (Figure 6F, 6G and 6H, respectively) 
143 
 
compared to GFP-AAV injected animals. Similar to the results from microglial cell cultures, we 
also found an increase in the longest-shortest path (Figure 6I), which is an indication of the total 
breadth of the microglial branches from the endpoint of one branch to the endpoint of the furthest 
branch. We went on to measure cell soma descriptors such as cell soma total area and roundness 
using ImageJ. This is because some reports have described alternative phenotype morphology with 
a thin cell body, whereas classical activation leads to a larger cell soma (Gonzalez et al. 2014). 
Interestingly, we found that PK2-AAV was able to significantly reduce the roundness of the cell 
soma, and therefore more of a thinner morphology (Figure 6J). However, PK2-AAV did not 
increase cell soma size compared to control, whereas the GFP AAV injection did significantly 
increase microglial cell soma area (Figure 6K). This increase of the cell soma by GFP-AAV could 
be due to injury from the stereotaxic injection used to add the virus, whereas PK2-AAV was able 
to attenuate this injection-induced change. Taken together, these data demonstrate that PK2-AAV 
is able to induce a morphological change in microglial cells that is similar to what has been 
described as alternatively activated microglia. These results also demonstrate that the Analyze 
skeleton ImageJ plugin can be a tool used to determine activation states of microglia.  
 
PK2-AAV 2/5 attenuates MPTP-induces microglial morphology changes 
 Several groups, including our lab (Ghosh et al. 2012, Ghosh et al. 2016), have shown that 
MPTP leads to an increase in microglial activation and inflammation (Costa et al. 2013, Kim et al. 
2012, Lofrumento et al. 2011). Our lab previously demonstrated that PK2-AAV could protect 
dopaminergic neurons from MPTP-induced cell death. Therefore, we wanted to determine if PK2-
AAV could attenuate the MPTP-induced activation of microglial cells in the mouse striatum. 
Using Iba1 DAB immunostaining to look at the microglial cells in the striatum (Figure 7A top 
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panel), we converted the images into binary and then the images were skeletonized (Figure 7A 
middle panel). Using the Analyze skeleton ImageJ plugin, the skeletonized images were converted 
to analyze the microglial branches, junctions, endpoints and branch length. As expected, MPTP 
induced a significant reduction in microglial branches, junctions, endpoints and branch length 
(Figure 7B, 7C, 7D and 7E, respectively) compared to saline injected animals. Interestingly, PK2-
AAV not only significantly attenuated the MPTP-induced morphological changes, but increased 
all of the metrics significantly more than the saline group. Importantly, GFP-AAV had no effect 
on MPTP-induced microglial morphology changes, so the injection and the virus did not lead to 
any protection. We then went on to show that MPTP caused a significant increase in the microglial 
cell soma size, that PK2-AAV was able to significantly attenuate and bring back to control levels 
(Figure 7F). These results demonstrate that PK2 overexpression in vivo can attenuate the MPTP-
induced microglial classical activation morphology. 
 
PK2 receptor antagonist PKRA7 exacerbates MPTP-induced microglial morphology 
changes 
Our lab previously found that MPTP treatment increases PK2 production and secretion in 
dopaminergic neurons. Since we found that PK2 overexpression can lead to attenuation of MPTP-
induced morphological changes, we wanted to use a prokineticin receptor antagonist to determine 
if blocking prokineticin signaling would exacerbate of the phenotype. We injected PKRA7, a 
specific prokineticin receptor antagonist, intraperitoneally once a day starting one day before the 
first MPTP injection and continued giving PKRA7 injections daily until sacrifice 12 days after the 
first injection. We injected MPTP 18mg/kg once a day for 5 days and then sacrificed the animals 
7 days after the last MPTP injection. This is a well characterized MPTP subacute paradigm that 
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leads to neuronal loss and neuroinflammation (Petroske et al. 2001, Meredith and Rademacher 
2011b). Again, we used the Iba1 DAB immunostaining and Analyzed skeleton ImageJ plugin to 
measure the morphology changes (Figure 8A). We found that this MPTP paradigm also led to a 
microglial morphology shift towards a classical phenotype, and PKRA7 significantly exacerbated 
the MPTP-induced loss of microglial branches, junctions, endpoints (Figure 8B, 8C, and 8D, 
respectively). Interestingly, PKRA7 also exacerbated the de-ramification of the microglia, leading 
to both significantly reduced branch length and increased cell soma area (Figure 8E and 8F). These 
results demonstrate that blocking the MPTP-increased PK2 signaling to microglial cells that it 
exacerbates the MPTP-induced microglial classical activation morphology.  
 
PKR1 chemical agonist IS20 induces alternative activation phenotype in microglial cells 
 Recently, Gasser et al. created a selective PKR1 agonist, IS20, and demonstrated that this 
agonist could protect cardiomyocytes from a myocardial infarction (Gasser et al. 2015). Dr. 
Desaubry was gracious enough to send us some of the compound so that we could test the ability 
of this agonist to perform a similar function as rPK2 and PK2 OE in a microglial cell culture. 
Interestingly, we found that IS20 treatment on primary microglia for 8 hours significantly 
increased the gene expression of alternative activation markers such as Jmjd3, Arginase1, Mrc1, 
and IGF-1. While at the same time significantly decreasing or having no effect on classical 
activation markers such as NOS2, IL-1β, IL-6, and TNFα compared to control (Figure 9A). We 
followed these results with Western blotting (Figure 9B) of Jmjd3 (Figure 9C) and Arginase1 
(Figure 9D) to demonstrate that these alternative activation proteins are significantly increased 
with IS20 treatment compared to control. We went on to perform immunofluorescence microscopy 
for both Jmjd3 and Arginase-1 to visualize the protein levels (Figure 9E). Analyzing the 
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immunofluorescence from these images showed us that IS20 significantly increased both Jmjd3 
(Figure 9F) and Arginase-1 (Figure 9G) in these cultured primary microglial cells compared to 
control. These results were confirmed by using IL-4 as a positive control, and that treatment led to 
an even greater increase in the immunofluorescence of both Jmjd3 and Arginase-1. These results 
demonstrate that the PKR1 agonist IS20 can induce alternative activation of cultured microglial 
cells. 
 Similar to PK2 overexpression, we wanted to examine the morphology of the cultured 
primary microglia with IS20 treatment. Iba1 immunofluorescent images were used to skeletonize 
and then analyzed using the Analyze skeleton ImageJ plugin (Figure 9H). We found that IS20 
treatment was able to increase microglial branches, junctions, and endpoints (Figure 9I, 9J, and 
9K, respectively). Overall microglial branch length was also significantly increased with IS20 
treatment (Figure 9L). A positive control of IL-4 treatment was used to demonstrate that a protein 
known to induce alternative activation led to a similar phenotype to what was seen with both PK2 
overexpression and IS20 treatment. Taken together, these results demonstrate that the PK2-
induced alternative activation is most likely through the PKR1 receptor, however some signaling 
through PKR2 cannot be ruled out. This is the first example known to the authors of a non-peptide 
chemical that can induce alternative activation in microglial cells.  
 
Discussion 
Inflammation is a normal, beneficial function that can help to keep the CNS in a healthy 
state. However, in neurodegenerative diseases such as Parkinson’s disease, the neuroinflammation 
becomes excessive and can exacerbate neurodegeneration (Imamura et al. 2003, Panicker et al. 
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2015). In PD, there is an increase in classically activated microglia in the nigro-striatal region 
which is accompanied by an increase in inflammatory factors. Several anti-inflammatory drugs 
have demonstrated the ability to help protect dopaminergic neurons both in cell culture and animal 
models of PD (Asanuma and Miyazaki 2008). However, it is still unclear if anti-inflammatory 
drugs, such as NSAIDs, have a significant effect on the progression of the disease. Therefore, there 
is a need for research into pathways that can reduce this increased inflammatory response and 
protecting the dopaminergic neurons from cell death. Our lab previously found that Prokineticin-
2 production and secretion is increased in dopaminergic neurons both in animal models of PD and 
in post-mortem PD patients compared to age-matched controls (Gordon and Neal et al., 
unpublished.). Koyama et al demonstrated that microglia express the prokineticin receptors, 
therefore the increased PK2 secreted from dopaminergic neurons could signal to the microglia 
(Koyama et al. 2006). We confirmed that primary mouse microglia produce both of the 
prokineticin receptors, with significantly more PKR1 expressed compared to PKR2. Human 
recombinant PK2 addition onto cultured primary mouse microglia led to a dose dependent increase 
in calcium, an expected outcome with successful PK2 signaling. Therefore, PK2 could play an 
important role as a neuron-microglia signaling molecule in the progression of Parkinson’s disease.  
Microglial activation has been seen in many of the neurodegenerative disorders, and this 
activation is implicated in the disease progression. However, the activation states of microglia have 
become a hot topic in the neuroscience field, with many reports demonstrating that certain stimuli 
can lead to a specific phenotype in microglia (Tang and Le 2016). With excessive sustained 
inflammation found in PD there is a need to find therapies that can shift microglia towards more 
of an alternative activation phenotype. The Jmjd3-Irf4 axis has been used to determine alternative 
activation in both macrophages and microglia (Satoh et al. 2010). Jmjd3 was found to be essential 
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in microglial alternative activation, and knockout of Jmjd3 led to a skewing towards more 
classical, or pro-inflammatory, phenotypes (Tang et al. 2014). The induction of Jmjd3 by 
recombinant human PK2, PK2 overexpression and the PKR1 agonist, along with the increase in 
Arginase-1 and Mrc1 in cultured primary mouse microglia indicate that PK2 signaling leads to the 
shift towards an alternative activation phenotype. This is further evident with the increase in the 
transcription factor Irf4, which has been implicated in shifting microglia to an alternative 
phenotype. Similarly, the rPK2-induced reduction of classical activation markers basal levels such 
as intracellular ROS, nitrite and proinflammatory cytokine production in cultured primary 
microglia demonstrates that PK2 signaling does not increase basal levels of any classical activation 
markers. This is the first instance known to the authors of a neuronal protein that can modulate 
microglial phenotype towards an alternative phenotype through the activation of the Jmjd3-Irf4 
signaling pathway. 
Inflammatory factors such as reactive oxygen and nitrogen species are increased in 
neurodegenerative diseases, such as PD. Lipopolysaccharide is a membrane component of gram-
negative bacteria that can illicit an inflammatory response in microglia, and this molecule has been 
used to study neuroinflammation for many years. We found that LPS increased both intracellular 
reactive oxygen and nitric oxide in primary microglia, and that rPK2 treatment could significantly 
attenuate the production of these damaging molecules. Mitochondrial dynamics can signify the 
energy demands of the cell, and particularly in microglia it can indicate whether the cell is 
activated. Olah et al found that LPS stimulated microglia had a reduced basal oxidative respiration 
compared to control, wheras IL-4 stimulation was not able to induce a similar effect (Orihuela et 
al. 2016).  We found that recombinant PK2 can attenuate the LPS-induced reduction in 
mitochondrial basal respiration and ATP production.  An increase in the gene expression of both 
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Nrf2 and Bcl2 with rPK2 treatment indicates that prokineticin signaling can increase protection 
against mitochondrial dysfunction and therefore reduce the effects from a pro-inflammatory 
stimulus. Similarly, rPK2 treatment was able to significantly attenuate LPS-induced gene 
expression and protein level of pro-inflammatory cytokines TNFα, IL-6, and IL-12. This opens up 
the idea that PK2 can reduce the production of inflammatory mediators through the protection 
against mitochondrial dysfunction. More studies are required to determine if prokineticin signaling 
can have a similar protective effect against other toxicants that affect microglial mitochondria, 
such as aggregated proteins or heavy metals.  
 Overexpression of PK2 in vivo by injecting an AAV 2/5 into the striatum can protect 
dopaminergic neurons from MPTP-induced cell death (Gordon and Neal et al., unpublished). This 
same PK2-AAV is able to increase gene expression and protein levels of alternative activation 
markers in the mouse striatum while significantly reducing the classical activation marker basal 
gene expression. The specific localization of the PK2-AAV-induced increases in Jmjd3 and 
Arginase-1 protein levels in Iba1-positive cells demonstrates that PK2 signaling can shift microglia 
towards an alternative activation phenotype. This data confirms that the cell culture results and 
demonstrates that PK2 signaling can induce alternative activation of microglia in vivo. 
Morphological assessment of microglial phenotypes both in vitro and in vivo can be a 
powerful tool to investigate how microglia act in health and disease. This method gives 
reproducible results and can be used across different treatment paradigms and even disease models. 
There are only a few reports that look into a morphological assessment of microglial phenotypes, 
with no clear description for alternatively activation. It is known that classical activation leads to 
a de-ramification of the microglial processes and hypertrophy of the cell soma. However, 
alternative activation has only been described as having a thin cell body and increased branches 
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(Nimmerjahn et al. 2005, Ransohoff and Perry 2009). Both in primary mouse microglial cell 
culture and in the mouse striatum PK2 overexpression led to an increase in the number of 
microglial branches, junctions and endpoints while not increasing the cell soma size. Therefore, 
PK2 signaling does not lead to the de-ramification of microglial processes or the hypertrophy of 
the cell soma seen with toxicant treatment in cell culture and animal models of PD. This was 
confirmed with similar results using the PKR1 agonist and IL-4, a known inducer of alternative 
activation in microglia. Importantly, PK2-AAV was able to rescue the MPTP-induced de-
ramification and cell soma hypertrophy of microglia in the striatum, similar to what IL-4 has been 
shown to do in cell culture (Wirjatijasa et al. 2002). Importantly, preventing MPTP-increased PK2 
signaling with a receptor antagonist can exacerbate the MPTP-induced morphological effects in 
microglia. PK2 signaling is able to reduce the MPTP-induced classical activation of microglia in 
the mouse striatum and in the absence of PK2 signaling there is an increase in classically activated 
microglia. Therefore, Prokineticin-2 is the only known signaling molecule other than IL-4 that can 
signal from neurons to microglia and shift the microglia to an alternatively activated phenotype. 
This study demonstrates that Prokineticin-2 is a protective factor in Parkinson’s disease by 
inducing alternative activation of microglia and reducing inflammation to go along with the 
previous results of PK2 directly signaling to protective pathways in dopaminergic neurons. 
 
Materials and Methods 
Reagents  
DMEM/F12, fetal bovine serum (FBS), L-glutamine, IR-dye tagged secondary antibodies, 
Hoechst nuclear stain, penicillin, streptomycin, and other cell culture reagents were purchased 
from Invitrogen (Gaithersburg, MD). Recombinant PK2 was purchased from Peprotech. The 
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primary antibody for Iba1 was ordered from Abcam. The Arginase1 antibody was ordered from 
Thermo. The Jmjd3 antibody was purchased from The Bradford protein assay kit was purchased 
from Millipore. Bio-Rad Laboratories (Hercules, CA). DCF-DA intracellular ROS fluorescent dye 
was purchased from Calbiochem.  
Cell culture and animal studies 
Primary mouse microglia were obtained from whole brain homogenate of 0-3 day mouse 
pups. Microglia were collected, isolated and maintained according to previous methods (Gordon 
et al. 2011) using DMEM/F12 media(GIBCO) (10% heat-inactive FBS, 100 U/ml penicillin, 100 
g/ml streptomycin, 2mM L-glutamine, 2mM sodium pyruvate, 100µM non-essential amino acids 
(Invitrogen)) to grow the cells in an incubator at 37°C with 5% CO2. The media was changed on 
the 5th day of culture and then the microglia were isolated on the 16th day of culture. Isolation of 
microglia was performed using the CD11b labeling kit from StemCell, according to previous 
methods (Gordon et al. 2011). The isolated microglia were counted and seeded into cell culture 
plates for treatment. 
All animal procedures were approved by Iowa State University’s Institutional Animal Care 
and Use Committee (IACUC). All mice were housed under a 12-h light cycle in a climate-
controlled mouse facility (22 ± 1°C) with food and water available ad libitum. Based upon the 
outcomes of preliminary studies, we estimated error variances of 15% for biochemical and 
neurochemical endpoints and 20% for histological measures.  Setting alpha=0.05, we calculated 
sample sizes (n) of 8-10 animals per group, which has worked well for us in previous animal 
studies conducted in our laboratory (Ghosh et al. 2012, Ghosh et al. 2013). We used all male 
animals for all studies. All mice were pre-screened for normal baseline performance during 
behavioral assessments conducted prior to randomly assigning animals to experimental groups. 
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Investigators involved with data collection and analysis were not blinded to group allocation. 
MPTP studies were performed as previously described (Zhang et al. 2007c), using C57BL/6NCrl 
mice (8-10 weeks of age). For the PK2 rAAV neuroprotection experiments, C57BL/6NCrl mice 
were injected i.p. with 20 mg/kg MPTP, or equal volumes of saline (vehicle), once daily for four 
consecutive days and sacrificed 24 h after the last MPTP injection. For PKRA7 experiments, 
C57BL/6 mice were injected i.p. with 18 mg/kg MPTP, or equal volumes of saline (vehicle), once 
daily for three consecutive days. PKRA7 (20 mg/kg/day) was given i.p. 24 h before MPTP 
treatment and continued once daily for 10 consecutive days until sacrifice. Mice were euthanized 
at the indicated time points and samples processed for either IHC, qRT-PCR or Western blotting. 
Stereotaxic surgery 
C57BL/6NCrl mice (8-10 weeks of age) were anesthetized using a ketamine/xylazine 
mixture. The Angle 2 stereotaxic instrument was used with a 10-mL Hamilton syringe to inject the 
rAAV directly into the striatum at the following stereotaxic coordinates in relation to Bregma 
(mm): -2 ML, 0.5 AP, -4 DV. After drilling a hole in the skull, 3 μl of rAAV viral particles (~9 x 
1012 total viral particles) were injected into the brain.  The animal was allowed to recover for four 
weeks to maximize viral gene expression before behavioral testing, sacrificing or any treatment 
paradigm. 
Quantitative PCR 
Primary mouse microglia were seeded out into 6 well plates at 2 x 106 cells per well. 
Treatments were performed in DMEM/F12 media supplemented with 2% FBS, penicillin (100 
U/ml), streptomycin (100 μg/ml), 2 mM L-glutamine, 2mM sodium pyruvate and 100µM non-
essential amino acids. Cells were treated for 8 h with rPK2 (25nM), rPK2 cotreated with PC-7 
(1uM), IS20 (10uM), or rIL-4 (20ng/mL). After treatment, cells were collected, pelleted, and 
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resuspended in lysis buffer with β-mercaptoethanol. RNA was isolated using Absolutely RNA 
Miniprep, an RNA isolation kit from Stratagene. RT-PCR was performed using an cDNA synthesis 
system (Applied Biosystems) to convert the RNA into cDNA. Expression levels were determined 
using real-time PCR with Qiagen RT2 SYBR Green master mix and prevalidated using the qPCR 
mouse primers from SuperArray/Qiagen, or from previous literature (SA Biosciences)(Tang et al. 
2014). For normalization of each sample, the mouse gene 18SrRNA (Cat. No. PPM57735E) was 
used as the housekeeping gene. The amount of each template was optimized empirically to 
maximize efficiency without inhibiting the PCR reaction. According to manufacturer’s guidelines, 
dissociation curves and melting curves were run to ensure that single amplicon peaks were 
obtained without any non-specific amplicons. The results are reported as fold change in gene 
expression, which was determined using the ΔΔCt method using the threshold cycle (Ct) value for 
the housekeeping gene and for the respective gene of interest in each sample. 
Western blotting 
Microglia were collected after treatment, lysed using modified RIPA buffer, homogenized, 
sonicated, and centrifuged as previously described (Kaul et al. 2003, Kitazawa et al. 2002). The 
supernatants were collected and proteins were normalized, then stored with loading buffer and 
DTT. Samples were run on a Sodium Dodecyl Sulfate (SDS) gel electrophoresis. Normalized 
protein samples were loaded into each well and first separated in a 4% stacking gel and then 
through a 12-18% resolution gel. Proteins were then transferred to a nitrocellulose membrane. 
After transfer, the membranes were blocked using Western blocking buffer (Rockland 
Immunochemicals). Primary antibodies directed to the protein of interest  in Rockland blocking 
buffer were then added to the membranes and stored overnight at 4°C. A Secondary antibody 
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specific to the primary antibody was added  to the membrane in blocking buffer for 1 h. Either β-
actin or α-tubulin was used to confirm equal loading into each well of the gels. The membranes 
were read using the Odyssey infra-red imaging system. 
Immunocytochemistry and Immunohistochemistry 
For immunocytochemistry, cells were plated onto coverslips in 24-well plates coated with 
0.1% poly-D-Lysine. After cells were treated, 4% formaldehyde was used to fix the cells for 30 
min. The cells were washed with PBS wash buffer. Then blocking buffer containing 2% BSA, 
0.2% Triton X-100, and Tween was added to the wells for 1 hour. The cells were incubated with 
primary antibodies in 2% BSA at 4°C overnight. Next, an Alexafluor dye-conjugated secondary 
antibody in 2% BSA was added and incubated at room temperature on a shaker for 1 h. After 
washing Hoechst counterstain was added to the cells for 5-6 min to label nuclei. Coverslips were 
washed several times then mounted onto slides with Fluoromount mounting media. Cells were 
imaged under a Nikon 2000U microscope with a SPOT camera, and all images were processed in 
MetaMorph 5.7 (Universal Imaging, Downingtown, PA). 
For histology, mice were anesthetized using the ketamine-xylazine mixture and cardiac 
perfusion of 4% PFA was used to fix the brain before being extracted and stored in 4% PFA at 
4°C. After 48 h, brains were washed with PBS, and placed into a 30% sucrose solution for at least 
24 h. The brains were then embedded in Optimal Cutting Temperature (OCT) compound and 
frozen into blocks for sectioning. Brains were sectioned on a Cryostat (CryoStar NX70, Thermo 
Scientific) at -20°C and placed into Cryosolution (30% Sucrose, Ethylene glycol, and PBS). 
Sections were then washed with PBS and permeabilized with blocking buffer (2% BSA, 0.1% 
Triton X-100, and Tween) for 1 h at room temperature. Antibodies directed to the protein of 
interest were then incubated with the sections overnight at 4°C. After washing with PBS, the 
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sections were incubated with Alexafluor dye-conjugated secondary antibodies for 1 h at room 
temperature. After washing with PBS, Hoechst dye (1:5000) was added to the sections for 5 min 
at room temperature to stain nuclei. Sections were then mounted on slides using the Fluoromount 
mounting medium (Molecular probes) according to the manufacturer’s instructions. An inverted 
fluorescent microscope (Nikon TE-2000U) was used to visualize the sections, and a Spot digital 
camera (Diagnostic Instruments, Inc) was used to capture images.  
Microglia morphological assessment 
Iba1 immunofluorescence in primary mouse microglia (species and dilution) and DAB 
immunostaining of mouse striatum sections (Species and dilution) was used to mark the microglia. 
20X and 60X images were take using an inverted fluorescent microscope (Nikon TE-2000U). 
Images were imported into ImageJ for morphological analysis. Morrison et al. demonstrated that 
the microglial processes could be analyzed using an ImageJ plugin named Analyze Skeleton 
(Morrison and Filosa 2013). Fluorescent and DAB images were converted to binary, and then 
skeletonized in the ImageJ software. The skeletonized image is then fed into the Analyze Skeleton 
plug in (Arganda-Carreras et al. 2010) without pruning ends and measuring the long/short branch 
distance. The longest/short path calculation and applications come from a previous source (Fraas 
et al. 2014). Detailed information of branch, junction and endpoint number along with branch 
length metrics is displayed in the results window for the entire image. The results were transferred 
to an Excel spreadsheet and sorted to only show information with branch numbers between 10 and 
300 to remove any non-cellular background. Results were then compared to the number of counted 
cells in the field to then determine each of the morphology metrics per cell. Multiple fields were 
used for each coverslip or section, and then 2-3 biological replicates were used for each 
experiment. At least 200 cells were measured for each of the morphology assessments. Cell soma 
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size and roundness is measured in the same Iba1 images in ImageJ by freehand selection outlining 
each cell soma and then select the “area” and “shape descriptors” analytes to measure. A minimum 
of 30 cells were analyzed for each treatment in analyzing the soma descriptors, with at least 2 
biological replicates for each experiment. 
Mitochondrial dynamics 
To analyze the mitochondrial energy dynamics in primary mouse microglia, the XFe24 
Seahorse analyzer was used to measure OCR and ECAR levels. Microglia were plated on Seahorse 
plates at 100,000 cells in each well and allowed to attach overnight in growth media. Cells were 
then washed with serum free DMEM/F12 media 3 times and 500ul of treatment was added to the 
wells in serum free DMEM/F12 for 8 hours. After the 8 hours, the cells were washed 2 times with 
the Seahorse base media supplemented with sodium pyruvate and glutamine. The MitoStress test 
was performed according to the manufacturer’s guidelines. The cells were left in the 500ul of the 
Seahorse base media supplemented with sodium pyruvate and glutamate. After testing correct 
concentrations of the chemicals, 0.75uM of oligomycin, 2uM of FCCP, and 0.5uM 
rotenone/antimycin was added to the cells to measure mitochondrial dynamics. Analysis was 
performed through the MitoStress Results Generator found on the Agilent website.  
Intracellular ROS generation and Nitric Oxide measurement 
The fluorescent probe 2’,7’-dichlorodi-hydrofluorescein diacetate (DCFH-DA) 
(Calbiochem) was used to determine the level of intracellular reactive oxygen species (iROS). 
Primary mouse microglia were treated with 200 nM LPS in RPMI media with 2% FBS or co-
treated with 25nM recombinant PK2 (rPK2) along with the LPS treatment. After treatment, the 
cells were washed with warm HBSS media, and then incubated with 100 µl of 40 µM DCFH-DA 
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in HBSS for 1 h. The fluorescence intensity of the signal was determined using a Synergy-2 multi-
mode microplate reader at an excitation of 485 nm and an emission of 530 nm. After subtracting 
the control fluorescent signal as background, an increase in fluorescence intensity of treatments 
was expressed as an increase in iROS, as previously described (Gordon et al. 2012).  
Nitric oxide production by primary microglia was measured indirectly by quantification of 
nitrite in the supernatant using the Griess reagent (Sigma-Aldrich). Microglia were plated in poly-
D-lysine-coated 96-well plates at 1 × 105 cells/well. Cells were treated with 250ng/ml of LPS for 
24 h; and after 100 μl of supernatant was collected from each well, an equal volume of the Griess 
reagent was added. The samples were incubated on a plate shaker at room temperature for 15 min 
until a stable color was obtained. The absorbance at 540 nm was measured using the Synergy 2 
multimode microplate reader, and the nitrite concentration was determined from a sodium nitrite 
standard curve. 
Fluo-4 calcium mobilization assay  
A Fluo-4 NW assay kit (Molecular probes) was used to test calcium mobilization in primary mouse 
microglia resulting from nanomolar concentrations of rPK2. Cells were plated overnight into 96-
well plates in growth media. Cells were then washed with HBSS and incubated with the Fluo-4 
NW dye for one hour. Each plate was then read kinetically using a Synergy-2 multi-mode 
microplate reader. After obtaining background readings by reading each plate every 50 ms for 20 
sec, rPK2 was injected at the indicated nanomolar concentrations. The net change in fluorescent 
signal (Dt), read every 50 ms for 3 min, was obtained after subtracting the background from the 
maximum signal for each sample. 
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Data analysis 
Data analysis was performed using the Prism 4.0 software package (GraphPad Software, 
San Diego, CA). The data was first analyzed using one-way ANOVA and then Tukey’s post-test 
was performed to compare all treatment groups. Differences of p<0.05 were considered 
statistically significant. The Student's t-test was used when two groups were being compared. 
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Figures 
 
Figure 1. Prokineticin-2 can signal to primary mouse microglia and increases intracellular 
calcium (A) Quantitative real time PCR for Prokineticin receptor gene expression, with PKR1 
expressed significantly higher than PKR2. (B) Representative Western blot for PKR1 and PKR2 
in primary mouse microglia showing higher PKR1 compared to PKR2 and no significant change 
with LPS treatment. (C) Different cellular localization pattern for PKR2 (Green, right panel) and 
PKR1 (Green, left panel) with the nucleus stained with Hoechst (Blue). Expression of PKR2 was 
peri-nuclear whereas PKR1 expression was localized more on the periphery of the cell. (D) 
Calcium mobilization (flux) dose-dependently induced by rPK2 in primary mouse microglia, with 
calcium-free HBSS used as a control treatment. Data represented by group mean ± SEM and 
experiments were repeated at least twice. Asterisks denote a significant difference between rPK2 
treatment and the control (** p<0.01, and *** p<0.001).   
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Figure 2. Prokineticin-2 induces alternative activation phenotype in primary mouse microglia. 
(A-D) Quantitative real-time PCR analysis for the gene expression of alternative activation 
markers Jmjd3 (A), Irf4 (B), Arginase-1 (C) and Mrc1 (D). Data represented by group mean ± SEM 
and experiments were repeated at least three times. Asterisks denote a significant difference between 
rPK2 treatment and the control or rPK2 co-treated with PC-7 (** p<0.01, and *** p<0.001). (E) 
Representative Western blot with immunofluorescence band intensity quantification for Jmjd3 
(left panel) and Arginase-1 (right panel). (F) Immunofluorescence microscopy for Jmjd3 (Green, 
top panel) and Arginase-1 (Green, bottom panel) with the nucleus stained with Hoechst (Blue). 
(G-H) Integrated density of immunofluorescence quantification for Jmjd3 (G) and Arginase-1 (H), 
showing that rPK2 increases the protein level of both proteins compared to control and rPK2 co-
treated with PC-7. Data represented by group mean ± SEM and experiments were repeated at least 
twice. Asterisks denote a significant difference between rPK2 treatment and the control or rPK2 
co-treated with PC-7 with experiments repeated at least twice (** p<0.01, and *** p<0.001). 
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Figure 3. Prokineticin-2 attenuates LPS-induced mitochondrial bioenegetic dysfunction and 
production of ROS and NO production in primary mouse microglia. (A) DCF-DA fluorescent dye 
measurement for intracellular ROS, shows that rPK2 treatment can significantly reduce LPS-
induced iROS levels. (B) Quantitative real-time PCR gene expression analysis for anti-oxidant 
genes, demonstrating that rPK2 treatment can induce Nrf2, and Prdx2 (C) Representative Western 
blot for Nrf2 protein level. (D) Quantitative real-time PCR gene expression analysis for Bcl2. Data 
represented by group mean ± SEM and experiments were repeated at least three times. Asterisks 
denote a significant difference between rPK2 treatment and the control or rPK2 co-treated with 
PC-7 (** p<0.01, and *** p<0.001). (E-F) Mitochondrial dynamics in primary microglia with LPS 
and PK2 treatment. Recombinant PK2 treatment attenuates LPS-induced reduction in 
mitochondrial dysfunction, demonstrated by oxygen consumption rate (OCR) plot (F), 
quantification of basal respiration (G, left panel) and quantification of ATP production (G, right 
panel). (G) Griess assay for measurement of nitric oxide in supernatants from treated microglia, 
showing that rPK2 can significantly attenuate LPS-induced nitric oxide production. (H) 
Quantitative real-time PCR gene expression analysis for NOS2. Data represented by group mean 
± SEM and experiments were repeated at least two times. Asterisks denote a significant difference 
between rPK2 treatment and the control or rPK2 co-treated with PC-7 (* p<0.05, ** p<0.01, and 
*** p<0.001). 
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Figure 4. Reduction in pro-inflammatory cytokine production with Prokineticin treatment in 
primary mouse microglia. (A-C) Quantitative real-time PCR gene expression analysis for 
proinflammatory cytokines, which showed that rPK2 treatment reduced basal TNF (A), IL-12 (B), 
and IL-6 (C) gene expression compared to control. (D) Pro-inflammatory cytokine protein levels 
measured in the primary mouse microglia conditioned media treated with rPK2 using the Bioplex 
200 multi-plex system for TNFα, IL-12 and IL-6. (E-G) Pro-inflammatory cytokine protein levels 
measured in the primary mouse microglia conditioned media treated with LPS and LPS co-treated 
with PK2 using the Bioplex 200 multi-plex system for TNFα (E), IL-12 (F) and IL-6 (G). Data 
represented by group mean ± SEM and experiments were repeated at least two times. Asterisks 
denote a significant difference between rPK2 treatment and the control or rPK2 co-treated with 
PC-7 (* p<0.05, ** p<0.01, and *** p<0.001). 
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Figure 5. Prokineticin-2 overexpression in vitro induces alternative activation of primary mouse 
microglia. (A) Representative Western blots for Jmjd3, Arginase-1, and GFP show that Lenti-viral 
PK2 overexpression was successful with increased GFP levels. (B-C) Protein band densitometric 
quantification for Jmjd3 (B), Arginase-1 (C) and Nrf2 (D) demonstrating that PK2 overexpression 
increases these alternative activation marker protein levels. (E) ImageJ skeletonization after 
converting the Iba1 immunofluorescent image (top panel) into a binary image. ImageJ Analyze 
Skeleton plug-in image (bottom panel) from the skeletonized image (middle panel) with process 
branches (Orange), junctions (Purple), and endpoints (Blue). (F-I) Measurements of the microglia 
processes. Analysis for the average number of process branches (F), process junctions (G), process 
endpoints (H) and longest shortest branch path (I) per Iba1-positive cell shows that PK2 
overexpression significantly increased average cell process metrics compared to Control, and GFP 
overexpression. Data represented by group mean ± SEM and experiments were repeated at least 
twice. Asterisks denote a significant difference between PK2 OE and the control and GFP OE (* 
p<0.05, ** p<0.01, and *** p<0.001). 
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Figure 6. PK2-AAV 2/5 overexpression induces alternative activation of microglia in the mouse 
striatum. C57/Bl6 mice were stereotaxically injected in the stiatum with either PK2-AAV 2/5 or 
GFP-AAV 2/5 and allowed to reach maximal viral gene expression for four weeks. (A) 
Quantitative real-time PCR gene expression analysis for classical or alternative activation markers. 
PK2-AAV significantly increased alternative activation markers such as Jmjd3, Irf4, Arginase-1 
and Mrc1, while significantly decreasing classical activation markers such as iNOS, TNFα, IL-1β, 
IL-6 and IL-12. (B) Representative Western blot for Jmjd3 and Arginase-1 with densitometric 
quantification of the bands showing that PK2-AAV significantly increases Jmjd3 (left panel) and 
Arginase-1 (right panel). Data represented by group mean ± SEM and experiments were perfomed 
with at least 4 animals run with technical replicates. Asterisks denote a significant difference 
between PK2 OE and the control and GFP OE (* p<0.05, ** p<0.01, and *** p<0.001). (C-D) 
Immunofluorescent images of Jmjd3 (C) and Arginase-1 (D)(Green) in Iba1-positive cells (Red) 
in the mouse striatum with the nucleus stained with Hoechst (Blue). (E) Iba1 DAB immunostain 
image (top panel) was converted into a binary image and skeletonized (middle panel). ImageJ 
Analyze Skeleton plug-in image (bottom panel) with process branches (Orange), junctions 
(Purple), and endpoints (Blue). (F-I) Measurements of the microglia processes. Analysis for the 
average number of process branches (F), process junctions (G), process endpoints (H) and longest 
shortest branch path (I) shows that PK2-AAV significantly increased average cell process metrics 
compared to Control, and GFP-AAV. (J-K) Microglial cell soma shape descriptors. (J) ImageJ 
quantification of cell soma roundness in Iba1-positive cells. (K) ImageJ quantification of cell soma 
area in Iba1-positive cells. Data represented by group mean ± SEM and experiments were 
perfomed with at least 3 animals with multiple visual fields per animal section. Asterisks denote a 
significant difference between PK2 OE and the control and GFP OE (** p<0.01, and *** p<0.001).  
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Figure 7. PK2-AAV 2/5 attenuates MPTP-induced classical activation of microglia in the mouse 
striatum. (A) Iba1 DAB immunostain image (top panel) was converted into a binary image and 
skeletonized (middle panel). ImageJ Analyze Skeleton plug-in image (bottom panel) with process 
branches (Orange), junctions (Purple), and endpoints (Blue). (B-E) Measurements of the microglia 
processes. Analysis for the average number of process branches (B), process junctions (C), process 
endpoints (D) and longest shortest branch path (E) shows that PK2-AAV significantly attenuated 
the MPTP-induced loss of cell process metrics. (F) Iba1 immunostaining microscopy images in 
ImageJ with the cell soma outlined and the quantification of the cell soma area (right panel). Data 
represented by group mean ± SEM and experiments were perfomed with at least 3 animals with 
multiple visual fields per animal section. Asterisks denote a significant difference between PK2 
OE and the control and GFP OE (*** p<0.001).  
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Figure 8. Prokineticin receptor antagonist exacerbates MPTP-induced classical activation 
morphology in microglia of the mouse striatum. (A) Iba1 DAB immunostain image (top panel) 
was converted into a binary image and skeletonized (middle panel). ImageJ Analyze Skeleton 
plug-in image (bottom panel) with process branches (Orange), junctions (Purple), and endpoints 
(Blue). (B-E) Measurements of the microglia processes. Analysis for the average number of 
process branches (B), process junctions (C), process endpoints (D) and longest shortest branch 
path (E) shows that PKRA7 significantly increased the MPTP-induced loss of cell process metrics. 
(F) Iba1 immunostaining microscopy images in ImageJ with the cell soma outlined and the 
quantification of the cell soma area (right panel). Data represented by group mean ± SEM and 
experiments were perfomed with at least 3 animals with multiple visual fields per animal section. 
Asterisks denote a significant difference between MPTP+PKRA7 and the control and PKRA7 
alone groups (** p<0.01, and *** p<0.001). 
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Figure 9. PKR1 agonist, IS20, promotes alternative activation of primary mouse microglia. (A) 
Quantitative real-time PCR gene expression analysis for classical or alternative activation markers. 
IS20 significantly increased alternative activation markers such as Jmjd3, Arginase-1 and Mrc1, 
while significantly decreasing classical activation markers such as iNOS, TNFα, IL-1β, and IL-6. 
(B-D) Representative Western blot (B) for Arginase-1 and Nrf2 with densitometric quantification 
of the bands showing that IS20 significantly increases Arginase-1 (C) and Nrf2 (D). Data 
represented by group mean ± SEM and experiments were perfomed with at least two times. 
Asterisks denote a significant difference between IS20 and the control (* p<0.05, ** p<0.01, and 
*** p<0.001). (E-G) Immunofluorescence microscopy for Jmjd3 (Green, top panel) and Arginase-
1 (Green, bottom panel) with the nucleus stained with Hoechst (Blue) (E). Integrated density of 
immunofluorescence quantification for Jmjd3 (F) and Arginase-1 (G), showing that IS20 increases 
the protein level of both proteins compared to control. (H) ImageJ skeletonization after converting 
the Iba1 immunofluorescent image (top panel) into a binary image. ImageJ Analyze Skeleton plug-
in image (bottom panel) from the skeletonized image (middle panel) with process branches 
(Orange), junctions (Purple), and endpoints (Blue). (I-L) Measurements of the microglia 
processes. Analysis for the average number of process branches (I), process junctions (J), process 
endpoints (K) and longest shortest branch path (L) per Iba1-positive cell shows that IS20 treatment 
significantly increased average cell process metrics compared to control. Data represented by 
group mean ± SEM and experiments were repeated at least twice. Asterisks denote a significant 
difference between IS20 and the control (* p<0.05, ** p<0.01, and *** p<0.001). 
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Abstract 
The mechanisms behind astrocyte activation in Parkinson’s disease (PD) are poorly 
understood. With significant crosstalk between neurons and astrocytes, neuronal-secreted factors 
could play an important role as modulators of astrocyte activation. Previously, our lab found that 
dopaminergic neurons produce and secrete higher levels of the chemokine-like signaling protein 
Prokineticin-2 (PK2) in cell culture, animal models of PD, and in post-mortem PD patients 
compared to age-matched controls. Astrocytes express the prokineticin receptors, and exogenously 
added PK2 can activate signaling pathways in cultured astrocytes. Herein, we demonstrate that 
PK2 can induce astrocyte activation, both in vitro and in vivo. Importantly, functional studies in 
primary mouse astrocytes reveal that PK2 signaling in astrocytes reduces pro-inflammatory 
factors, while increasing anti-oxidant proteins such as Arginase1 and Nrf2. Furthermore, we found 
that a non-peptide prokineticin receptor 1 chemical agonist is able to similarly induce this 
185 
 
alternative activation of astrocytes. Importantly, PK2 treatment was also able to increase 
extracellular glutamate uptake by increasing gene expression of the glutamate transporter GLAST. 
Collectively, our results reveal a novel neuron-astrocyte signaling pathway important for 
alternative astrocyte activation, and a new potential therapeutic avenue for Parkinson’s disease and 
other neurodegenerative diseases. 
 
Introduction 
 Astrocytes are important for brain homeostasis and neuronal health, including the 
production of neurotrophic factors and uptake of extracellular glutamate. Also, during central 
nervous system (CNS) injury, astrocytes become activated in a process commonly referred to as 
astrogliosis, and some studies use astrocyte activation as a marker for damaged neurons (Ferraguti 
et al. 2001, Hu et al. 2016). Activated astrocytes have also been identified in Parkinson’s disease 
(PD) patients (Forno et al. 1992, Wakabayashi et al. 1999), and multiple animal models of PD 
have demonstrated an increase in astrogliosis (Yasuda et al. 2008, Teismann et al. 2003, Saura et 
al. 2003). However, the mechanisms behind astrocyte activation are not completely understood. 
Currently, researchers are debating whether activated astrocytes are beneficial or harmful in CNS 
injury, including PD. Interestingly, some results indicate that astrocytes respond to different 
stimuli by shifting to different activation phenotypes, similar to the classical and alternative 
phenotype activation states seen in macrophages and microglia (Jang et al. 2013a). Therefore, 
ligands that activate astrocytes could lead to either a classical, pro-inflammatory activation or 
alternative, anti-inflammatory activation state, and should be investigated in the search for 
potential therapeutics for neurodegenerative diseases.  
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 Prokineticin-2 (PK2) is a small chemokine-like signaling protein that was originally found 
to potently contract gastrointestinal muscles (Li et al. 2001). It is a homologue to MIT1, a non-
venomous protein in mamba snake venom, and a frog skin protein, Bv8 (Schweitz et al. 1999, 
Ferrara et al. 2004). Subsequently, two G-protein coupled receptors were identified as prokineticin 
receptors, PKR1 and PKR2 (Lin et al. 2002b). Signaling through these receptors mediates various 
physiological functions throughout the body, including hematopoiesis, angiogenesis, reproductive 
functions, innate immunity (Monnier and Samson 2008) and cardiomyocyte protection (Urayama 
et al. 2007a). In the healthy CNS, PK2 also plays a role in modulating circadian rhythms, olfactory 
bulb biogenesis (Ng et al. 2005, Zhou and Cheng 2005), energy expenditure and homeostasis 
(Zhou et al. 2012), and neuroprotection (Melchiorri et al. 2001, Landucci et al. 2016). PK2 
expression is generally induced in areas of increased inflammation, including the gut (Watson et 
al. 2012), and the brain (Cheng et al. 2012). Our lab previously established that dopaminergic 
neurons secrete soluble PK2 when treated with TNFα in vitro, and in multiple in vivo mouse 
models of PD, and we detected it in human postmortem PD patients (Gordon and Neal et al., 
unpublished). In that study, we found that PK2 inhibited MPTP neurotoxicant-mediated 
dopaminergic neuronal death both in vitro and in vivo. We concluded that dopaminergic neurons 
produced PK2 as a potential compensatory reaction to stressful conditions, such as mitochondrial 
dysfunction and neuroinflammation. We were also able to determine that PKR2 is expressed in 
dopaminergic neurons in vitro and in the mouse substantia nigra. Previous studies found that the 
PKR2 gene is expressed at a higher level in the brain compared to PKR1 (Lin et al. 2002b). 
However, the PKR1 gene is expressed at a higher level in astrocytes and microglia in the brain 
compared to PKR2 (Zhou 2006). Interestingly, PK2 treatment induces cell proliferation and 
  
187 
 
intracellular calcium mobilization in cultured astrocytes. Based on the observations of soluble PK2 
being secreted from damaged dopaminergic neurons and that PK2 signals to astrocytes, we 
investigated the role of PK2 signaling in astrocytes of the brain. 
 
Results 
Receptors for secreted Prokineticin-2 are expressed on primary mouse and human astrocytes 
 To determine what role the chemokine-like protein PK2 plays in astrocytes, we first tested 
our primary mouse astrocytes to characterize prokineticin receptor expression. Using qRT-PCR 
with validated primers (Qiagen) we found that both the PKR1 and PKR2 genes are expressed in 
primary mouse astrocyte cells and primary human astrocytes (Figure 1A). However, PKR1 was 
expressed over 12-fold higher than the expression of PKR2 in both mouse and human astrocytes, 
which is consistent with previous results in mouse astrocytes (Koyama et al. 2006). Additionally, 
we characterized the protein level of the prokineticin receptors using both Western blot (Figure 
1B) and fluorescence microscopy (Figure 1C). The Western blot clearly shows higher PKR1 
protein when compared to PKR2 protein levels in the same primary mouse astrocyte samples. The 
fluorescence microscopy images demonstrate that PKR1 is localized to the periphery of the cell, 
whereas PKR2 has higher expression closer to the nucleus. Prokineticin receptors are GPCRs that 
can be linked to Gi, Gq or Gs (Zhou 2006). Signaling through Gq induces intracellular calcium 
mobilization, Gs increases cAMP levels, whereas Gi inhibits the other two pathways. Therefore, 
we tested whether adding recombinant human PK2 (rPK2) to isolated primary mouse astrocytes 
could cause functional changes, such as increased intracellular calcium, and cell proliferation. The 
Fluo4-NW intracellular calcium dye revealed that intracellular calcium levels spiked significantly 
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in an rPK2 dose-dependent manner when compared to adding calcium-free HBSS alone (Figure 
1D). The spike in calcium was blocked using a prokineticin receptor inhibitor, PC-7, thus 
indicating its specificity to the PK2 signaling. These results verify that rPK2 is capable of eliciting 
a signaling response in astrocytes through one of the prokineticin receptors. Recombinant PK2 
treatment was also able to significantly increase primary mouse astrocyte cell proliferation when 
compared to control, as measured by the CyQuant dye assay of astrocyte cell numbers (Figure 1E). 
Taken together, these results verify previous research on PK2 in astrocytes, elucidate cellular 
localization of the two prokineticin receptors in astrocytes and demonstrate that our model will 
work for prokineticin signaling in astrocytes. 
 
Prokineticin-2 overexpression increases GFAP level, astrocyte numbers and soma size 
 Normal resting astrocytes have thin cell bodies, thin processes, and express a low level of 
glial fibrillary acidic protein (GFAP). When astrocytes become activated, the soma and primary 
processes undergo hypertrophy, and the astrocytes express higher levels of GFAP (Pekny and 
Pekna 2014).  Previous results demonstrated that PK2 could activate immune cells and modulate 
systemic inflammation (Monnier and Samson 2008), therefore we investigated if PK2 could 
similarly affect astrocytes in the mouse striatum. We developed a way to overexpress PK2 tagged 
to GFP in vivo using an AAV 2/5 viral delivery system under the power of the CMV promoter. 
We injected PK2-AAV into the mouse striatum and waited 4 weeks for maximal expression. The 
PK2 tagged to GFP was found throughout most of the striatum as seen by fluorescence microscopy. 
Interestingly, GFAP increased significantly in the striatum of PK2-AAV injected animals (Figure 
2A). Similarly, Western blotting of the striatum demonstrated that GFAP protein levels had  
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increased in the striatum of PK2-AAV injected animals (Figure 2B). These results indicate that 
overexpression of PK2 in the striatum increases protein levels of GFAP, and therefore astrocyte 
activation. 
 To further characterize the astrocyte activation elicited by PK2 overexpression, we 
performed DAB immunostaining for GFAP on sections from either GFP-AAV or PK2-AAV 
injected animals. The control striatum contained cells with characteristics resembling resting 
astrocytes with thin cell bodies, thin processes, low GFAP expression and fewer cells that were 
GFAP-positive. Consistent with Western blotting results, the PK2-AAV injection increased the 
number of GFAP-positive cells in the striatum, which also exhibited cell soma hypertrophy, 
obvious hypertrophy of primary processes, and an increased amount of GFAP protein 
immunostaining (Figure 2C). In contrast, GFP-AAV failed to significantly increase any of these 
characteristics when compared to control. Taken together, these results demonstrate that PK2 
overexpression induces significant morphological changes in GFAP-positive cells that are 
indicative of astrocyte activation.   
 
Prokineticin-2 overexpression reduces the number of astrocyte processes and endpoints 
 Another indication of astrocyte activation is the retraction of cytoplasmic processes (Kang 
et al. 2014).  Since images of GFAP DAB immunostained mouse striatal sections seemed to reveal 
fewer astrocytic processes in PK2-AAV injected animals, we analyzed astrocyte processes using 
an ImageJ plugin developed to measure branching (Morrison and Filosa 2013). The GFAP DAB 
immunostain images were uploaded into ImageJ (Figure 3A), converted into binary images, and 
finally reduced to a skeleton image (Figure 3B). This skeleton image was then analyzed to show 
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every branch (orange), junction (purple) and endpoint (blue) (Figure 3C), allowing us to determine 
the number of branches and junctions, length of processes and number of endpoints. PK2-AAV 
significantly reduced the number of astrocyte processes when compared to control, whereas GFP-
AAV did not (Figure 3D). Also, the number of astrocytic process endpoints per cell was 
significantly reduced by the PK2-AAV injection (Figure 3E). Taken together, these results add 
another quantitative measure demonstrating that PK2 overexpression can activate astrocytes in 
vivo.  
 
Recombinant soluble PK2 induced wound healing in primary mouse and human astrocytes 
 Since a reduction in the number of processes and endpoints in astrocytes in vivo could be 
because those cells are currently migrating or preparing for migration, we tested whether rPK2 
stimulates astrocyte migration. To measure cell migration, we utilized a scratch-wound technique, 
wherein a pipet tip was used to create a “wound” on a confluent layer of astrocytes. Comparing 
the width of the “wound” at 0 hours and 24 hours after rPK2 treatment will give the distance that 
the cells migrated (Figure 4A). The results demonstrate that recombinant PK2 treatment in both 
the U373 human astrocytoma cell line and primary human astrocytes significantly increased 
wound closure (healing) over control treatment (Figure 4B and C). This is the first report 
demonstrating that prokineticin signaling can lead to increased wound healing in astrocytes.  
 
Recombinant human PK2 induces chemotaxis in the U373 human astrocyte cell-line 
 In the injured or diseased CNS, astrocytes become activated and migrate to the site of 
injury. Several factors, including TGFβ and bFGF, have demonstrated the ability to cause astrocyte 
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migration (Huang et al. 2012, Holland and Varmus 1998). Prokineticin-2 is a chemokine-like 
protein that has been demonstrated to modulate the activation and migration of several systemic 
cell types, such as macrophages and monocytes (Martucci et al. 2006, Ferrara et al. 2004). The 
ability of PK2 to induce the migration of other cell types and increase astrocyte wound healing, 
prompted us to examine whether PK2 could be a chemotactic protein for astrocytes. We tested 
chemotaxis with PK2 treatment in the U373 human astrocytoma cell line using the 2D chemotaxis 
slide (Ibidi, Martinsried, Germany), on which the cells are seeded into a strip in between two media 
reservoirs (Figure 5A). For the experiment, one of these reservoirs holds only media, while the 
other holds the putative chemotactic factor in media. The design principle behind the Ibidi 
chemotaxis slide is for the slide to allow the chemotactic protein to reach the cells at a 
concentration curve that is stable for 48 hours. Therefore, the cells in the middle strip will migrate 
more towards the chemotactic protein-containing reservoir than towards the media-only reservoir 
if the protein is able to cause chemotaxis in astrocytes. The U373 human astrocytes were seeded 
onto the slide about 10 hours before the treatment was started. Images were taken of the cells after 
seeding, and before and after adding the treatment media, to ensure cells were present and appeared 
healthy. Two migration experimental platforms were used. One platform created a chemical 
gradient between PK2 in one media reservoir and control in the opposing reservoir, while the other 
platform lacked a chemical gradient with identical controls in both of its media reservoirs as a 
negative control. Images were taken at 10x magnification once every hour for 18 hours after the 
treatment was added to the reservoirs. The images were compiled and stitched together for manual 
tracking of cells. Images taken at 0 hr and 18 hr for the PK2 migration platform are shown, with 
two red arrows (0 hr and 18 hr) indicating migration of one cell and two blue arrows (0 hr and 18 
hr) indicating migration of a different cell (Figure 5B).  The Ibidi manual cell tracking plugin for 
192 
 
ImageJ was used to quantify migration parameters. One individual cell was manually selected at 
its 0 hr time point and then manually selected at each subsequent time point to form a migration 
track for that cell. Migration tracks were performed for over 50 cells on each experimental platform 
and then compiled to get migration metrics (Figure 5C). The tracks were analyzed with respect to 
both of the slide’s two dimensional axes, with the treatment reservoirs representing the y-axis and 
horizontal movement on the x-axis. The forward migration index on the y-axis (yFMI) indicates 
the distance traveled by a single cell towards a treatment reservoir, with a larger index indicating 
a stronger chemotactic effect. The PK2 experimental platform generated a significant increase in 
the yFMI towards the reservoir containing rPK2, and as expected, the control platform showed no 
significant yFMI towards either reservoir (Figure 5D). The x-axis forward migration index (xFMI) 
showed that neither platform induced an increase in xFMI, or lateral movement in the cell reservoir 
perpendicular to the chemical gradient being tested. Therefore, rPK2 induced a directed migration 
towards one reservoir because directed migration comes from an increased yFMI and little to no 
change in the xFMI, which was what we observed. PK2 also increased the migration velocity, or 
distance travelled each hour, of the analyzed cells (Figure 5E), indicating that the cell migration 
towards the PK2 reservoir was faster than was the cell migration in the control platform. Similarly, 
rPK2 treatment increased the total accumulated distance of the astrocytes as well as the Euclidean 
distance, or the straight line distance travelled from the origin. Comparing the accumulated 
distance and the Euclidean distance informs us about the directionality of cell migration, with a 
directionality score close to 1 indicating a straight line cell migration. Recombinant PK2 treatment 
significantly increased the directionality score over control treatment. Collectively, these results 
demonstrate for the first time that PK2 is a chemotactic factor increasing astrocyte cell migration, 
similar to what was seen in systemic immune cells. 
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Prokineticin-2 shifts mitochondrial metabolism towards an energetic phenotype 
Prokineticin-2 can induce mitochondrial biogenesis and help protect the mitochondria from 
toxicant-induced stress in neurons (Gordon and Neal et al, unpublished), therefore we wanted to 
examine the possible role of PK2 acting on the astrocyte mitochondria. Powerful and accurate 
descriptor for shifts in astrocyte cellular responses include mitochondrial metabolism, oxidative 
respiration, and glycolysis. Studies reported that astrocytes primarily rely on mitochondrial 
oxidative metabolism for energy production and that mitochondrial dynamics shift when exposed 
to pro-inflammatory stimuli or in response to neuronal activity (Motori et al. 2013, Hertz, Peng 
and Dienel 2007), indicating that mitochondrial dynamics can be a strong marker of astrocyte 
activation. Therefore, we wanted to determine whether PK2-induced activation of astrocytes can 
change the cellular mitochondrial dynamics. We used the Seahorse XFe24 instrument looking at 
both primary mouse astrocytes (Fig. 6A) and the U373 human astrocytoma cell line (Fig. 6E). In 
the primary mouse astrocytes, treatment with recombintant PK2 (rPK2) for 8 hours leads to an 
increase in the basal oxygen consumption rate, or OCR, (Fig. 6B) and ATP production (Fig. 6C). 
We also looked into the cell energy phenotype by comparing the OCR, and the extracellular 
acidification rate, or ECAR, to determine the response to treatment. Higher OCR would indicate a 
shift in mitochondrial dynamics towards a more aerobic phenotype, whereas a higher ECAR would 
indicate a shift towards more a more glycolytic phenotype. Interestingly, rPK2 treatment induced 
the astrocyte cells to increase both OCR and ECAR levels compared to the control. This increase 
by rPK2 leads to a cell energy phenotype that would be more energetic, because it increased both 
energy production pathways in the primary mouse astrocytes (Fig. 6D). When we performed 
similar treatment of rPK2 for 8 hours in the U373 human astrocytoma cell line we found similar 
194 
 
results. Basal OCR (Fig. 6F) and ATP production (Fig. 6G) were significantly increased with rPK2 
treatment compared to the control. The rPK2 treatment was also able to increase the ECAR levels 
in the U373 cell line, which along with the increased OCR leads to a shift towards a more energetic 
cell energy phenotype (Fig. 6H). Taken together, these data demonstrate that recombinant PK2 is 
able to induce a mitochondrial dynamic shift towards a more energetic phenotype indicating 
astrocyte activation.  
 
Recombinant human PK2 and PK2 overexpression reduces production of pro-inflammatory 
cytokines and increases astrocyte anti-oxidant response elements 
 Studies have demonstrated that activated astrocytes can either exacerbate inflammation, by 
producing pro-inflammatory cytokines (Hirsch et al. 2003, Rappold and Tieu 2010), or help protect 
against inflammation, through anti-oxidant response elements such as Nrf2 and reduced 
glutathione (Vargas et al. 2008, Dias, Junn and Mouradian 2013b).  Therefore, astrocyte activation 
could be detrimental or therapeutic, depending upon the signals that the astrocytes produce. Some 
studies postulate that it could be a situation similar to microglia, where depending upon the signal 
the cell will activate specific pathways that leads either to M1, classic activation and pro-
inflammatory, or an M2, alternative activation and anti-inflammatory, phenotype (Jang et al. 
2013a). Knowing that PK2 can activate astrocytes, we then wanted to investigate whether PK2-
induced astrocyte activation would lead to the production of inflammatory or anti-oxidant 
elements. First, we wanted to determine whether recombinant PK2 would lead to an increase in 
the production and release of pro-inflammatory cytokines. Recombinant PK2 was added to 
primary mouse astrocytes for 8 hours for qPCR analysis for pro-inflammatry cytokines or 12 hours 
to check for cytokine secretion in the media. Gene expression analysis with rPK2 treatment showed 
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that there was no change in inflammatory cytokines IL-1β, IL-6, and TNFα (Figure 7A). The 
conditioned media from the 12-hour treatment was then run on a Bioplex 200 for pro-inflammatory 
cytokines IL-1β, IL-6, and TNFα. Interestingly, we surprisingly found that rPK2 conditioned 
media significantly reduced the basal levels of all three of these pro-inflammatory cytokines 
(Figure 7B). These results indicate that PK2 can lead to activation of astrocytes, but there is no 
increase in the production or release of pro-inflammatory cytokines. Next, we wanted to determine 
whether rPK2 could induce an anti-oxidant or anti-inflammatory response in primary mouse 
astrocytes.  
 Arginase-1 and iNOS, or nitric oxide synthase, are enzymes that compete for l-argenine. 
This allows arginase to modulate the amount of nitric oxide, or NO, that is produced by iNOS. 
Therefore, the ratio of Arginase-1 to iNOS gene expression and protein level is an important 
indicator of whether a cell is inducing inflammation or protecting against it. Previous studies 
indicate that astrocytes can produce more arginase1 during stressful conditions, such as a stroke, 
in the brain. Using quantitative PCR for primary mouse astrocyte samples treated with rPK2 for 
8hrs, we tested the gene expression for Arginase1 and iNOS. Interestingly, PK2 treatment 
significantly increased Arginase1 gene expression, while also significantly decreased iNOS gene 
expression (Figure 7C). Protein levels of iNOS were also found to be decreased by 
immunofluorescence microscopy (Figure 7D). Overexpression of Nrf2 in astrocytes has 
demonstrated the ability to protect dopaminergic neurons from neurotoxicity (Gan et al. 2012). 
Therefore, we wanted to check the expression of Nrf2 and an anti-oxidant gene downstream of 
Nrf2 in peroxiredoxin-2, or Prdx2. We found that rPK2 treatment significantly increased the gene 
expression of both Nrf2 and Prdx2 (Figure 7E) and the protein level of Nrf2 by 
immunofluorescence microscopy and Western blotting techniques (Figure 7F and 7G). These 
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results indicate that exogenously added recombinant PK2 can induce astrocytes to produce anti-
oxidant and anti-inflammatory factors such as arginase1and Prdx2.  
 Next, we used a lenti-viral delivery system to either overexpress PK2 tagged to GFP or 
control GFP overexpression in primary mouse astrocytes (Figure 8A). Gene expression analysis 
shows that PK2 overexpression increased both Arginase1 and Nrf2, while there was no change in 
the iNOS gene expression level (Figure 8B). We then wanted to examine the secretion of pro-
inflammatory cytokines IL-1β, IL-6, TNFα in conditioned media of primary mouse astrocytes 
overexpressing PK2. Interestingly, there was no change in the protein levels in the conditioned 
media from PK2 overexpressing cells compared to GFP infected cells (Figure 8C). Similarly, we 
found Nrf2 protein level increased with PK2 overexpression compared to control cells and GFP 
overexpression cells (Figure 8D bottom left panel). STAT6 phosphorylation has been implicated 
in alternative activation of microglia and macrophages, therefore we wanted to measure STAT6 
phosphorylation in PK2-induced astrocyte activation. Interestingly, we found that PK2 
overexpression significantly increased phosphorylated STAT6 protein level compared to GFP 
overexpression, whereas total STAT6 protein level did not change (Figure 8D bottom middle and 
right panel). Taken together, these results demonstrate that PK2 overexpression shift astrocytes to 
produce more anti-oxidant proteins such as Arginase-1 and Nrf2 with no change in pro-
inflammatory cytokine secretion, similarly to our results with recombinant PK2.  
 
PKR1 agonist promotes alternative activation of astrocytes in cell culture 
The prokineticin receptors are GPCRs, or G-protein coupled receptors. This receptor class 
has been exploited for pharmaceutical therapies in different disease models (Ghanemi 2015). Our 
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previous results of PK2 activating astrocytes led us to use a non-peptide compound to activate the 
prokineticin signaling pathways in astrocytes. Gasser et al. originally tested PKR1 agonist 
compounds to use for protection of cardiomyocytes in the heart. They found that IS20 was able to 
activate the prokineticin signaling pathways, such as Akt and ERK, and that it was able to protect 
cardiomyocytes from a myocardial infarction (Gasser et al. 2015). Therefore, we wanted to 
determine if IS20 was capable of activating astrocytes in a similar manner to recombinant and 
overexpression of PK2 since astrocytes mainly produce the PKR1 receptor compared to PKR2. 
First, we found that IS20 could significantly increase mitochondrial respiration and ATP 
production similar to that seen with rPK2 treatment (Figure 9A). Also, we found a similar shift in 
the cellular energy phenotype towards a more energetic role compared to control treatment. These 
results indicate that IS20 can activate astrocytes in a similar manner to recombinant PK2 protein 
treatment. Next, we used quantitative real-time PCR to examine the gene expression of genes 
previously seen in astrocyte activation. We found that anti-oxidant genes such as Arginase-1 and 
Nrf2 were significantly increased, whereas iNOS gene expression decreased compared to the 
control (Figure 9B). We validated the gene expression results by examining the protein level of 
these key activation proteins using Western blotting techniques. In concordance with our qPCR 
results, we found Arginase-1 and Nrf2 significantly increased compared to control (Figure 9C). 
Taken together, these results demonstrate that IS20, a non-peptide PKR1 agonist, is able to activate 
astrocytes and increase anti-oxidant protein expression of Arginase-1 and Nrf2.  
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Prokineticin signaling increases glutamate uptake through upregulation of GLAST in 
cultured astrocytes 
 Astrocytes are known to help protect neurons through multiple ways, with one of those 
protective mechanisms being the uptake of glutamate to prevent excitotoxicity (Sattler and 
Rothstein 2006). Pro-inflammatory cytokines, such as TNFα, have been found to decrease the 
expression of glutamate transporters, especially GLAST (Dumont et al. 2014). Therefore, we 
wanted to determine whether rPK2 treatment could lead to a change in the ability of primary mouse 
astrocytes to take up extracellular glutamate. Using radio-labeled glutamate, we found that treating 
primary mouse astrocytes for 8 hours with PK2 or the PKR1 chemical agonist IS20, along with 
IL-4 as a positive control, could increase overall glutamate uptake in these cells compared to 
control cells (Figure 10A). Astrocytes that are cultured without the presence of neurons will 
express very low levels of GLT-1, however GLAST is expressed at a normal level (Swanson et al. 
1997). Therefore, we measured the gene expression of GLAST in primary mouse astrocytes, and 
found that recombinant PK2 treatment increased the gene expression of GLAST, in a similar 
manner of IL-4 treatment (Figure 10B). Taken together, these data indicate that PK2 signaling can 
lead to functional changes in astrocytes that would lead to a reduction of extracellular glutamate 
through upregulation of the glutamate transporter GLAST, and could potentially protect neurons 
from excitotoxicity. 
 
Discussion 
 Astrocytes play important roles in maintaining a healthy CNS and become activated during 
the progression of Parkinson’s disease, and other neurodegenerative diseases. Astrocyte activation 
199 
 
in not very well understood, and only recently has it been discovered that astrocytes can respond 
differently depending on the stimuli. Proinflammatory cytokines such as TNFα and IL-1β can 
stimulate astrocytes to propagate inflammation through the production of more inflammatory 
cytokines, whereas stimulation with the anti-inflammatory cytokine IL-4 led to a reduction in 
astrocyte-produced pro-inflammatory cytokines (Jang et al. 2013a). Neuron-astrocyte signaling 
therefore could play a key role in the progression of PD, and finding factors from neurons that can 
influence astrocyte activation is an important research avenue for neurodegenerative diseases. 
Previously, our lab found that dopaminergic neurons produce and secrete the chemokine-like 
signaling protein Prokineticin-2 both in Parkinson’s disease patients and in animal models of PD. 
Interestingly, astrocytes express the mRNA for the two prokineticin receptors, mainly PKR1, and 
that PK2 can increase astrocyte proliferation (Koyama et al. 2006). In the present study we found 
that the prokineticin receptors protein level is similar to what was seen at the mRNA level, and 
recombinant human PK2 was able to dose-dependently increase both intracellular calcium levels, 
and cell proliferation in primary mouse astrocytes and a human astrocyte cell line. Also, this is the 
first study to show the protein levels and cellular localization of the prokineticin receptors in 
astrocytes. Interestingly, by analyzing the branch patterns of astrocytes with PK2 we found 
reduced number of astrocyte branches and endpoints compared to GFP overexpression. This could 
be due to the cell migrating and will remove some of the processes that are connected to other 
cells. Prokineticin signaling has been implicated in the migration of several cell types (Lin et al. 
2002b, Ayari et al. 2010, Monnier and Samson 2008), so it was not surprising to find that PK2 was 
able to increase both wound healing and migration of human astrocytes. Collectively, these results  
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along with previous knowledge demonstrate an important finding, that PK2 secreted from 
damaged neurons can signal to astrocytes, causing them to migrate to the site of injury and 
proliferate.  
 Astrocyte activation has been used as a marker for neurodegeneration and 
neuroinflammation, but it still not understood what role this activation plays in the normal or 
diseased states of the CNS. Herein, we demonstrated that PK2 can induce astrocyte activation both 
in vitro, by analyzing mitochondrial dynamics, and in vivo in the striatum of mice evident by the 
PK2-induced increase in the number of GFAP-positive cells, the amount of GFAP immunostaining 
per cell, and the increased soma size of astrocytes. We previously found that PK2 can increase 
mitochondrial biogenesis in neurons, and the increase in basal respiration of astrocytes could 
indicate a similar mechanism. However, it is more likely that activated astrocytes require more 
energy for proliferation and migration similar to previous reports for mitochondrial dynamics in 
microglia (Jiang and Cadenas 2014, Orihuela et al. 2016).  This would explain the increase in 
migration and proliferation of astrocytes with PK2 treatment, because astrocyte activation 
increases both of these functions. These results implicate Prokineticin-2 as a factor behind the 
increased number of activated astrocytes seen in the nigro-striatal pathway in animal models of 
PD and in PD patients. In PD there is an increase in PK2 production and secretion from 
dopaminergic neurons and PK2 then can signal to cause astrocytes to activate and migrate to the 
damaged neurons. 
 Astrocytes are traditionally viewed as support cells for the neurons of the CNS, however 
astrocytes can contribute to inflammatory damage of the CNS with certain stimuli. Interestingly, 
studies have shown that overexpression of Nrf2 in astrocytes is able to protect dopaminergic 
neurons from cell death (Gan et al. 2012). Therefore, it could be an important Parkinson’s disease 
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therapeutic avenue to look for stimuli that increase antioxidant proteins, such as Nrf2, in astrocytes. 
Importantly, Prokineticin-2 signaling in astrocytes does not increase inflammatory factors such as 
pro-inflammatory cytokines, or iNOS. On the other hand, PK2 is able to increase protective factors 
in such as Arginase-1, but most importantly an increase in Nrf2 both at a gene level and protein 
level in astrocytes. Interestingly, the non-peptide PKR1 agonist was also able to activate cultured 
astrocytes and increased both Arginase-1 and Nrf2 protein level. Therefore, this increase in anti-
oxidant proteins paired with the lack of increase in pro-inflammatory cytokines means that PK2-
activated astrocytes could lead to a more neuroprotective phenotype. Further, prokineticin 
signaling increases glutamate uptake by increasing the gene expression of GLAST in cultured 
astrocytes and therefore leading protection of neuroprotection. This is the first study to show that 
Prokineticin-2 signaling can alternatively activate astrocytes, induce migration and produce 
neuroprotective factors such as Nrf2, along with increased glutamate uptake. This opens the 
opportunity for using prokineticin signaling as a possible therapeutic opportunity to protect 
dopaminergic neurons in Parkinson’s disease through reducing astrocyte-produced inflammation. 
Further studies into neuron-glia crosstalk could be an important avenue for therapeutic approaches 
of neurodegenerative diseases.  
 
Matereials and Methods 
Reagents  
DMEM, MEM media, fetal bovine serum (FBS), L-glutamine, IR-dye tagged secondary 
antibodies, Hoechst nuclear stain, penicillin, streptomycin, and other cell culture reagents were 
purchased from Invitrogen (Gaithersburg, MD). Recombinant PK2 was purchased from Peprotech. 
The primary antibody for PKR1, PKR2, Nrf2 was ordered from Santa Cruz Biotechnology Inc. 
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(Santa Cruz, CA). GFAP was obtained from Millipore. We purchased the phosphorylated STAT6 
and Native STAT6 antibodies from Cell Signaling. The Arginase1 antibody was ordered from 
Thermo. The Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA). 
Fluo4 calcium assay and CyQuant kit was ordered through Invitrogen. 
Cell culture and animal studies 
Human U373 astrocytoma cells (ATCC), were grown in MEM media supplemented with 10% 
FBS, penicillin (100 U/ml), streptomycin (100 μg/ml), according to ATCC instructions. U373 cells 
were maintained in an incubator at 37°C with 5% CO2. Primary mouse astrocytes were obtained 
from whole brain homogenate of 0-3 day mouse pups. Astrocytes were collected, isolated and 
maintained according to previous methods (Gordon et al., 2011) using DMEM media (10% heat-
inactive FBS, 100 U/ml penicillin, 100 g/ml streptomycin, glutamate 2mM) to grow the cells. 
Primary human astrocytes were obtained from Lonza. 
Quantitative PCR 
Mouse astrocyte cells or U373 cells were seeded out into 75-mm3 flasks at 2.5 x 106 cells per flask. 
Treatments were performed in either MEM or DMEM media supplemented with 2% FBS, 
penicillin (100 U/ml), streptomycin (100 μg/ml), and 2 mM L-glutamine. Cells were treated for 8 
h with rPK2 (25nM) or rPK2 cotreated with PC-7 (1uM). After treatment, cells were collected, 
pelleted, and resuspended in lysis buffer with β-mercaptoethanol. RNA was isolated using 
Absolutely RNA Miniprep, an RNA isolation kit from Stratagene. RT-PCR was performed using 
an cDNA synthesis system (Applied Biosystems) to convert the RNA into cDNA. Expression 
levels were determined using real-time PCR with Qiagen RT2 SYBR Green master mix and 
prevalidated using the qPCR mouse primers from SuperArray/Qiagen (Qiagen). For normalization 
of each sample, the mouse gene 18SrRNA (Cat. No. PPM57735E) was used as the housekeeping 
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gene. The amount of each template was optimized empirically to maximize efficiency without 
inhibiting the PCR reaction. According to manufacturer’s guidelines, dissociation curves and 
melting curves were run to ensure that single amplicon peaks were obtained without any non-
specific amplicons. The results are reported as fold change in gene expression, which was 
determined using the ΔΔCt method using the threshold cycle (Ct) value for the housekeeping gene 
and for the respective gene of interest in each sample. 
Western blotting 
Astrocytes were collected after treatment, lysed using modified RIPA buffer, homogenized, 
sonicated, and centrifuged as previously described (Kaul et al., 2003; Kitazawa et al., 2002). 
Supernatants were collected and proteins were normalized, then stored with loading buffer and 
DTT. Samples were run on a Sodium Dodecyl Sulfate (SDS) gel electrophoresis. Normalized 
protein samples were loaded into each well and first separated in a 4% stacking gel and then 
through a 12-18% resolution gel. Proteins were then transferred to a nitrocellulose membrane. 
After transfer, the membranes were blocked using Western blocking buffer (Rockland 
Immunochemicals). Primary antibodies, in blocking buffer were then added to the membranes and 
stored overnight at 4°C. A Secondary antibody specific to the primary antibody was added (in 
either blocking buffer or in 5% low-fat dry milk solution) to the membrane for 1 h. Either β-Actin 
or α-Tubulin was used to confirm equal loading into each well of the gels. The membranes were 
read using the Odyssey infra-red imaging system. 
Immunocytochemistry 
For immunocytochemistry, cells were plated onto coverslips in 24-well plates coated with 0.1% 
poly-D-Lysine. After cells were treated, 4% formaldehyde was used to fix the cells for 30 min. 
The cells were washed with PBS wash buffer. Then blocking buffer containing 2% BSA, 0.2% 
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Triton X-100, and Tween was added to the wells for 1 hour. The cells were incubated with primary 
antibodies in 2% BSA at 4°C overnight. Next, an Alexafluor dye-conjugated secondary antibody 
in 2% BSA was added and incubated at room temperature on a shaker for 1 h. After washing 
Hoechst counterstain was added to the cells for 5-6 min to label nuclei. Coverslips were washed 
several times then mounted onto slides with Fluoromount mounting media. Cells were imaged 
under a Nikon 2000U microscope with a SPOT camera, and all images were processed in 
MetaMorph 5.7 (Universal Imaging, Downingtown, PA). 
For histology, mice were anesthetized using the ketamine-xylazine mixture and cardiac perfusion 
of 4% PFA was used to fix the brain before being extracted and stored in 4% PFA at 4°C. After 
48 h, brains were washed with PBS, and placed into a 30% sucrose solution for at least 24 h. The 
brains were then embedded in Optimal Cutting Temperature (OCT) compound and frozen into 
blocks for sectioning. Brains were sectioned on a Cryostat (CryoStar NX70, Thermo Scientific) at 
-20°C and placed into Cryosolution (30% Sucrose, Ethylene glycol, and PBS). Sections were then 
washed with PBS and permeabilized with blocking buffer (2% BSA, 0.1% Triton X-100, and 
Tween) for 1 h at room temperature. Antibodies directed to the protein of interest were then 
incubated with the sections overnight at 4°C. After washing with PBS, the sections were incubated 
with Alexafluor dye-conjugated secondary antibodies for 1 h at room temperature. After washing 
with PBS, Hoechst dye (1:5000) was added to the sections for 5 min at room temperature to stain 
nuclei. Sections were then mounted on slides using the Fluoromount mounting medium (Molecular 
probes) according to the manufacturer’s instructions. An inverted fluorescent microscope (Nikon 
TE-2000U) was used to visualize the sections, and a Spot digital camera (Diagnostic Instruments, 
Inc) was used to capture images. 
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Scratch-wound migration assay 
To assess wound healing, astrocytes were allowed to grow to a confluent monolayer in 6 well 
plates. Once the cells are fully confluent, a 1000ul pipet tip was used to make the scratch through 
the cells. A scratch was made from top to bottom and from left to right, to form a plus sign of a 
scratch to identify similar imaging areas. Cells were washed 3 times with serum free media, 
treatments were added and wells were imaged for 0 hour timepoint. Endpoint images were taken 
at 24 hours after treatment using an inverted fluorescent microscope (Nikon TE-2000U). 
Measurement of the scratch width was randomly assessed in each group and expressed in microns. 
This experiment was repeated with a three total wells for each treatment. 
2D Chemotaxis assay 
The chemotaxis assay was performed using Ibidi 2D chemotaxis chambers that were purchased 
from Ibidi. The assay was performed according to the manufacturer’s guidelines. The U373 
astrocytoma cell line was seeded into the middle line of each chamber and allowed to adhere to 
the plate overnight. The 10% serum containing DMEM growth media was washed twice with 
serum free DMEM media, then either serum free media or recombinant PK2 was introduced 
through one of the experimental reservoirs. The cells were imaged at 0 hours to ensure that the 
cells were still attached and then imaged every hour for 18 hours at 10X magnification. Images 
were taken using an inverted fluorescent microscope (Nikon TE-2000U) and collated using ImageJ 
software. Cells were tracked to measure migration parameters with the Ibidi Manual Tracking 
software. A minimum of 50 cells were followed for each treatment to determine overall migration 
parameters.  
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Mitochondrial dynamics 
To analyze the mitochondrial energy dynamics in both primary mouse astrocytes and the U373 
human astrocyte cell line, the XFe24 Seahorse analyzer was used to measure OCR and ECAR 
levels. Astrocytes were plated on Seahorse plates at 80,000 cells in each well and allowed to attach 
overnight in growth media. Cells were then washed with serum free DMEM media 3 times and 
500ul of treatment was added to the wells in serum free DMEM for 8 hours. After the 8 hours, the 
cells were washed 2 times with the Seahorse base media supplemented with sodium pyruvate and 
glutamine. The MitoStress test was performed according to the manufacturer’s guidelines. The 
cells were left in the 500ul of the Seahorse base media supplemented with sodium pyruvate and 
glutamate. After testing correct concentrations of the chemicals, 0.75uM of oligomycin, 1uM of 
FCCP, and 0.5uM rotenone/antimycin was added to the cells to measure mitochondrial dynamics. 
Analysis was performed through the MitoStress Results Generator found on the Agilent website.  
Fluo-4 calcium mobilization and CyQuant proliferation assay  
A Fluo-4 NW assay kit (Molecular probes) was used to test calcium mobilization in 
primary mouse astrocytes resulting from nanomolar concentrations of rPK2. Cells were plated 
overnight into 96-well plates in growth media. Cells were then washed with HBSS and incubated 
with the Fluo-4 NW dye for one hour. Each plate was then read kinetically using a Synergy-2 
multi-mode microplate reader. After obtaining background readings by reading each plate every 
50 ms for 20 sec, rPK2 was injected at the indicated nanomolar concentrations. The net change in 
fluorescent signal (Dt), read every 50 ms for 3 min, was obtained after subtracting the background 
from the maximum signal for each sample. 
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 Astrocyte proliferation was measured using the CyQuant dye according to manufacturer’s 
guidelines. A standard curve of cell numbers was generated by seeding out the astrocytes into a 
24-well plate. The same number of astrocytes were seeded into the experimental wells. After 48 
hour of incubation with treatment of control or different doses of rPK2 (5, 10, 25 or 50nM), 50 µl 
of CyQUANT NF Cell Proliferation Assay reagent was added to each well after aspiration of 
medium. After incubation for 30 minutes at 37°C, fluorescence was measured (excitation 485 nm, 
emission 538 nm) using the Synergy-2 multi-mode microplate reader. Fluorescent values were 
compared to the standard curve of cell numbers to generate the treatment induced cell number.  
 
Glutamate uptake assay 
Primary mouse astrocytes were plated into a 24-well plate with 120,000 cells per well. The 
astrocytes were treated with rPK2, IS20 or neither in serum free DMEM media for 8 hours. After 
the 8 hour treatment, three washes with Krebs-Ringer buffer was used to wash away the treatment 
media. The cells were then incubated with 2µCi radioactive Glutamte for 15 minutes along with 
100µM L-Glutamine in warm Krebs-Ringer buffer. Remove media and washed three times ice 
cold Krebs-Ringer buffer to stop uptake. Lyse the cells in 1N NaOH and collect the sample. The 
radioactivity was measured with a liquid scintillation counter (Tri-Crab 4000, Packard Instrument 
Co.) after the addition of a 5-ml scintillation mixture to each vial. The specific dopamine uptake 
was expressed as mean values of counts. 
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Data analysis 
Data analysis was performed using the Prism 4.0 software package (GraphPad Software, San 
Diego, CA). The data was first analyzed using one-way ANOVA and then Tukey’s post-test was 
performed to compare all treatment groups. Differences of p<0.05 were considered statistically 
significant. The Student's t-test was used when two groups were being compared. 
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Figure 1. Prokineticin-2 can signal to primary mouse astrocytes through increased intracellular 
calcium and cell proliferation. (A) Quantitative real time PCR for prokineticin receptor gene 
expression, with PKR1 expressed over 2000 fold higher than PKR2. (B) Different cellular 
localization pattern for PKR2 (Red, top panel) and PKR1 (Red, bottom panel) in GFAP (Green) 
positive astrocytes and the nucleus stained with Hoechst (Blue). Expression of PKR2 was peri-
nuclear whereas PKR1 expression was localized more on the periphery of the cell. (C) 
Representative Western blot for PKR1 and PKR2 in primary mouse astrocytes showing higher 
PKR1 compared to PKR2 and no significant change with LPS treatment. (D) Calcium mobilization 
(flux) dose-dependently induced by rPK2 in primary mouse astrocytes, with calcium-free HBSS 
used as a control treatment. (E)  CyQuant cell proliferation assay used to show dose-dependent 
increase in primary mouse astrocyte cell proliferation. Asterisks denote a significant difference 
between rPK2 treatment and the control (* p<0.05, ** p<0.01, and *** p<0.001). 
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Figure 2. Prokineticin-2 overexpression induces astrocyte activation in vivo. C57/Bl6 mice were 
stereotaxically injected in the stiatum with either PK2-AAV 2/5 or GFP AAV 2/5 and allowed to 
reach maximal viral gene expression for four weeks. (A) Expression of the PK2 tagged to GFP 
and GFAP protein levels by fluorescence microscopy. Brain sections were probed with anti-GFP 
(Green) and anti-GFAP (Red) antibodies and imaged to show an increase in GFAP around the 
areas of PK2-tagged GFP expression (2X left panel and 20X right panel). (B) Representative 
Western blot for GFAP in the mouse striatum showing that there is an increase in GFAP with the 
PK2-AAV. (C) GFAP-DAB immunostaining of the striatum (20X magnification top panel) with 
insets zoomed into one cell. (D-F) Cell counting of GFAP-positive cells (D), immunostaining 
quantification of GFAP for each cell (E) and cell soma size measurement of GFAP-positive cells 
(F) in the mouse striatum showing that PK2-AAV increases both the number of GFAP-positive 
cells and the amount of GFAP, and increases cell soma size in these cells compared to GFP-AAV 
injected and control striatum.  
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Figure 3. Prokineticin-2 overexpression reduces number of astrocyte processes. (A-C) Converting 
GFAP-DAB images for measurement of astrocyte processes with PK2-AAV or GFP-AAV 
injection in the striatum.  (A) GFAP-DAB immunostaining for control, PK2-AAV and GFP-AAV 
injected striatum (zoomed in images from 20X magnification). (B) ImageJ skeletonization after 
converting the GFAP-DAB image into a binary image. (C) ImageJ analyze skeleton plug-in image 
from the skeletonized image with process branches (Orange), junctions (Purple), and endpoints 
(Blue). (D-E) Measurement of the astrocyte processes. Analysis for the average number of process 
branches (D) and process endpoints (E) per GFAP-positive astrocyte shows that PK2-AAV 
significantly reduced average cell process branches compared to Control, and GFP-AAV.  
219 
 
 
 
Figure 4. Recombinant PK2 treatment induces astrocyte wound healing. (A) Scratch-wound assay 
images for control, rPK2 and 10% FBS as a positive control from 0 hours (top panel) and 24 hours 
post scratch (bottom panel) with scale bars randomly placed down the scratch to measure the 
wound width. (B-C) Analysis of total migration distance travelled from 0 hour to 24 hours showing 
that rPK2 treatment increases wound healing in the U373 human astrocyte cell line (B) and in 
primary human astrocytes (C). Experiment was repeated twice with three biological replicates in 
each treatment. Asterisks denote statistical significance between treatments and the control (*** 
p<0.001).   
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Figure 5. Prokineticin-2 increases U373 astrocyte migration. (A) Ibidi 2D migration chamber 
setup to demonstrate experimental design of testing a chemoattractant, such as PK2, from one 
chamber to measure directional migration. (B) Phase contrast images from 0 hour (left panel) and 
18 hours (right panel) after addition of treatment to the reservoirs for the slide with PK2 treatment 
coming from the top of the image. Two separate individual cell are marked both in the 0 hour and 
the 18 hour (Red and Blue arrows). (C) Migration tracking plots of individual cell migration tracks 
with either control (left panel) or PK2 treated (right panel) platforms, along with a rose plot for the 
migration tracks (bottom panels). (D-H) Analysis of the 2D migration chambers comparing either 
control or PK2 treated platforms. Measurement for the single cell y-axis forward migration index 
(D), migration velocity (E), total accumulated migration distance (F), Euclidean migration distance 
(G), and migration directionality all shows that PK2 significantly increases the directional 
migration of U373 astrocytes. Measurements were performed with at least 50 cells in each 
treatment group, and asterisks denote statistical significance between the PK2 and control 
treatments (* p<0.05, ** p<0.01, and *** p<0.001). 
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Figure 6. PK2 increases induces shift in astrocyte mitochondrial dynamics and energy production. 
(A-B) XFe24 Seahorse Mitochondrial stress test on primary mouse astrocytes(A) and the U373 
human astrocyte cell line (B). Analysis of the mitochondrial respiration rate with the respiration 
plot (A and B, left panel) along with basal respiration measurement (A and B, middle panel) and 
ATP production measurement (A and B, right panel) shows that PK2 treatment causes a significant 
induction of oxidative respiration in astrocytes. Cellular phenotype plot comparing OCR on the y-
axis and ECAR on the x-axis (A and B, bottom panel) shows that PK2 treatment increases overall 
energy production in primary mouse astrocytes and the U373 human astrocyte cell line. At least 
four biological replicates for each treatment with asterisks denote statistical significance of SEM 
between PK2 and control treatments (* p<0.05, and **p<0.01). 
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Figure 7. PK2 induces alternative activation of primary mouse astrocytes. (A) Quantitative real 
time PCR analysis for the pro-inflammatory cytokines IL-1β and TNFα. (B) Pro-inflammatory 
cytokine protein levels measured in the primary mouse astrocyte conditioned media using the 
Bioplex 200 multi-plex system for IL-1β (left panel), IL-6 (middle panel), and TNFα (right panel). 
(C-D) Recombinant PK2 treatment increases anti-oxidant factors in primary mouse astrocytes. (C) 
Quantitative real-time PCR analysis for Arginase-1 (Left panel) and iNOS (Right panel). (D) 
Fluorescence microscopy images of iNOS protein level. (E-F) Recombinant PK2 treatment 
increases anti-oxidant factors in primary mouse astrocytes. (E) Quantitative real-time PCR gene 
expression analysis for Nrf2 (Left panel) and Prdx2 (Right panel). (F) Fluorescence microscopy 
images detecting iNOS protein levels. (G) Western blot analysis for Nrf2 shows that PK2 treatment 
can increase Nrf2 protein level where PC7 can attenuate this increase, with β-Actin as an internal 
loading control.  
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Figure 8. PK2 overexpression promotes alternative activation of primary mouse astrocytes. (A) 
Fluorescence microscopy detects GFP to confirm Lenti-viral overexpression of PK2. (B)  
Quantitative real-time PCR gene expression analysis for Arginase1, Nrf2 and iNOS with PK2 
overexpression. (C) Western blot analysis of PK2 overexpression for Nrf2, phosphorylated STAT6 
and native STAT6, with β-Actin as an internal loading control. Asterisks denote statistical 
significance between PK2 treatment and either control or PC7 (* p<0.05, ** p<0.01, and *** 
p<0.001). 
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Figure 9. PKR1 agonist promotes alternative activation of primary mouse astrocytes. (A) 
Mitochondrial dynamics measured with XFe24 Seahorse instrument and mitochondrial stress test 
(Left panel) to compare IS20 to control for basal respiration and ATP production (Middle panels). 
Cell energy phenotype plot (right panel) comparing OCR (y-axis) and ECAR (x-axis) shows that 
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IS20 shifts astrocyte mitochondria to a more energetic phenotype. (B) Quantitative real-time PCR 
gene expression analysis for Arginase1, Mrc1, Nrf2, Prdx2 and iNOS with IS20 treatment 
compared to control. (C) Western blot for Arginase1 and Nrf2 comparing IS20 treatment and 
control, with β-Actin as an internal loading control. Asterisks denote statistical significance 
between IS20 treatment and control (* p<0.05, ** p<0.01, and *** p<0.001). 
 
 
Figure 10. Prokineticin signaling increases glutamate uptake in cultured astrocytes through 
induction of GLAST gene expression. (A) Exogenously added radioactive glutamate levels in 
primary mouse astrocytes. (B) Quantitative real-time PCR gene expression analysis for GLAST 
with PK2 and IL-4 treatment compared to control. Asterisks denote statistical significance between 
PK2, IS20 or IL-4 treatment and control (* p<0.05, ** p<0.01, and *** p<0.001). 
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Abstract 
 Parkinson’s disease (PD) is characterized by the selective loss of dopaminergic neurons in 
the substantia nigra region of the brain. A major scientific focus has been developing ways to 
protecting these neurons from cell death. One such avenue of research has been investigating the 
use of proteins that are known to activate cell survival signals in neurons, such as neurotrophic 
factors. The most studied neurotrophic factor in PD is glial cell-line derived neurotrophic factor, 
or GDNF.  GDNF has been found to protect dopaminergic neurons from cell death in both cell 
culture and animal models of PD. However, clinical trials for GDNF therapies in PD patients have 
demonstrated mixed results. Therefore, the search continues for factors that increase endogenous 
GDNF and could protect neurons through other pathways. Our lab previously found that 
dopaminergic neurons produce higher levels of the chemokine-like protein Prokineticin-2 (PK2) 
in animal models of PD and in PD patients compared to age-matched controls. PK2 is a secreted 
signaling protein that can signal to both microglia and astrocytes in the brain. Herein, we found 
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that prokineticin signaling can lead to increased gene expression and protein level of GDNF in 
mouse and human astrocytes. Interestingly, the PK2-induced GDNF increase was able to protect 
human dopaminergic neuronal cells from MPP+-induced cell death. Collectively, Prokineticin-2 is 
a novel protein that we found which could modulate GDNF expression in astrocytes, and therefore 
induce astrocytes to protect dopaminergic neurons through the increased GDNF protein levels. 
 
Introduction 
 Parkinson’s disease is characterized by the selective loss of dopamine producing neurons 
in the Substantia Nigra (SN) region of the brain. It is currently unknown what causes these neurons 
to undergo apoptosis, and there is no treatment available to prevent this cell loss. Research in the 
Parkinson’s disease field has focused on finding a treatment that can either protect or restore these 
dopaminergic neurons. Glial-derived neurotrophic factor, GDNF, was first identified as a protein 
in the TGFβ family that is secreted from astrocytes in the central nervous system. Neurotoxic 
studies in vitro demonstrated that exogenously added GDNF could be neuroprotective against 
dopaminergic neuronal apoptosis (Lin et al. 1993). Interestingly, Parkinson’s disease patients were 
found to have significantly reduced levels of GDNF in the SN region in comparison to age-
matched controls (Chauhan et al. 2001). Therefore, GDNF has become an interesting factor for 
current study for a possible treatment of Parkinson’s disease due to the ability to protect and restore 
dopaminergic neurons. Several studies in the last decade have demonstrated that GDNF 
overexpression can increase neuroprotection both in cell culture and animal models of Parkinson’s 
disease (Andereggen et al. 2009, Elsworth et al. 2008, Sandhu et al. 2009). 
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 Similar to the in vitro studies that showed GDNF could induce neuronal survival and 
neurite outgrowth (Lin et al. 1993, Kaddis et al. 1996), many studies have demonstrated that GDNF 
can protect against MPTP (Tomac et al. 1995, Gash et al. 1996) or 6-OHDA (Lu and Hagg 1997) 
induced behavioral deficits and neuronal loss with GDNF injections either intraventricular, 
intrastriatal and intranigral injections. However, clinical trials in humans have offered mixed 
results to GDNF therapy of Parkinson’s disease. Firstly, GDNF is not able to cross the blood brain 
barrier (BBB) and therefore intracranial infusion through injections or pumps is the only feasible 
option for a GDNF protein therapy. Unfortunately, GDNF intracranial infusion in human patients 
was not able to significantly improve the unified Parkinson’s disease rating scale (UPDRS), and 
actually lead to adverse effects such as anorexia and weight loss (Lang et al. 2006a, Hovland et al. 
2007). Researchers have since tried to deliver GDNF by different routes, such as intranasal 
(Migliore et al. 2014), transplantation of GDNF expressing cells (Liu et al. 2013), and gene therapy 
using viral vectors (Wang et al. 2002, Tereshchenko et al. 2014). Results from these studies are 
encouraging, however, it seems as though increased GDNF alone is not enough to significantly 
affect the progression of Parkinson’s disease. 
 Prokineticin-2 is a small chemokine-like protein first identified to potently contract 
gastrointestinal muscles (Li et al. 2001). PK-2 is an 86 amino acid signaling protein that is the 
mammalian homologue of MIT1, a non-toxic protein in mamba snake venom, and Bv8, found in 
frog skin. Prokineticin-2 has many physiological functions throughout the human body, from the 
testis, ovaries, heart, to the brain. Among other functions, PK2 can promote cell survival and 
growth, and in other tissues it can cause an increase in inflammation and nociception. Prokineticin-
2 signaling has been studied in several areas of the brain, and the prokineticin receptors, PKR1 
and PKR2, are expressed throughout most of the central nervous system. PK2 plays a role in 
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everything from olfactory bulb neurogenesis (Ng et al. 2005), regulating circadian rhythms and 
autonomic functions (Zhou and Cheng 2005, Li et al. 2006b, Li et al. 2009, Yuill et al. 2007), 
thermo regulation and energy expenditure (Zhou et al. 2012),  and leads to reduced food intake 
and weight loss (Beale et al. 2013, Gardiner et al. 2010). One of the most interesting functions of 
PK2 is the ability to be neuroprotective against several different toxicants. Melchiorri et al. first 
demonstrated that PK2 could protect against NMDA excitotoxicity in the cerebellum (Melchiorri 
et al. 2001). Then, our group was the first to identify that PK2 can protect dopaminergic neurons 
from MPP+-induced cell death (unpublished). PK2 is a secreted protein, and both microglia and 
astrocytes produce the receptors to bind PK2 (Koyama et al. 2006). Therefore, we wanted to 
investigate the role PK2 could play in astrocytes, the support cells of the CNS. 
 
Results 
Prokineticin-2 intracellular signaling leads to an induction of GDNF gene expression  
 Prokineticin-2 signals through two cognate G-protein coupled receptors (GPCRs), PKR1 
and PKR2. These two receptors are highly, and Zhou et al demonstrated that both receptors can 
signal through either Gi, Gq, or Gs, depending on cell type or location of the cell (Zhou 2006). 
Prokineticin-2 signaling is therefore known to cause an increase in intracellular calcium, cell 
proliferation and migration, and activation of the MAPK pathway that can be blocked by a 
prokineticin receptor antagonist or inhibitors of the specific pathways (Chen et al. 2005). Since we 
confirmed that astrocytes express both prokineticin receptors (Neal et al., unpublished)(Koyama 
et al. 2006), we wanted to characterize the cell signaling pathways that could be activated by this 
signaling protein in primary mouse astrocytes. Consistent with previous reports that PK2 can 
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activate the MAPK pathway, we found an increase in the protein levels of both phosphorylated 
MEK and phosphorylated ERK with recombinant PK2 (rPK2) treatment (Figure 1A). Activation 
of the MAPK pathways can have many different downstream effects, one of which is 
phosphorylation and activation of the CRE binding protein, or CREB (Cargnello and Roux 2011). 
Similarly, PK2 has been implicated in increasing levels of cyclic AMP, which has been found to 
increase activation of the CREB transcription factor. Measuring the activation of the CREB 
protein, by phosphorylation, using Western blotting techniques we found that rPK2 treatment in 
primary mouse astrocytes increased the levels of phosphorylated CREB. The CREB transcription 
factor has been implicated in the induction of several neurotrophic factors, such as GDNF and 
BDNF (Brain derived neurotrophic factor)(Saavedra et al. 2008). Therefore, we wanted to 
determine whether rPK2 treatment on primary human astrocytes could lead to changes in 
neurotrophic factor gene expression by using a quantitative PCR array that can measure 80 
different genes in a single sample. Interestingly, we found that rPK2 treatment on primary human 
astrocytes led to changes in several genes, including an increase in GDNF gene expression (Fig 
1A).  
 Astrocytes can protect neurons by several different mechanisms, including glutamate 
synthesis and neurotrophic factor release. Glial cell-line derived neurotrophic factor, GDNF, is a 
protein that is can be secreted from astrocytes and has demonstrated the ability to protect 
dopaminergic neurons from apoptosis (Lin et al. 1993). GDNF gene expression studies have 
indicated that increased intracellular calcium levels and activation of the MAPK pathway could 
induce GDNF expression levels (Saavedra et al. 2008).  After finding that rPK2 could activate 
these specific cell signaling pathways, we wanted to investigate whether rPK2 could induce GDNF 
gene expression in primary mouse astrocytes. Several different transcription factors have been 
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found to regulate the GDNF promoter, such as CREB and SP1. To confirm our previous findings 
that rPK2 treatment can induce GDNF gene expression, we performed promoter studies to 
determine if rPK2 treatment can activate the GDNF promoter. Our lab was able to obtain a 3.6kb 
fragment of the GDNF promoter already cloned into a luciferase plasmid that has already been 
proven to be an effective measurement of GDNF promoter activity (Brodbeck, Besenbeck and 
Englert 2004). We transfected the U373 astrocytoma cell-line with the GDNF promoter plasmid 
and then treated the cells with or without rPK2 for 8 hours. Interestingly, we found that rPK-2 
treatment significantly increased activity of the GDNF promoter compared to GFP vector control 
(Fig 1D). This data indicates that recombinant human PK2 treatment in a human astrocyte cells 
can induce GDNF promoter activation. Taken together, this is the first evidence that Prokineticin-
2 can activate cell signaling pathways and transcription factors that can lead to activation of the 
GDNF promoter in astrocytes. 
 Several studies have looked into the effect of adding either exogenous GDNF or using gene 
therapy techniques to increase the level of GDNF to protect dopaminergic neurons in Parkinson’s 
disease models and clinical trials on patients (Grondin et al. 2002, Tomac et al. 1995, Bjorklund 
et al. 2000, Kordower et al. 2000). However, the clinical trials for GDNF replacement therapy 
have had mixed results depending on the location and method of delivery (Gill et al. 2003, Slevin 
et al. 2005, Lang et al. 2006a). With the knowledge that Prokineticin-2 can signal to astrocytes 
through PKR1/2 and increase intracellular calcium levels and activate the MAPK pathway, our lab 
investigated whether PK2 can induce astrocytes to produce more GDNF. To begin, we used qPCR 
with validated primers for mouse GDNF, to analyze primary mouse astrocyte cell culture after 
adding exogenous rPK2. We found that there was a significant induction of GDNF gene expression 
with 25nM rPK2 treatment (Figure 1E). This induction was partially blocked when cells were co-
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treated with the prokineticin receptor antagonist PC-7. We then used Western blotting to confirm 
that exogenous PK2 can also increase the GDNF protein. After treating primary mouse astrocytes 
with rPK2 for 10hrs we discovered that there was a significant increase in GDNF protein levels 
with rPK2 treatment using Western blotting when compared to control (Figure 1F). Since GDNF 
needs to be secreted to have a neuroprotective effect, we used an ELISA to determine whether 
rPK2 treatment on primary mouse astrocytes can increase the amount of secreted GDNF. We used 
a chemical, Golgi-block, which inhibits the secretory pathway, and therefore would leave any 
GDNF protein that is produced to remain inside the cell. Recombinant PK2 treatment caused a 
significant increase in GDNF protein level of astrocyte cell lysates treated with the secretion 
inhibitor when compared to control treatment (Figure 1G). GDNF protein levels also increased 
slightly with rPK2 even without the Golgi-block, however it was not significant (data not shown). 
Overall these results indicate that exogenously added PK2 can increase levels of GDNF in primary 
mouse astrocytes, and that the PK2-induced increase in GDNF production is also secreted from 
the cells.  
 
Soluble exogenous PK2 increases production and secretion of GDNF in U373 human 
astrocytoma cell line 
 Previous literature has indicated that the expression of GDNF is different between mouse 
and human cells (Hunot et al. 1996).   Following the results from the mouse astrocytes, we wanted 
to determine whether PK2 could induce an increase in GDNF production in human astrocytes. To 
test this, our lab added exogenous rPK2 to the U373 human astrocytoma cell-line and checked 
GDNF levels by qPCR for gene expression, along with Western blotting, ELISA and ICC for 
protein levels. The gene expression levels were tested with validated qPCR primers for the human 
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GDNF and 18s ribosomal genes. We found that an 8 hour rPK2 treatment on the U373 cells 
induced a 3-fold increase in GDNF gene expression (Figure 2A). Following the gene expression 
results, our lab wanted to investigate whether rPK2 could induce a change in GDNF protein level 
in this human astrocytoma cell-line. Using immunocytochemistry techniques our lab was able to 
find that rPK2 treatment on the U373 cells induces a visible difference in GDNF protein levels. 
We quantified the fluorescence from the GDNF ICC and found that the rPK2 treatment lead to 
about a 50% increase in GDNF protein levels inside the cell (Figure 2B). Similarly, we used 
Western blotting and ELISA to confirm the protein changes that we found with the ICC. Western 
blotting techniques demonstrate that rPK2 treatment on U373 cells induces over a 2.5-fold increase 
in GDNF protein levels that is significantly attenuated when co-treated with a PK2-receptor 
antagonist, PC-7 (Figure 2C). Consistent with the GDNF Western blot, when we performed an 
ELISA for GDNF on rPK2 treated U373 conditioned media, we discovered that there was a 
significant increase in secreted GDNF protein levels in the rPK2 treated samples compared to the 
control, and PC-7 was able to significantly attenuate this increase (Figure 2D). Together, these 
results indicate that recombinant PK2 treatment can induce GDNF production and secretion in 
human astrocytes 
PK2 overexpression in the human astrocyte cell line increases GDNF-induced 
neuroprotection of human dopaminergic neurons 
Since we determined that exogenously added recombinant human PK2 protein could 
induce GDNF production in both mouse and human astrocytes, we next wanted to investigate 
whether genetic overexpression of GDNF could elicit a similar response in the U373 human 
astrocyte cell line. We infected U373 human astrocytes with PK2 tagged to GFP or GFP alone for 
24 hours and then changed the media. The cells were collected 24 hours later to ensure maximal 
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expression of the protein. First, we confirmed that the U373 cells were successfully overexpressing 
the proteins by GFP immunofluorescence (Figure 3A) and by Western blotting for the GFP protein 
(Figure 3B). Once we confirmed that the cells were overexpressing PK2, we used Western blotting 
techniques to measure the levels of the GDNF protein and activation of the CREB transcription 
factor (Figure 3C). Interestingly, we found that PK2 overexpression was able to increase the levels 
of phosphorylated CREB (Figure 3D, left panel), similar to that which was seen with rPK2 
treatment, whereas total CREB protein levels did not change (Figure 3D, right panel). GDNF 
protein levels were also significantly increase in the U373 cell lysates with PK2 overexpression 
compared to both control and GFP overexpressing cells (Figure 3E). To determine if the amount 
of PK2-induced GDNF protein could be neuroprotective, we overexpressed PK2 in U373 cells and 
conditioned the media for 24 hours. We added the conditioned media with or without MPP+ on 
differentiated human LUHMES cells. PK2 conditioned media was able to significantly protect 
against cell death when compared to MPP+ alone by using an MTS assay (Figure 3F). This 
protection was attenuated with pre-treatment of LUHMES cells with RPI-1, a Ret inhibitor. 
Therefore, the amound of GDNF produced and secreted from PK2 overexpressing astrocytes could 
protect neurons from cell death, and importantly the Ret inhibitor was able to attenuate this 
protection. Collectively, this data demonstrates that PK2 signaling can not only induce GDNF in 
mouse astrocytes, but can do the same action in a human astrocytoma cell line and produce enough 
GDNF to be neuroprotective against MPP treatment. These results have important implications in 
translating this work from mouse cell culture into finding the potential role PK2 may play in human 
PD patients. 
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Soluble exogenous PK2 induces an increase in gene expression and protein level of GDNF in 
primary human astrocytes 
 Cultured cell lines have historically been found to differ in expression of certain proteins 
when compared to primary cells. Therefore, we wanted to test our hypothesis in primary human 
astrocytes to get as close to that of the human CNS. Similar to U373 cells the primary human 
astrocytes treated with rPK2 for 8 hours showed significantly increased GDNF gene expression 
compared to control (Figure 4A). Western blotting also demonstrated that human recombinant 
PK2 can significantly increase GDNF protein level in human primary astrocyte cultures (Figure 
5B). We then used confocal microscopy images to visually demonstrate that rPK2 treatment 
induced GDNF protein level in these primary human astrocytes, and fluorescent intensity 
quantification shows that it is significantly more GDNF compared to the control (Figure 5C, 
bottom panel). Interestingly, recombinant PK2 treatment also increased GDNF protein levels in 
the media after 12 hours of treatment and was attenuated with co-treatment of PC-7 (Figure 5D). 
These results indicate that PK2 signaling in primary human astrocytes can also lead to increased 
production of GDNF. 
 
PK2 overexpression AAV infection induces an increase in GDNF levels in the mouse 
Striatum compared to GFP AAV infected tissues 
 Several groups have used an AAV delivery system to increase neuroprotection by 
overexpressing GDNF in animal models of PD (Bjorklund et al. 2000, Kordower 2003).  We 
wanted to use a similar approach to overexpress PK2 in the striatum and confer neuroprotection. 
Our lab previously demonstrated that this PK2-AAV 2/5 injection strategy could protect 
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dopaminergic neurons against MPTP-induced cell death (unpublished). We stereotaxically 
injected the PK2-AAV 2/5 or GFP-AAV 2/5 into the mouse striatum and let the gene reach 
maximal expression at 4 weeks, and then we sacrificed the mice. Interestingly, using quantitative 
real-time PCR we found that PK2-AAV was able to significantly increase GDNF gene expression 
compared to GFP AAV injected animals (Figure 5A). This was confirmed by using Western 
blotting techniques for the GDNF protein, showing that PK2-AAV significantly increases GDNF 
protein level in the mouse striatum compared to GFP-AAV (Figure 5B). We then used 
immunofluorescent microscopy 2X magnification images to demonstrate that the striatum with 
PK2-AAV injection had increased GDNF protein levels compared to the control striatum and the 
GFP-AAV injected striatum (Figure 5C). Similarly, 10X images of the same striatum indicate that 
the cells producing the PK2 are not the cells that have increased GDNF levels (Figure 5D). Taken 
together, these data confirm the cell culture results and demonstrate that PK2 overexpression in 
vivo can induced GDNF production in the mouse striatum.  
 
The PKR1 agonist, IS20, increases GDNF production in primary mouse astrocytes 
 Gasser et al. recently developed a non-peptide chemical agonist for the PK2 receptor PKR1 
(Gasser et al. 2015). They used this chemical, IS20, to protect cardiomyocytes during myocardial 
infarctions in mice, mainly through activation of the ERK and Akt pathway. We used this chemical 
agonist in primary mouse astrocytes to determine whether activation of PKR1 would lead to the 
increased GDNF that we have found using recombinant and overexpression PK2. First, we treated 
primary mouse astrocytes with IS20 10µM for 8 hours and found that GDNF gene expression 
significantly higher compared to control treatement (Figure 6A). Similarly, Western blot of for the 
GDNF protein showed that IS20 also increased the GDNF protein level in the primary mouse 
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astrocyte protein lysates (Figure 6B). Next, we used immunofluorescence microscopy to confirm 
that the GDNF protein is higher in the cell cytosol with rPK2 treatment, and fluorescence intensity 
quantification shows that rPK2 treatment significantly increased the GDNF protein level compared 
to control (Figure 6C). Taken together, these data implicate the PKR1 receptor as being at least 
partially responsible for relaying the signal of PK2 treatment into the production of GDNF in 
astrocytes. However, it cannot be ruled out that PKR2 can also have a role, since there is no 
selective PKR2 receptor agonist available to test. Astrocytes normally express PKR1 at a much 
higher level than PKR2 under basal conditions, and therefore would indicate that PKR1 is the 
major signaling receptor of the exogenous PK2 protein to astrocytes. 
 
Discussion 
 GDNF is a major potential therapeutic option for Parkinson’s disease by providing 
neurotrophic support for dopaminergic neurons of the substantia nigra. GDNF has demonstrated 
the ability to protect neurons both in vitro and in vivo, and reduce behavioral deficits in animal 
models of PD (Lin et al. 1993, Kramer and Liss 2015). However, clinical trials of GDNF therapies 
have had mixed results but have shown some promise. Therefore, any factor that can induce GDNF 
expression and release in the CNS can be relevant for PD research. This report has uncovered a 
novel role for Prokineticin-2 signaling in the brain and particularly astrocytes. First, consistent 
with previous findings (Koyama et al. 2006) in mouse astrocytes, we found that recombinant 
human PK2 (rPK2) increased activation of the MAPK pathway. Similarly, rPK2 treatment was 
able to induce activation of the transcription factor CREB. GDNF transcription is known to be 
regulated by several transcription factors in the CNS, including CREB, NFκB and SP1. Several 
signaling pathways, including MAPK, PKC and PKA, have also been implicated in the induction 
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of GDNF gene expression (Saavedra et al. 2008). We confirmed that PK2-induced activation of 
these signaling pathways induced GDNF gene expression, by performing a promoter analysis to 
show that PK2 signaling can increase the GDNF promoter activity. This is the first evidence that 
the chemokine-like protein Prokineticin-2, or prokineticin signaling in general, can lead to the 
activation of the GDNF promoter.  
We then demonstrated for the first time that recombinant human Prokineticin-2 is able to 
induce GDNF production and secretion in primary mouse astrocytes and a human astrocyte cell 
line in vitro. Following these results, we went on to show that rPK2 can also increase GDNF gene 
expression and protein levels in primary human astrocytes. Importantly, we confirmed that the 
GDNF produced by PK2 overexpression in the human astrocyte cell line is able to significantly 
attenuate MPP+ neurotoxicity of differentiated human dopaminergic neuronal LUHMES cells that 
was attenuated with RPI-1 blocking the GDNF protection. These results indicate that PK2 can 
induce astrocytes to produce and secrete sufficient amounts of GDNF to protect dopaminergic 
neurons from MPP+ induced neurotoxicity in vitro. Therefore, we are the first to demonstrate that 
a protein increased in dopaminergic neurons during inflammatory or toxic conditions can induce 
neuronal protection through the increase of the neurotrophic factor GDNF from astrocytes.  
 Prokineticin signaling has been implicated in the survival of several different systemic cell 
types (LeCouter et al. 2004a, Lin et al. 2002b, Urayama et al. 2007a), neurogenesis (Ng et al. 2005) 
and neuroprotection (Melchiorri et al. 2001, Landucci et al. 2016). The basis for these studies was 
our discovery that PK2 is produced and secreted by dopaminergic (DA) neurons after neurotoxic 
insult in vitro and that postmortem Parkinson’s disease patients had an elevated level of PK2 when 
compared to age-matched controls. Interestingly, we went on to find that exogenously added 
recombinant PK2 could protect DA neurons from MPTP-induced toxicity in vitro (unpublished).  
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Our previous results demonstrating that PK2 is neuroprotective, taken together with the current 
findings indicate that Prokineticin-2 is a potential therapeutic target for Parkinson’s disease. To 
our knowledge, this is the first report showing that PK2 can signal in human astrocytes and increase 
the GDNF promoter activity, gene expression and protein level. More research is needed to 
determine which of the two receptors the PK2 uses to signal through in astrocytes, but our results 
indicate that the prokineticin-induced cell signaling in astrocytes is most likely through the PKR1 
receptor. This study suggests that the use of the prokineticin receptor 1 agonist, IS20, could have 
wide-ranging implications for Parkinson’s disease and possibly other neurodegenerative diseases. 
However, knowledge of prokineticin signaling in diseases of the CNS is limited and specific cell 
types involved in this signaling could lead to other therapeutic options. 
 
Materials and Methods 
Reagents  
DMEM, MEM media, fetal bovine serum (FBS), L-glutamine, IR-dye tagged secondary 
antibodies, Hoechst nuclear stain, penicillin, streptomycin, and other cell culture reagents were 
purchased from Invitrogen (Gaithersburg, MD). Recombinant human PK2 was purchased from 
Peprotech. The primary antibody for GDNF was ordered from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA). The GPF antibody was purchased from Abcam. The Phosphorylated CREB and 
the Native CREB were ordered from Cell Signaling. The Bradford protein assay kit was purchased 
from Bio-Rad Laboratories (Hercules, CA). The GDNF EMAX ELISA kit was obtained from 
Promega.  
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Cell culture and animal studies 
Human U373 astrocytoma cells (ATCC), were grown in MEM media supplemented with 10% 
FBS, penicillin (100 U/ml), streptomycin (100 μg/ml), according to ATCC instructions. U373 cells 
were maintained in an incubator at 37°C with 5% CO2. Primary astrocytes were obtained from 
whole brain homogenate of 0-3 day mouse pups. Astrocytes were collected, isolated and 
maintained according to previous methods (Gordon et al., 2011) using DMEM media (10% heat-
inactive FBS, 100 U/ml penicillin, 100 g/ml streptomycin, glutamate 2mM) to grow the cells. 
Primary human astrocytes were obtained from Lonza. 
Quantitative PCR 
Mouse astrocyte cells or U373 cells were seeded out into 75-mm3 flasks at 2.5 x 106 cells per flask. 
Treatments were performed in either MEM or DMEM media supplemented with 2% FBS, 
penicillin (100 U/ml), streptomycin (100 μg/ml), and 2 mM L-glutamine. Cells were treated for 8 
h with rPK2 (25nM) or rPK2 cotreated with PC-7 (1uM). After treatment, cells were collected, 
pelleted, and resuspended in lysis buffer with β-mercaptoethanol. RNA was isolated using 
Absolutely RNA Miniprep, an RNA isolation kit from Stratagene. RT-PCR was performed using 
an cDNA synthesis system (Applied Biosystems) to convert the RNA into cDNA. Expression 
levels were determined using real-time PCR with Qiagen RT2 SYBR Green master mix and 
prevalidated using the qPCR mouse primers from SuperArray/Qiagen. For normalization of each 
sample, the mouse gene 18SrRNA (Cat. No. PPM57735E) was used as the housekeeping gene. 
The amount of each template was optimized empirically to maximize efficiency without inhibiting 
the PCR reaction. According to manufacturer’s guidelines, dissociation curves and melting curves 
were run to ensure that single amplicon peaks were obtained without any non-specific amplicons. 
The results are reported as fold change in gene expression, which was determined using the ΔΔCt 
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method using the threshold cycle (Ct) value for the housekeeping gene and for the respective gene 
of interest in each sample. 
Western blotting 
Astrocytes were collected after treatment, lysed using modified RIPA buffer, homogenized, 
sonicated, and centrifuged as previously described (Kaul et al., 2003; Kitazawa et al., 2002). 
Supernatants were collected and proteins were normalized, then stored with loading buffer and 
DTT. Samples were run on a Sodium Dodecyl Sulfate (SDS) gel electrophoresis. Normalized 
protein samples were loaded into each well and first separated in a 4% stacking gel and then 
through a 12-18% resolution gel. Proteins were then transferred to a nitrocellulose membrane and 
allowed to transfer overnight in a 4°C refrigerator at 23-30 volts. After transfer, the membranes 
were blocked using either Western blocking buffer (Rockland Immunochemicals) or with 5% 
nonfat dry milk powder. Membranes were washed several times in wash buffers comprising either 
PBS containing 0.05% Tween (PBST) or Tris buffer saline containing 0.05% Tween (TBST). 
Primary antibodies, in either blocking buffer or in a 5% bovine serum albumin (BSA) solution, 
were then added to the membranes and stored overnight at 4°C. After another 4-5 washes, a 
secondary antibody specific to the primary antibody is added (in either blocking buffer or in 5% 
low-fat dry milk solution) to the membrane for 1 h. Either β-Actin or α-Tubulin was used to 
confirm equal loading into each well of the gels. The membranes were washed another 4-5 times 
with wash buffer, and then the membranes were read using the Odyssey infra-red imaging system. 
GDNF ELISA 
Astrocyte cells were seeded into either 96-well plate or 75mm3 flask. Treated cells in DMEM or 
MEM media supplemented with 2% FBS for 12 hours, then collected the media and the cells 
separately. The astrocyte conditioned media (ACM) was then centrifuged at max speed for 5 
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minutes to remove any cell debris. The GDNF ELISA was performed according to the 
manufacturer’s instructions. The signal was measured using the Synergy-2 multi-mode microplate 
reader. 
 
Immunocytochemistry 
For immunocytochemistry, cells were plated onto coverslips in 24-well plates coated with 0.1% 
poly-D-Lysine. After cells were treated, 4% formaldehyde was used to fix the cells for 30 min. 
The cells were washed 4-5 times with PBS wash buffer. Then blocking buffer containing 2% BSA, 
0.2% Triton X-100, and Tween was added to the wells for 1 h to permeabilize the cells. The cells 
were incubated with primary GDNF (Mouse polyclonal, 1:500 dilution) antibodies in 2% BSA at 
4°C overnight. After 4-5 more washes, an Alexafluor dye-conjugated secondary antibody in 2% 
BSA was added and incubated at room temperature on a shaker for 1 h. Cells were then washed 4-
5 times before adding Hoechst counterstain for 5-6 min to label nuclei. After 4-5 more washes, 
coverslips were mounted onto slides with Fluoromount mounting media. Cells were imaged under 
a Nikon 2000U microscope with a SPOT camera, and all images were processed in MetaMorph 
5.7 (Universal Imaging, Downingtown, PA). 
For histology, mice were anesthetized using the ketamine-xylazine mixture and cardiac perfusion 
of 4% PFA was used to fix the brain before being extracted and stored in 4% PFA at 4°C. After 
48 h, brains were washed 5 times with PBS, and placed into a 30% sucrose solution for at least 24 
h. The brains were then embedded in Optimal Cutting Temperature (OCT) compound and frozen 
into blocks for sectioning. Brains were sectioned on a Cryostat (CryoStar NX70, Thermo 
Scientific) at -20°C and placed into Cryosolution (30% Sucrose, Ethylene glycol, and PBS). 
Sections were then washed with PBS and permeabilized with blocking buffer (2% BSA, 0.1% 
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Triton X-100, and Tween) for 1 h at room temperature. Antibodies directed to GDNF (Mouse 
polyclonal, 1:500) were then incubated with the sections overnight at 4°C. After 4 washes with 
PBS, the sections were incubated with Alexafluor dye-conjugated secondary antibodies for 1 h at 
room temperature. After several more washes with PBS, Hoechst dye (1:5000) was added to the 
sections for 5 min at room temperature to stain nuclei. Sections were then mounted on slides using 
the Fluoromount mounting medium (Molecular probes) according to the manufacturer’s 
instructions. An inverted fluorescent microscope (Nikon TE-2000U) was used to visualize the 
sections, and a Spot digital camera (Diagnostic Instruments, Inc) was used to capture images. 
GDNF Promoter studies 
The GDNF promoter luciferase plasmid was generously provided by Dr. Englert’s lab from their 
manuscript (Brodbeck et al. 2004). First, the plasmid was transfected into U373 cells by home-
made Amaxa solutions and electroporation and allowed the cells to recover for 24 hours. Each 
transfection was performed with 2 µg of reporter constructs along with 0.2 µg of pcDNA3-LacZ 
to normalize transfection efficiencies. Then the cells were treated with PK2 for 8 hours. Cells were 
harvested and lysed in 150 µl of Reporter Lysis Buffer (Promega), and assayed for luciferase 
activity using the Synergy-2 multi-mode microplate reader. 
MTS cell survival assay 
MTS cell viability assay was performed, as described previously (Jin et al. 2014b). Briefly, 
differentiated LUHMES cells were seeded onto 96-well plates and treated at differentiation day 5. 
After treatment, 20 µl of MTS solution was added to each well, and the plates were incubated at 
37°C and 5% CO2 for 2 h. Measurements were made at 490 nm using a fluorescence microplate 
reader (SpectraMax Gemini XS, Molecular Devices). 
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Data analysis 
Data analysis was performed using the Prism 4.0 software package (GraphPad Software, San 
Diego, CA). The data was first analyzed using one-way ANOVA and then Tukey’s post-test was 
performed to compare all treatment groups. Differences of p<0.05 were considered statistically 
significant. The Student's t-test was used when two groups were being compared. 
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Figure 1. Prokineticin-2 can signal to astrocytes and induces GDNF production. (A) 
Representative Western blot for phosphorylated MEK and phosphorylated ERK with control or 
rPK2 treatment. (B) Representative Western blot for phosphorylated CREB. (C) Quantitative real 
time PCR array results in primary human astrocytes using the ∆∆Ct method, with a table of 
common neurotrophic factors and their gene expression fold change. (D) Analysis of the GDNF 
promoter upstream of the luciferase gene, values were normalized using β-glactosidase values. (E) 
Quantitative real time PCR results for gene expression of GDNF in primary mouse astrocytes. (F) 
Representative Western blot for GDNF protein levels with control of PK2 treatment in primary 
mouse astrocytes, with β-Actin used as a loading control. (G) GDNF ELISA results for primary 
mouse astrocytes conditioned media to detect secreted GDNF protein levels. Asterisks denote a 
significant difference between rPK2 treatment and the control (* p<0.05, ** p<0.01, and *** 
p<0.001). 
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Figure 2. Recombinant Prokineticin-2 induces GDNF expression in the U373 human astrocytoma 
cell line. (A) Quantitative real time PCR results for gene expression of GDNF in U373 cells 
expressed as fold change compared to control. (B) Fluorescence microscopy images for GDNF 
protein level, with control, PK2 or PK2 co-treated with PC-7. (C) Representative Western blot for 
GFDF in the U373 astrocytes showing that there is an increase in GDNF with the rPK2 treatment, 
with β-Actin used as a loading control. Densitometric band quantification bin the bottom panel. 
(D) GDNF ELISA results for the U373 astrocytes conditioned media to detect secreted GDNF 
protein levels. Asterisks denote a significant difference between rPK2 treatment and the control (* 
p<0.05, ** p<0.01, and *** p<0.001).  
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Figure 3. Prokineticin-2 overexpression increases GDNF expression in the U373 human 
astrocytoma cells. (A) Fluorescent microscopy images to detect GFP protein levels ensuring either 
GFP or PK2-GFP overexpression. (B) Representative Western blot for GFP in PK2 or GFP 
overexpressing astrocytes, with β-Actin used as a loading control. (C) Representative Western blot 
for GDNF, phosphorylated CREB at S133, and Native CREB, with β-Actin used as a loading 
control. (D-E) Densitometric quantification of Western blot protein bands in PK2 or GFP 
overexpressing astrocytes. Quantification of Western blot proteins for phospohorylated CREB (D, 
left panel) and native CREB (D, right panel) indicate that PK2 overexpression increases 
phosphorylated CREB levels. Similarly, quantification of the GDNF protein band (E) found an 
increase with PK2 overexpression compared to control and GFP overexpression. (F) MTS assay 
results quantifying cell survival of human LUHMES cells treated with astrocyte conditioned 
media, from either PK2 or GFP overexpressing cells, along with the Ret inhibitor, RPI-1. Asterisks 
denote a significant difference between rPK2 treatment and the control (* p<0.05, ** p<0.01, and 
*** p<0.001). 
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Figure 4. Recombinant Prokineticin-2 induces GDNF expression in the primary human astrocytes. 
(A) Quantitative real time PCR results for gene expression of GDNF in primary human astrocytes 
expressed as fold change compared to control. (B) Representative Western blot for GFDF in the 
U373 astrocytes showing that there is an increase in GDNF with the rPK2 treatment. (C) 
Fluorescence microscopy images for GDNF protein level, treated with control or rPK2. 
Fluorescence intensity quantification in the bottom panel. (D) GDNF ELISA results for the U373 
astrocytes conditioned media to detect secreted GDNF protein levels. Asterisks denote a 
significant difference between rPK2 treatment and the control (*** p<0.001).  
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Figure 5. PK2-AAV 2/5 induces GDNF expression in the mouse striatum. (A) Quantitative real 
time PCR results for gene expression of GDNF in striatum tissue of mice injected with either GFP 
or PK2-AAV. (B) Representative Western blot for GFDF in the U373 astrocytes showing that 
there is an increase in GDNF with the rPK2 treatment. (C) Fluorescence microscopy 2X 
magnification images for GFP and GDNF protein level in the mouse striatum. Demonstrating an 
increase in the GDNF protein level in the striatum injected with PK2-AAV and not with GFP-
AAV injection. (D) Fluorescence microscopy 10X magnification images for GFP and GDNF 
protein level in the mouse striatum. Asterisks denote a significant difference between rPK2 
treatment and the control (* p<0.05 and * p<0.01).  
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Figure 6. PKR1 agonist, IS20, induces GDNF expression in the primary mouse astrocytes. (A) 
Quantitative real time PCR results for gene expression of GDNF in primary mouse astrocytes 
expressed as fold change compared to control. Mouse 18srRNA used as a loading control. (B) 
Representative Western blot for GFDF in the primary mouse astrocytes showing that there is an 
increase in GDNF with the IS20 treatment. (C) Fluorescence microscopy images for GDNF 
protein level, treated with control or IS20. Fluorescence intensity quantification in the panel to the 
right. Asterisks denote a significant difference between rPK2 treatment and the control (* p<0.05 
and *** p<0.001). 
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CHAPTER VI 
 
GENERAL CONCLUSION AND FUTURE DIRECTIONS 
 
This section presents a general overview of the results described in the thesis, with special 
emphasis on future directions and overall implications of these findings for the pathogenesis and 
progression of PD. The major findings pertaining to each research manuscript and their specific 
implications are covered in the ‘Results’ and ‘Discussion’ sections of each chapter. 
 
 
Figure 1. Overall schematic of 
Prokineticin-2 signaling in 
Parkinson’s disease 
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Prokineticin-2 neuroprotective signaling is mediated through the ERK and Akt pathways 
The findings reported in Chapter II demonstrate that PK2 is highly induced following 
dopaminergic neuron injury in cell culture and animal models of PD and is also elevated in 
postmortem human PD brains. This is the first evidence for the induction of PK2 expression in 
dopaminergic neurons following injury, thus indicating an intriguing new function for PK2 in the 
pathophysiology of PD. Our results suggest that PK2 expression is most likely induced at early 
stages of PD by physiological insults including oxidative stress, mitochondrial dysfunction and 
neuroinflammation. Evidence for this was manifested by increased PK2 levels in MitoPark mice, 
which have a genetic deletion of the TFAM protein specifically in dopaminergic neurons. 
Mitochondrial dysfunction occurs in the MitoPark mouse model because the loss of TFAM 
cripples mitochondrial DNA replication and transcription. Additional evidence came from TNFα 
stimulation, which rapidly enhancedPK2 expression in dopaminergic neurons. Further studies are 
being performed to determine whether environmental stressors induce PK2 expression during early 
stages to protect dopaminergic neurons from neurotoxic insults. Identificating the transcription 
factors involved in this mitochondrial dysfunction-induced PK2 activation would facilitate the 
development of novel ways to induce PK2 and broaden our understanding its role in PD. Studies 
are currently being conducted to identify the molecular underpinnings of PK2 upregulation in 
dopaminergic neurons. 
Studies using models of cerebellar excitotoxicity and ischemia suggest that PK2 could be 
a neuroprotective protein (Melchiorri et al. 2001, Landucci et al. 2016). The PKR2 receptor is 
expressed in dopaminergic neurons in cell culture, and in vivo in both mouse and human 
dopaminergic neurons. We found that either the recombinant protein or overexpression of PK2 
protects dopaminergic neurons from MPP+/MPTP-induced cell death. PK2 treatment increased the 
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activation of both ERK and Akt signaling pathways in the N27 dopaminergic neuronal cell line. 
We found that the neuroprotection induced by PK2 treatment was abolished by PD98059 and API-
1, which are pharmacological inhibitors of ERK and Akt, respectively. Several different 
neurotrophic factors exert their protective effects through the Akt pathway (Duronio 2008, 
Downward 2004, Orike et al. 2001, Brunet, Datta and Greenberg 2001). Activation of the Akt 
pathway was reported to protect neurons in disease models of ischemia, PD and Alzheimer’s 
disease (Zhang et al. 2016, Ries et al. 2009, Wang et al. 2015). Therefore, PK2 could potentially 
act through similar cell signaling pathways used by neurotrophic factors to protect neurons. Our 
MPTP and PKRA7 experiments provided further evidence for PK2 acting like a neurotrophic 
factor. Using PKRA7 to block MPTP-induced endogenous PK2 signaling significantly increased 
dopaminergic neuronal cell death. This indicates that PK2 expression by dopaminergic neurons 
during toxic insults could protect against some neurodegeneration as depicted in Figure 1. 
Therefore, PK2 signaling could be harnessed to slow the progression of PD by increasing PK2 
above endogenously produced levels. PK2-AAV overexpression in the mouse nigrostriatal system 
demonstrated that higher levels of PK2 protected against MPTP-induced behavioral deficits and 
TH+ neuronal cell loss. Further studies are still needed to examine the effectiveness of PK2 in other 
genetic models of PD including LRRK mutant mice. 
Importance of PK2-induced mitochondrial biogenesis in neurons 
 Mitochondrial dysfunction has been implicated in the progression of PD (Schon and 
Przedborski 2011). Mitochondrial complex I activity is lower in the substantia nigra of PD patients 
compared to age-matched controls, and several PD toxicants such as rotenone, MPTP, and 6-
OHDA are potent mitochondrial complex I inhibitors. Interestingly, genetic knockout of the master 
regulator of mitochondrial biogenesis, TFAM, in mice leads to the development of 
264 
 
neurodegenerative diseases such as PD (Ekstrand et al. 2007). Similarly, a genetic mutation in 
TFAM is also a moderate risk factor for AD (Belin et al. 2007). Mitochondrial biogenesis can 
become compromised with aging, thereby increasing the risk of developing age related 
neurodegenerative diseases such as PD. Recombinant PK2 treatment and overexpression of PK2 
in dopaminergic neuronal cell lines led to protection against MPP+-induced mitochondrial 
dysfunction and increased the expression of mitochondrial protective proteins such as Bcl2. 
Interestingly, overexpression of PK2 also led to a significant increase in the gene expression of the 
mitochondrial biogenesis regulators PGC-1α and TFAM, and increased the total number of 
mitochondria in cells. The action of PK2 signaling to increase mitochondrial biogenesis and 
mitochondrial protective proteins could help neurons survive against any toxicants or destructive 
factors that target the mitochondria. Similarly, this indicates that PK2 signaling could play a major 
part in preventing age-related problems in the CNS. 
PK2 promotes glial cell-induced neuroprotection by reducing of inflammatory factors 
 In Chapters III and IV, we investigated the roles that PK2 plays in both microglia and 
astrocytes, with Figure 1 summarizing the PK2 signaling seen in these two cell types. Due to 
previous reports that PK2 could increase inflammation in systemic immune cells and that blocking 
PK2 signaling could reduce some systemic inflammation (Martucci et al. 2006, Giannini et al. 
2009), we hypothesized that PK2 signaling in glial cells would lead to an increased inflammatory 
response. Surprisingly, we found the complete opposite result. Both recombinant PK2 treatment 
and PK2 overexpression reduced basal levels of inflammatory factors such as nitric oxide and 
intracellular ROS in microglia, while increasing anti-inflammatory factors such as Arginase1 and 
Nrf2. Similarly increased Nrf2 and Arginase1 levels were found in astrocytes. Moreover, in both 
cell types, basal levels of the pro-inflammatory cytokines TNFα, IL-6 and IL-12 were either 
265 
 
decreased or unchanged compared to controls. We reproduced the same effects seen in cell culture 
in an in vivo mouse model via PK2-AAV overexpression in the nigrostriatal system, which 
decreased the gene expression of pro-inflammatory factors such as nitric oxide synthase (NOS2) 
and pro-inflammatory cytokines relative to GFP-AAV control injections. Interestingly, rPK2 
treatment significantly attenuated LPS-induced production of ROS, RNS, pro-inflammatory 
cytokines and mitochondrial dysfunction in primary mouse microglia. Taken together, these data 
indicate that PK2 signaling increases anti-oxidant and anti-inflammatory factors, while reducing 
pro-inflammatory mediators increased by an inflammatory stimulus. This is the first report of PK2 
attenuating inflammation and promoting anti-inflammatory factors, and therefore points to 
prokineticin signaling as a potential therapeutic anti-inflammatory molecule for treatment of 
neurodegenerative diseases. 
These interesting results conflict with previous results found in peripheral tissues due to 
several factors. First, and perhaps most importantly, is that microglia found in the brain respond 
differently than microglia found in the brain stem and especially macrophages found more 
peripherally (Olson 2010, Greter, Lelios and Croxford 2015). Therefore, the cell type-specific 
differences could lead to differential responses to factors such as PK2. Secondly, prokineticin 
signaling involves complex interactions between differential receptor expression, phosphorylation 
and heterodimerization. Along with this, prokineticin receptors can signal through different G- 
proteins and could therefore lead to distinct downstream signaling pathways in different cells and 
conditions. Currently, no studies have investigated cell signaling in peripheral immune cells such 
as macrophages that could be compared with what we found in brain-resident microglia. Lastly, 
any detrimental effects reported for PK2/Bv8 signaling originated from the use of picomolar 
ranges of the recombinant protein, or blocking prokineticin signaling using a receptor antagonist. 
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However, all the beneficial effects of PK2 signaling have been found in the nanomolar ranges of 
recombinant PK2 or overexpression. This indicates dual roles for PK2, wherein it either increases 
peripheral inflammation at lower (picomolar) concentrations or reduces in CNS inflammation at 
higher (nanomolar or above) concentrations.  
PK2 promotes astrocyte-induced neuroprotection by producing the neurotrophic factor 
GDNF 
 Neurotrophic factors are important in the development and maintenance of neurons. 
Several neurotrophic factors have been found to potently protect dopaminergic neurons from cell 
death, including GDNF, Neuturin, BDNF, and CDNF. Prokineticin signaling activates particular 
cell signaling pathways, including the cyclic AMP and MAPK pathways (Ngan and Tam 2008). 
Increased cAMP can lead to activation of the CREB transcription factor. Both pathways, CREB 
and MAPK, have been implicated in activating the gene expression of several neurotrophic factors, 
including GDNF. We found that recombinant and overexpressed PK2 increased GDNF mRNA 
and protein expression in cultured mouse and human astrocytes. Astrocyte-conditioned media 
treated with PK2 could protect N27 dopaminergic neurons from MPP+-induced cell death that 
could be attenuated by blocking GDNF signaling through the Ret receptor using the chemical 
antagonist RPI-1. This demonstrates that PK2-induced GDNF is produced at high enough levels 
to protect dopaminergic neurons from toxicant-induced cell death. Therefore, PK2 signaling could 
offer druggable targets for increasing GDNF levels in the CNS. 
Our preliminary data suggests that PK2 also increases GDNF in other cell types such as 
cultured microglia, neurons, and bone marrow derived stem cells (BMSCs). Importantly, if PK2 
signaling could increase GDNF from multiple cell types, then the therapeutic potential drastically 
increases to where the increase in GDNF could reach across the entire CNS if necessary. The 
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increased GDNF production in the BMSCs also opens up the option for PK2-enhancing stem cell 
replacement therapies, since previous studies have demonstrated that increased GDNF and other 
neurotrophic factors can enhance stem cell incorporation and survival (Ren et al. 2013). Studies 
are currently underway in our lab to investigate the potential for PK2 to increase GDNF in other 
cell types such as neurons, microglia, and BMSCs. 
The cell signaling required to produce other neurotrophic factors is similar to that of 
GDNF, mainly in the form of CREB and MAPK signaling. Therefore, it is possible that PK2 could 
increase neurotrophic factors other than GDNF. For instance, BDNF is protective in animal models 
of PD and its expression can be increased with activation of the CREB transcription factor (Spina 
et al. 1992, Tao et al. 1998). Similarly, cerebral dopamine neurotrophic factor (CDNF) is a potent 
neurotrophic factor for dopaminergic neurons (Lindholm and Saarma 2010). Preliminary data in 
our lab shows that PK2 can increase CDNF in astrocyte cultures, and possibly BDNF as well. We 
are currently characterizing the PK2-induced CDNF increase in astrocytes. More studies are 
needed to find other cell type- specific neurotrophic factors that PK2 could potentially increase.  
PK2 in non-motor symptoms of PD 
The motor symptoms of PD are well-known and aid diagnosis of the disease. However, 
non-motor symptoms associated with PD include anosmia (loss of the sense of smell), sleep 
deficits, sexual dysfunction, weight loss and gastrointestinal problems. These non-motor 
symptoms typically emerge several years before the motor symptoms of PD. Interestingly, several 
of the known functions of PK2 signaling overlap with these non-motor symptoms. For instance, 
in peripheral tissues, PK2 functions in the formation and proper health of reproductive organs, 
such as the testes, and gastrointestinal motility. Also, the known functions of PK2 in the CNS 
include the formation and maintenance of the olfactory bulbs, regulation of circadian rhythms, and 
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energy homeostasis in the hypothalamus (Cheng et al. 2002, Ng et al. 2005, Beale et al. 2013, 
Matsumoto et al. 2006, Hu et al. 2007). The evidence for PK2 affecting these non-motor symptoms 
is currently only circumstantial. However, the finding of differential PK2 signaling in PD models 
and in PD patients demonstrates that this protein might play a role in other areas of the disease. 
This includes other areas of the CNS, such as the olfactory bulbs or superchiasmatic nucleus, and 
peripherally, such as the gastrointestinal tract and reproductive organs. Further studies would be 
required to investigate differential PK2 expression in these areas in animal models and post-
mortem PD patients. Currently, our lab is investigating whether PK2 is a novel mediator in the 
non-motor symptoms of PD to better determine its potential for improving the quality of life for 
PD patients.   
Potential roles for PK2 in other neurodegenerative diseases 
 Oxidative stress and neuroinflammation are common disease mechanisms for most 
neurodegenerative diseases. Besides PD, other diseases like AD, amyotropic lateral sclerosis 
(ALS), Huntington’s disease (HD), ischemia and glaucoma have elevated levels of oxidative 
damage and neuroinflammation (Heneka et al. 2015, Lewis et al. 2012, Crotti and Glass 2015, 
Uttara et al. 2009, Soto and Howell 2014). Therefore, since PK2 can reduce neuroinflammation 
and oxidative stress in cell culture and animal models of PD, it is plausible that it could also have 
a similar effect in these other neurodegenerative diseases. We found that PK2 could directly reduce 
mitochondrial damage in neurons and reduce ROS levels in neuronal cells. Similarly, PK2 
signaling induced both astrocytes and microglia to produce factors that reduce inflammation and 
oxidative damage in neurons, such as Nrf2 and Arginase1. Figure 1 summarizes the PK2 signaling 
pathways that we have found in neurons, microglia and astrocytes. Interestingly, a recent AD study 
implicated PK2 in exacerbating amyloid-β-induced neurodegeneration (Severini et al. 2015). 
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However, the authors stated that the effects seen in their studies could be due to the use of 
picomolar amounts of PK2, and that higher doses did not show any adverse effects and could 
possibly be protective. The advent of PK2-AAV allows for the overexpression of PK2 in animal 
models of different diseases as well as the directed expression of the protein to specific regions-
of-interest without overexpressing PK2 throughout the body. Therefore, more studies are required 
for directed PK2 overexpression in different neurodegenerative diseases and models of ageing to 
determine if PK2 could induce positive effects on these different diseases. Similarly, the tissue- 
specific and stimulus-specific activation of PK2 cell signaling in the brain would be worth 
investigating for a detailed understanding of the diverse biological functions of PK2 in the CNS. 
Overall, PK2 is emerging as a key endogenous protein that could regulate physiological function 
of neurons as well as glial cells, impacting the course of disease onset and progression in the brain. 
Further studies are warranted to better understand the role of PK2 in PD and other 
neurodegenerative diseases.  
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dioxo-1,4,5,6-tetrahydro-[1,3,5]triazin-2-ylamino]-ethyl}-guanidine 
PD – Parkinson’s disease 
PET – Positron emission tomography 
Pgc1α – Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PK1 – Prokineticin-1 
PK2 – Prokineticin-2 
PK2β – Active, cleaved form of PK2L 
PK2L – Prokineticin-2 long isoform 
PKR1 – Prokineticin receptor 1 
PKR2 – Prokineticin receptor 2 
PKRA7 – chemical prokineticin receptor antagonist, C27H34CLFN2O4 
ROS – Reactive oxygen species 
RNS – Reactive nitrogen species 
rPK2 – Recombinant human Prokineticin-2 
SNpc – Substantia Nigra pars compacta 
SOD – Superoxide dismutase 
STAT – Signal transducer and activator of transcription 
STR – Striatum 
TFAM – Transcription factor A, Mitochondrial 
TH – Tyrosine hydroxylase 
TNFα – Tumor necrosis factor alpha 
UPDRS – Unified Parkinson’s disease rating scale 
UPS – Ubiquitin proteasomal system 
VTA – Ventral Tegmental Area 
331 
 
 
Acknowledgements 
 
I would like to thank Dr. Anumantha Kanthasamy for allowing me to be a part of this 
fantastic lab and exposing me to this exciting field of research. He has always encouraged me to 
become the best possible scientist and been very understanding when things have not always gone 
according to plan. I will always appreciate the advice and direction that he has given me, especially 
in the fact that he allowed me to pursue the research directions that interested me. He pushed me 
to grow into someone that can find a new project, plan the experiments, analyze and interpret the 
results, and write up the manuscript. This lab has been a wonderful place to work, and the best 
place for me to grow and learn. I definitely need to thank my co-major professor Dr. Arthi 
Kanthasamy and Dr. Vellareddy Anantharam for their great ideas, guidance, and research advice 
that have been an immense help. I would like to thank the members of my committee for their 
great advice and directions, as well as their important inputs during my POS meeting and prelims. 
The member of the DRKLAB have been an indispensable resource during my time in the lab. I 
will always remember the great times that we have shared and all of the help that I have received 
from these amazing scientists. Special recognition for Richard, Dilshan, Nikhil, Souvarish, 
Huajun, Monica, Dan, and Gary because they have elevated my research to heights that I could 
not achieve without all of their help.  A very special and important thanks has to go to my beautiful 
and amazing wife, Megan Smith. She has been there for me through the ups and downs of grad 
school, and supported me through it all. Words cannot describe how thankful I am to have her by 
my side through this process. I have to send a thank you to my son, Layne, for always putting a  
  
332 
 
smile on my face, even on the worst days. Lastly, I would like to thank my family, especially my 
supportive parents, for always being there for me and pushing me to be the best at everything that 
I do. There is absolutely no possible way that I could have reached this point without so many 
caring and supportive individuals that have made me a better person by knowing them. 
